Amyris (AMRSQ) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Jan. 31, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	AMYRIS, INC.
Trading Symbol	amrs
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		206,442,603
Entity Public Float			$ 75,100,000
Amendment Flag	false
Entity Central Index Key	1,365,916
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 11,992	$ 42,047
Restricted cash	216
Short-term investments	1,520	1,375
Accounts receivable, net of allowance of $479 and $479, respectively	4,004	8,687
Related party accounts receivable, net of allowance of $490 and $0, respectively	1,176	455
Inventories, net	10,886	14,506
Prepaid expenses and other current assets	5,872	6,534
Total current assets	35,666	73,604
Property, plant and equipment, net	59,797	118,980
Restricted cash	957	1,619
Equity and loans in affiliates	68	2,260
Other assets	13,150	13,635
Goodwill and intangible assets	560	6,085
Total assets	110,198	216,183
Current liabilities:
Accounts payable	7,943	3,489
Deferred revenue	6,509	5,303
Accrued and other current liabilities	24,268	13,565
Capital lease obligation, current portion	523	541
Debt, current portion	37,570	17,100
Total current liabilities	76,813	39,998
Capital lease obligation, net of current portion	176	275
Long-term debt, net of current portion	75,457	100,122
Related party debt	43,029	115,239
Deferred rent, net of current portion	9,682	10,250
Deferred revenue, net of current portion	4,469	6,539
Derivative liabilities	51,439	59,736
Other liabilities	7,589	9,087
Total liabilities	$ 268,654	$ 341,246
Commitments and contingencies (Note 6)
Stockholders’ deficit:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized, none issued and outstanding	$ 0	$ 0
Common stock - $0.0001 par value, 400,000,000 and 300,000,000 shares authorized as of December 31, 2015 and 2014; 206,130,282 and 79,221,883 shares issued and outstanding as of December 31, 2015 and 2014, respectively	21	8
Additional paid-in capital	926,216	724,669
Accumulated other comprehensive loss	(47,198)	(29,977)
Accumulated deficit	(1,037,104)	(819,152)
Total Amyris, Inc. stockholders’ deficit	(158,065)	(124,452)
Noncontrolling interest	(391)	(611)
Total stockholders' deficit	(158,456)	(125,063)
Total liabilities and stockholders' deficit	$ 110,198	$ 216,183

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Allowance for doubtful accounts (in Dollars)	$ 479	$ 479
Related party accounts receivable allowance (in Dollars)	$ 490	$ 0
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	300,000,000
Common stock, shares issued	206,130,282	79,221,883
Common stock, shares outstanding	206,130,282	79,221,883

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues
Renewable product sales	$ 14,032	$ 22,793	$ 14,428
Related party renewable product sales	864	646	1,380
Total product sales	14,896	23,439	15,808
Grants and collaborations revenue	19,257	19,835	22,664
Related party grants and collaborations revenue			2,647
Total grants and collaborations revenue	19,257	19,835	25,311
Total revenues	34,153	43,274	41,119
Cost and operating expenses
Cost of products sold	37,374	33,202	38,253
Loss on purchase commitments, impairment of property, plant and equipment and other asset allowances	34,166	1,769	9,366
Withholding tax related to conversion of related party notes	4,723
Impairment of intangible assets	5,525	3,035
Research and development	44,636	49,661	56,065
Sales, general and administrative	56,262	55,435	57,051
Total cost and operating expenses	182,686	143,102	160,735
Loss from operations	(148,533)	(99,828)	(119,616)
Other income (expense):
Interest income	264	387	162
Interest expense	(78,854)	(28,949)	(9,107)
Gain (loss) from change in fair value of derivative instruments	16,287	144,138	(84,726)
Loss from extinguishment of debt	(1,141)	(10,512)	(19,914)
Other income (expense), net	(1,423)	336	(2,553)
Total other income (expense)	(64,867)	105,400	(116,138)
Income (loss) before income taxes and loss from investments in affiliates	(213,400)	5,572	(235,754)
Benefit (provision) for income taxes	(468)	(495)	847
Net income (loss) before loss from investments in affiliates	(213,868)	5,077	(234,907)
Loss from investments in affiliates	(4,184)	(2,910)
Net income (loss)	(218,052)	2,167	(234,907)
Net (income) loss attributable to noncontrolling interest	100	119	(204)
Net income (loss) attributable to Amyris, Inc. common stockholders	$ (217,952)	$ 2,286	$ (235,111)
Net income (loss) per share attributable to common stockholders:
Basic (in Dollars per share)	$ (1.75)	$ 0.03	$ (3.12)
Diluted (in Dollars per share)	$ (1.75)	$ (0.90)	$ (3.12)
Weighted-average shares of common stock outstanding used in computing net income (loss) per share of common stock:
Basic (in Shares)	126,961,576	78,400,098	75,472,770
Diluted (in Shares)	126,961,576	121,859,441	75,472,770

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Comprehensive loss:
Net loss	$ (218,052)	$ 2,167	$ (234,907)
Foreign currency translation adjustment, net of tax	(16,901)	(9,798)	(7,191)
Total comprehensive loss	(234,953)	(7,631)	(242,098)
Income (loss) attributable to noncontrolling interest	100	119	(204)
Foreign currency translation adjustment attributable to noncontrolling interest	(320)	(92)	(89)
Comprehensive loss attributable to Amyris, Inc.	$ (235,173)	$ (7,604)	$ (242,391)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2012	$ 7	$ 666,233	$ (586,327)	$ (12,807)	$ (877)	$ 66,229
Balance (in Shares) at Dec. 31, 2012	68,709,660
Issuance of common stock upon exercise of stock options, net of restricted stock		1,489				1,489
Issuance of common stock upon exercise of stock options, net of restricted stock (in Shares)	777,099
Issuance of common stock in a private placement, net of issuance cost	$ 1	19,979				19,980
Issuance of common stock in a private placement, net of issuance cost (in Shares)	6,567,299
Shares issued from restricted stock unit settlement		(825)				(825)
Shares issued from restricted stock unit settlement (in Shares)	608,754
Issuance of warrants		1,330				1,330
Stock-based compensation		18,047				18,047
Foreign currency translation adjustment, net of tax				(7,280)	89	(7,191)
Net income (loss)			(235,111)		204	(234,907)
Balance at Dec. 31, 2013	$ 8	706,253	(821,438)	(20,087)	(584)	(135,848)
Balance (in Shares) at Dec. 31, 2013	76,662,812
Issuance of common stock upon exercise of stock options, net of restricted stock		2,133				2,133
Issuance of common stock upon exercise of stock options, net of restricted stock (in Shares)	779,490
Issuance of common stock in a private placement, net of issuance cost		4,000				4,000
Issuance of common stock in a private placement, net of issuance cost (in Shares)	943,396
Shares issued from restricted stock unit settlement		(1,822)				(1,822)
Shares issued from restricted stock unit settlement (in Shares)	836,185
Stock-based compensation		14,105				14,105
Foreign currency translation adjustment, net of tax				(9,890)	92	(9,798)
Net income (loss)			2,286		119	2,167
Balance at Dec. 31, 2014	$ 8	724,669	(819,152)	(29,977)	(611)	$ (125,063)
Balance (in Shares) at Dec. 31, 2014	79,221,883					79,221,883
Issuance of common stock upon exercise of stock options, net of restricted stock		18				$ 18
Issuance of common stock upon exercise of stock options, net of restricted stock (in Shares)	13,250					13,250
Issuance of common stock upon conversion of debt	$ 6	96,616				$ 96,622
Issuance of common stock upon conversion of debt (in Shares)	62,192,238
Issuance of common stock in a private placement, net of issuance cost	$ 2	24,624				24,626
Issuance of common stock in a private placement, net of issuance cost (in Shares)	16,025,642
Shares issued from restricted stock unit settlement		(333)				(333)
Shares issued from restricted stock unit settlement (in Shares)	908,877
Shares issued upon ESPP purchase		595				595
Shares issued upon ESPP purchase (in Shares)	385,892
Issuance of warrants		51,704				51,704
Stock-based compensation		9,134				9,134
Issuance of common stock upon exercise of warrants	$ 5	19,189				19,194
Issuance of common stock upon exercise of warrants (in Shares)	47,382,500
Foreign currency translation adjustment, net of tax				(17,221)	320	(16,901)
Net income (loss)			(217,952)		(100)	(218,052)
Balance at Dec. 31, 2015	$ 21	$ 926,216	$ (1,037,104)	$ (47,198)	$ (391)	$ (158,456)
Balance (in Shares) at Dec. 31, 2015	206,130,282					206,130,282

Consolidated Statements of Sto7

Consolidated Statements of Stockholders' Equity (Deficit) (Parentheticals) $ in Thousands	12 Months Ended
	Dec. 31, 2013USD ($)
Stock issuance costs	$ 21

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net income (loss)	$ (218,052,000)	$ 2,167,000	$ (234,907,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	12,920,000	14,969,000	16,639,000
Loss on disposal of property, plant and equipment	154,000	263,000	176,000
Impairment of intangible assets	5,525,000	3,035,000	0
Stock-based compensation	9,134,000	14,105,000	18,047,000
Amortization of debt discount and issuance costs	58,559,000	9,981,000	3,683,000
Loss from extinguishment of debt	1,141,000	10,512,000	19,914,000
Loss on purchase commitments, impairment of property, plant and equipment and other asset allowances	34,166,000	1,769,000	9,366,000
Withholding tax related to conversion of related party debt	4,723,000
Change in fair value of derivative instruments	(16,287,000)	(144,138,000)	84,726,000
Loss from investments in affiliates	4,184,000	2,910,000
Other non-cash expenses	(413,000)	(113,000)	211,000
Changes in assets and liabilities:
Accounts receivable	4,920,000	(1,217,000)	(4,365,000)
Related party accounts receivable	(649,000)	(4,000)	(484,000)
Inventories, net	4,470,000	(4,481,000)	(5,612,000)
Prepaid expenses and other assets	(4,297,000)	(2,907,000)	(2,743,000)
Accounts payable	4,373,000	(3,209,000)	(2,636,000)
Accrued and other liabilities	10,954,000	6,830,000	(9,275,000)
Deferred revenue	(89,000)	4,760,000	1,634,000
Deferred rent	(568,000)	60,000	(233,000)
Net cash used in operating activities	(85,132,000)	(84,708,000)	(105,859,000)
Investing activities
Purchase of short-term investments	(2,759,000)	(1,371,000)	(2,795,000)
Maturities of short-term investments	2,321,000	1,409,000	1,281,000
Change in restricted cash	240,000		(736,000)
Investment in joint venture		(2,075,000)
Loan to affiliate	(1,579,000)	(2,790,000)
Purchase of property, plant and equipment, net of disposals	(3,367,000)	(5,004,000)	(8,087,000)
Net cash used in investing activities	(5,144,000)	(9,831,000)	(10,337,000)
Financing activities
Proceeds from issuance of common stock, net of repurchases	614,000	2,488,000	1,134,000
Employees' taxes paid upon vesting of restricted stock units	(333,000)	(1,822,000)	(825,000)
Proceeds from issuance of common stock in private placements, net of issuance costs	24,625,000	4,000,000	19,980,000
Proceeds from exercise of warrants	285,000
Principal payments on capital leases	(729,000)	(1,045,000)	(1,366,000)
Proceeds from debt issued, net of discounts and issuance costs	66,931,000	83,171,000	10,535,000
Proceeds from debt issued to related party	10,850,000	49,862,000	65,000,000
Repayment of debt, net of discount	(40,819,000)	(5,733,000)	(3,277,000)
Net cash provided by financing activities	61,424,000	130,921,000	91,181,000
Effect of exchange rate changes on cash and cash equivalents	(1,203,000)	(1,203,000)	1,291,000
Net increase/(decrease) in cash and cash equivalents	(30,055,000)	35,179,000	(23,724,000)
Cash and cash equivalents at beginning of period	42,047,000	6,868,000	30,592,000
Cash and cash equivalents at end of period	11,992,000	42,047,000	6,868,000
Supplemental disclosures of cash flow information:
Cash paid for interest	9,425,000	6,910,000	2,978,000
Supplemental disclosures of non-cash investing and financing activities:
Acquisitions of property, plant and equipment under accounts payable, accrued liabilities and notes payable	(73,000)	114,000	2,261,000
Financing of equipment	613,000	617,000
Warrants issued in connection with issuance of convertible promissory notes			1,330,000
Financing of insurance premium under notes payable	53,000	166,000	425,000
Receivable of proceeds for options exercised			355,000
Capitalized taxes in property, plant and equipment			(8,572,000)
Debt issued related to an investment in joint venture			$ 68,000
Purchase of property, plant and equipment via deposit	(392,000)
Interest capitalized to debt	$ 6,354,000	5,590,000
Non-cash equity investment in joint venture		$ 1,281,000

Note 1 - The Company

Note 1 - The Company	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block [Abstract]
Nature of Operations [Text Block]	1. The Company Amyris, Inc. (or the Company) was incorporated in California on July 17, 2003 and reincorporated in Delaware on June 10, 2010 for the purpose of leveraging breakthroughs in bioscience technology to develop and provide renewable compounds for a variety of markets. The Company is currently applying its industrial synthetic biology platform to engineer, manufacture and sell high performance, low cost products into a variety of consumer and industrial markets, including cosmetics, flavors & fragrances (or F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels, and it is seeking to apply its technology to the development of pharmaceutical products. The Company's first commercialization efforts have been focused on a renewable hydrocarbon molecule called farnesene (Biofene®), which forms the basis for a wide range of products including emollients, flavors and fragrance oils and diesel fuel. While the Company's platform is able to use a wide variety of feedstocks, the Company is initially focused on Brazilian sugarcane. In addition, the Company is a party to various contract manufacturing agreements to support commercial production. The Company has established two principal operating subsidiaries, Amyris Brasil Ltda. (formerly Amyris Brasil S.A., or Amyris Brasil) for production in Brazil, and Amyris Fuels, LLC (or Amyris Fuels). The Company's renewable products business strategy is to focus on direct commercialization of specialty products while moving established commodity products into joint venture arrangements with leading industry partners. To commercialize its products, the Company must be successful in using its technology to manufacture its products at commercial scale and on an economically viable basis (i.e., low per unit production costs) and developing sufficient sales volume for those products to support its operations. The Company's prospects are subject to risks, expenses and uncertainties frequently encountered by companies in this stage of development. Liquidity The Company expects to fund its operations for the foreseeable future with cash and investments currently on hand, with cash inflows from collaborations and grants, cash contributions from product sales, and with new debt and equity financings. The Company's planned 2016 and 2017 working capital needs and its planned operating and capital expenditures are dependent on significant inflows of cash from new and existing collaboration partners and from cash generated from renewable product sales, and will also require additional funding from debt or equity financings. The Company has incurred significant operating losses since its inception and believes that it will continue to incur losses and negative cash flow from operations into at least 2017. As of December 31, 2015, the Company had negative working capital of $41.1 million, an accumulated deficit of $1,037.1 million and had cash, cash equivalents and short term investments of $13.5 million. The Company needs additional financing as early as the second quarter of 2016 to support its liquidity needs. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may be unable to meet its obligations under its existing debt facilities, which could result in an acceleration of its obligation to repay all amounts outstanding under those facilities, and it may be forced to liquidate its assets. As of December 31, 2015, the Company's debt, net of discount of $48.6 million, totaled $156.0 million, of which $37.6 million is classified as current. In addition to upcoming debt maturities, the Company's debt service obligations over the next twelve months are significant, including $15.5 million of anticipated cash interest payments. The Company's debt agreements contain various covenants, including certain restrictions on the Company's business that could cause the Company to be at risk of defaults, such as the requirement to maintain unrestricted, unencumbered cash in certain U.S. bank accounts an amount equal to at least 50% of the principal amount outstanding under its loan facility with Hercules Technology Growth Capital, Inc. (Hercules). In February 2016, the Company received a waiver from Hercules with respect to non-compliance with such requirement as of December 31, 2015. A failure to comply with the covenants and other provisions of the Company’s debt instruments, including any failure to make a payment when required would generally result in events of default under such instruments, which could permit acceleration of such indebtedness. If such indebtedness is accelerated, it would generally also constitute an event of default under the Company’s other outstanding indebtedness, permitting acceleration of such other outstanding indebtedness. Any required repayment of such indebtedness as a result of acceleration or otherwise would lower current cash on hand such that the Company would not have those funds available for use in its business or for payment of other outstanding indebtedness. Please refer to Note 5, “Debt” and Note 6, “Commitments and Contingencies” for further details regarding the Company's debt service obligations and commitments. The Company also has significant outstanding debt and contractual obligations related to capital and operating leases, as well as purchase commitments. In addition to the need for financing described above, the Company may take the following actions as early as the second quarter of 2016 to support its liquidity needs through the remainder of 2016 and into 2017: • Effect significant headcount reductions, particularly with respect to employees not connected to critical or contracted activities across all functions of the Company, including employees involved in general and administrative, research and development, and production activities. • Shift focus to existing products and customers with significantly reduced investment in new product and commercial development efforts. • Reduce production activity at the Company’s Brotas manufacturing facility to levels only sufficient to satisfy volumes required for product revenues forecast from existing products and customers. • Reduce expenditures for third party contractors, including consultants, professional advisors and other vendors. • Reduce or delay uncommitted capital expenditures, including non-essential facility and lab equipment, and information technology projects. • Closely monitor the Company’s working capital position with customers and suppliers, as well as suspend operations at pilot plants and demonstration facilities. Implementing this plan could have a negative impact on the Company's ability to continue its business as currently contemplated, including, without limitation, delays or failures in its ability to: • Achieve planned production levels; • Develop and commercialize products within planned timelines or at planned scales; and • Continue other core activities. Furthermore, any inability to scale-back operations as necessary, and any unexpected liquidity needs, could create pressure to implement more severe measures. Such measures could have an adverse effect on the Company's ability to meet contractual requirements, including obligations to maintain manufacturing operations, and increase the severity of the consequences described above.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (or GAAP) and with the instructions for Form 10-K and Regulations S-X. The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method to account for investments in companies, if its investments provide it with the ability to exercise significant influence over operating and financial policies of the investee. Consolidated net income or loss includes the Company’s proportionate share of the net income or loss of these companies. Judgments made by the Company regarding the level of influence over each equity method investment include considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. Principles of Consolidation The consolidated financial statements of the Company include the accounts of Amyris, Inc., its subsidiaries and two consolidated variable interest entities (or “VIEs”), with respect to which the Company is considered the primary beneficiary, after elimination of intercompany accounts and transactions. Disclosure regarding the Company’s participation in the VIEs is included in Note 7, "Joint Ventures and Noncontrolling Interest." Variable Interest Entities The Company has interests in joint venture entities that are VIEs. Determining whether to consolidate a VIE requires judgment in assessing (i) whether an entity is a VIE and (ii) if the Company is the entity’s primary beneficiary and thus required to consolidate the entity. To determine if the Company is the primary beneficiary of a VIE, the Company evaluates whether it has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company’s evaluation includes identification of significant activities and an assessment of its ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding and financing and other applicable agreements and circumstances. The Company’s assessment of whether it is the primary beneficiary of its VIEs requires significant assumptions and judgment. Use of Estimates In preparing the consolidated financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short term investments and accounts receivable. The Company places its cash equivalents and investments (primarily certificates of deposits) with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and short-term investments. The Company performs ongoing credit evaluation of its customers, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary. Customers representing 10% or greater of accounts receivable were as follows: December 31, Customers 2015 2014 Customer H 23 % ** Customer C 26 % 19 % Customer G 10 % ** Customer I * 23 % Customer E ** 28 % * No outstanding balance ** Less than 10% Customers representing 10% or greater of revenues were as follows: Years Ended December 31, Customers 2015 2014 2013 Customer B ** ** 15 % Customer C ** 10 % 10 % Customer E 37 % 47 % 20 % Customer F ** ** 12 % Customer J 10 % ** * * Not a customer ** Less than 10% Fair Value of Financial Instruments The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not available, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments’ complexity. The carrying amounts of certain financial instruments, such as cash equivalents, short term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The fair values of the loans payable, convertible notes and credit facility are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The loans payable, convertible notes and credit facility are carried on the consolidated balance sheet on a historical cost basis, because the Company has not elected to recognize the fair value of these liabilities. However, the Remaining Notes subject to the Maturity Treatment Agreement were revalued to fair value on July 29, 2015 (see Note 5 “Debt” for details). The Company estimates the fair value of the compound embedded derivatives for the convertible promissory notes to Total Energies Nouvelles Activités USA (formerly known as Total Gas & Power USA, SAS, or Total) (refer to Note 5, "Debt" for further details) using the Monte Carlo simulation valuation model that combines expected cash outflows with market-based assumptions regarding risk-adjusted yields, stock price volatility, probability of a change of control and the trading information of the Company's common stock into which the notes are or may become convertible. The Company estimates the fair value of the compound embedded derivatives for the first and second tranches of the August 2013 Financing (or, Tranche I Notes and Tranche II Notes, respectively) and the 2014 and 2015 144A Notes (as defined in Note 5, "Debt" and collectively, Convertible Notes) using the binomial lattice model in order to estimate the fair value of the embedded derivatives. A binomial lattice model generates two probable outcomes - one up and another down - arising at each point in time, starting from the date of valuation until the maturity date. A lattice model was used to determine if the Convertible Notes would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the Convertible Notes will be converted early if the conversion value is greater than the holding value and (ii) the Convertible Notes will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the Convertible Notes are called, then the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the Convertible Notes. Using this lattice method, the Company valued the embedded derivatives using the "with-and-without method", where the fair value of the Convertible Notes including the embedded derivatives is defined as the "with", and the fair value of the Convertible Notes excluding the embedded derivatives is defined as the "without". This method estimates the fair value of the embedded derivatives by looking at the difference in the values between the Convertible Notes with the embedded derivatives and the fair value of the Convertible Notes without the embedded derivatives. The lattice model uses the stock price, conversion rate, conversion price, maturity date, risk-free interest rate, estimated stock volatility and estimated credit spread. Changes in the inputs into these valuation models have a significant impact on the estimated fair value of the embedded derivatives. For example, a decrease (increase) in the estimated credit spread for the Company results in an increase (decrease) in the estimated fair value of the embedded derivatives. Conversely, a decrease (increase) in the stock price results in a decrease (increase) in the estimated fair value of the embedded derivatives. The changes during 2015, 2014 and 2013 in the fair values of the bifurcated compound embedded derivatives are primarily related to the change in price of the Company's underlying common stock and are reflected in the consolidated statements of operations as “Gain (loss) from change in fair value of derivative instruments.” Cash and Cash Equivalents All highly liquid investments purchased with an original maturity date of 90 days or less at the date of purchase are considered to be cash equivalents. Cash and cash equivalents consist of money market funds and certificates of deposit. Short Term Investments Investments with original maturities greater than 90 days that mature less than 1 year from the consolidated balance sheet date are classified as short-term investments. The Company classifies investments as short-term or long-term based upon whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. The Company invests its excess cash balances primarily in certificates of deposit. Certificates of deposits that have maturities greater than 90 days that mature less than one year from the consolidated balance sheet date are classified as short term investments. The Company classifies all of its investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity (deficit). Debt securities are adjusted for amortization of premiums and accretion of discounts and such amortization and accretion are reported as a component of interest income. Realized gains and losses and declines in value that are considered to be other-than-temporary are recognized in the statements of operations. The cost of securities sold is determined on the specific identification method. There were no significant realized gains or losses from sales of debt securities during the years ended December 31, 2015, 2014 and 2013. As of December 31, 2015 and 2014, the Company did not have any other-than-temporary declines in the fair value of its debt securities. Accounts Receivable The Company maintains an allowance for doubtful accounts receivable for estimated losses resulting from the inability of its customers to make required payments. The Company determines this allowance based on specific doubtful account identification and management judgment on estimated exposure. The Company writes off accounts receivable against the allowance when it determines a balance is uncollectible and no longer actively pursues collection of the receivable. Inventories Inventories, which consist of farnesene-derived products and flavor and fragrances ingredients are stated at the lower of cost or market and categorized as finished goods, work-in-process or raw material inventories. The Company evaluates the recoverability of its inventories based on assumptions about expected demand and net realizable value. If the Company determines that the cost of inventories exceeds its estimated net realizable value, the Company records a write-down equal to the difference between the cost of inventories and the estimated net realizable value. If actual net realizable values are less favorable than those projected by management, additional inventory write-downs may be required that could negatively impact the Company's operating results. If actual net realizable values are more favorable, the Company may have favorable operating results when products that have been previously written down are sold in the normal course of business. The Company also evaluates the terms of its agreements with its suppliers and establishes accruals for estimated losses on adverse purchase commitments as necessary, applying the same lower of cost or market approach that is used to value inventory. Cost is computed on a first-in, first-out basis. Inventory costs include transportation costs incurred in bringing the inventory to its existing location. Investments in Affiliates We use the equity method to account for our investments in affiliates. We include our proportionate share of earnings and/or losses of our equity method investees in the loss from investments in affiliates in the consolidated statements of operations. The carrying value of our investments in affiliates includes loans to affiliates. Investments in affiliates are carried at cost less impairment, as adjusted for market rates of interest imputed to non-market interest rate loans advanced to affiliates. Restricted Cash Cash accounts that are restricted to withdrawal or usage are presented as restricted cash. As of Derivative Instruments The Company makes limited use of derivative instruments, which includes currency interest rate swap agreements, to manage the Company's exposure to foreign currency exchange rate fluctuations and interest rate fluctuations related to the Company's Banco Pine S.A. loan (discussed below under Note 5, "Debt"). Changes in the fair value of the derivative contracts are recognized immediately in the consolidated statements of operations. Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e. host) are accounted for and valued as separate financial instruments. The Company evaluated the terms and features of its convertible notes payable and identified compound embedded derivatives requiring bifurcation and accounting at fair value because the economic and contractual characteristics of the embedded derivatives met the criteria for bifurcation and separate accounting due to the conversion options containing “make-whole interest” provisions, down round conversion price adjustment provisions and conversion rate adjustments,. Property, Plant and Equipment, net Property, plant and equipment, net are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the related assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. Depreciation and amortization periods for the Company’s property, plant and equipment are as follows: Machinery and equipment (in years) 7 - 15 Buildings (in years) 15 Computers and software (in years) 3 - 5 Furniture and office equipment (in years) 5 Vehicles (in years) 5 Buildings and leasehold improvements are amortized on a straight-line basis over the terms of the lease, or the useful life of the assets, whichever is shorter. Computers and software includes internal-use software that is acquired to meet the Company’s needs. Amortization commences when the software is ready for its intended use and the amortization period is the estimated useful life of the software, generally 3 to 5 years. Capitalized costs primarily include contract labor costs of the individuals dedicated to the development and installation of internal-use software. Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable or the estimated useful life is no longer appropriate. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the assets down to their estimated fair values. Fair value is estimated based on discounted future cash flows. There were $28.5 million, $1.8 million, and $7.7 million, of impairment charges recorded during the years ended December 31, 2015, 2014 and 2013, respectively. Goodwill and Intangible Assets Goodwill represents the excess of the cost over the fair value of net assets acquired from business combinations. Intangible assets are comprised primarily of in-process research and development (or IPR&D). The goodwill and IPR&D were recognized on an acquisition completed in 2011. Goodwill and intangible assets with indefinite useful lives are assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such a review. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. The Company makes significant judgments in relation to the valuation of goodwill and intangible assets resulting from business combinations. There are several methods that can be used to determine the estimated fair value of the IPR&D acquired in a business combination. We used the "income method," which applies a probability weighting that considers the risk of development and commercialization, to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets will be amortized over the remaining useful life or written off, as appropriate. Amounts recorded as IPR&D will begin being amortized upon the completion of development activities over the estimated useful life of the technology. The development activities have not been completed, and therefore the amortization of the acquired IPR&D has not begun. Factors that could trigger an impairment review include significant under-performance relative to expected historical or projected future operating results, significant changes in the manner of use of the acquired assets or the strategy for the Company's overall business or significant negative industry or economic trends. If this evaluation indicates that the value of the intangible asset may be impaired, we make an assessment of the recoverability of the net carrying value of the asset. If this assessment indicates that the intangible asset is not recoverable, based on the estimated discounted future cash flows of the technology over its expected life, we reduce the net carrying value of the related intangible asset to fair value. As a result of the impairment assessment of IPR&D, the Company recognized an impairment of its IPR&D asset of $5.5 million and $3.0 million for the years ended December 31, 2015 and 2014, respectively, and zero for the year ended December 31 2013. As of December 31, 2015, the Company's intangible assets had a carrying amount of zero. Noncontrolling Interest Changes in noncontrolling interest ownership that do not result in a change of control and where there is a difference between fair value and carrying value are accounted for as equity transactions. In April 2010, the Company entered into a joint venture with São Martinho S.A. (or São Martinho). The carrying value of the noncontrolling interest from this joint venture is recorded in the equity section of the consolidated balance sheets (see Note 7, "Joint Ventures and Noncontrolling Interest"). In January 2011, the Company entered into a production service agreement with Glycotech, Inc. (or Glycotech). The Company has determined that the arrangement with Glycotech qualifies as a VIE. The Company determined that it is the primary beneficiary. The carrying value of the noncontrolling interest from this VIE is recorded in the equity section of the consolidated balance sheets (see Note 7, "Joint Ventures and Noncontrolling Interest"). Revenue Recognition The Company recognizes revenue from the sale of renewable products, delivery of research and development services, and from governmental grants. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and collectability is reasonably assured. If sales arrangements contain multiple elements, the Company evaluates whether the components of each arrangement represent separate units of accounting. Product Sales The Company's renewable product sales do not include rights of return. Returns are only accepted if the product does not meet product specifications and such nonconformity is communicated to the Company within a set number of days of delivery. The Company offers a two year standard warranty provision for squalane products sold after March 31, 2012, if the products do not meet Company-established criteria as set forth in the Company's trade terms. The Company bases its return reserve on a historical rate of return for the Company's squalane products. Revenues are recognized, net of discounts and allowances, once passage of title and risk of loss has occurred and contractually specified acceptance criteria have been met, provided all other revenue recognition criteria have also been met. Grants and Collaborative Revenue Revenue from collaborative research services is recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research services fluctuate over the research term, the Company recognizes revenue using the proportionate performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by the Company. When up-front payments are received and the planned levels of research services do not fluctuate over the research term, revenue is recorded on a ratable basis over the arrangement term, up to the amount of cash received. When up-front payments are received and the planned levels of research services fluctuate over the research term, revenue is recorded using the proportionate performance method, up to the amount of cash received. Where arrangements include milestones that are determined to be substantive and at risk at the inception of the arrangement, revenue is recognized upon achievement of the milestone and is limited to those amounts whereby collectability is reasonably assured. Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met and only perfunctory obligations are outstanding. Cost of Products Sold Cost of products sold includes production costs of renewable products, which include cost of raw materials, amounts paid to contract manufacturers and period costs including inventory write-downs resulting from applying lower-of-cost-or-market inventory valuation. Cost of products sold also includes certain costs related to the scale-up in production of such products. Shipping and handling costs charged to customers are recorded as revenues. Shipping costs are included in cost of products sold. Such charges were not significant in any of the periods presented. Research and Development Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements and government grants, including internal research. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to others that conduct certain research activities on the Company’s behalf. Debt Extinguishment The Company accounts for the income or loss from extinguishment of debt in accordance with ASC 470, "Debt", which indicates that for all extinguishment of debt, the difference between the reacquisition price and the net carrying amount of the debt being extinguished should be recognized as gain or loss when the debt is extinguished. The gain or loss from debt extinguishment is recorded in the consolidated statements of operations under "other income (expense)" as "gain (loss) from extinguishment of debt". Income Taxes The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized. The Company recognizes and measures uncertain tax positions in accordance with Income Taxes subtopic 05-6 of ASC 740, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken in a tax return, in the consolidated financial statements. Additionally, the guidance also prescribes treatment for the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained. Currency Translation The Company considers the local currency to be the functional currency of the Company’s wholly-owned subsidiary in Brazil and of the Company's consolidated joint venture in Brazil. Accordingly, asset and liability accounts of those operations are translated into United States dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into United States dollars using historical rates. The revenues and expenses are translated using the exchange rates in effect when the transactions occur. Gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income (loss) on the consolidated balance sheets. Foreign currency differences arising from the translation of intercompany loans from a foreign currency into the functional currency of an entity, which are of a long-term investment nature (that is, settlement is not planned or anticipated in the foreseeable future) are recorded in “Accumulated other comprehensive income (loss)” on our Consolidated Balance Sheets. Foreign currency differences arising from the translation of other intercompany loans are recorded in “Other income (expense)” on our Consolidated Statements of Operations. Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The Company uses the Black-Scholes option pricing model to estimate the fair value of options granted, which is expensed on a straight-line basis over the vesting period. The Company accounts for restricted stock unit awards issued to employees based on the fair market value of the Company’s common stock. The Company accounts for stock options issued to nonemployees based on the estimated fair value of the awards using the Black-Scholes option pricing model. The Company accounts for restricted stock units issued to nonemployees based on the fair market value of the Company’s common stock. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in the Company’s consolidated statements of operations during the period the related services are rendered. Comprehensive Income (Loss) Comprehensive income (loss) represents all changes in stockholders’ deficit except those resulting from investments or contributions by stockholders. The Company’s foreign currency translation adjustments represent the components of comprehensive income (loss) excluded from the Company’s net income (loss) and have been disclosed in the consolidated statements of comprehensive loss for all periods presented. The components of accumulated other comprehensive loss are as follows (in thousands): December 31, 2015 2014 Foreign currency translation adjustment, net of tax $ (47,198 ) $ (29,977 ) Total accumulated other comprehensive loss $ (47,198 ) $ (29,977 ) Net Loss Attributable to Common Stockholders and Net Loss per Share The Company computes net loss per share in accordance with ASC 260, “Earnings per Share.” Basic net loss per share of common stock is computed by dividing the Company’s net loss attributable to Amyris, Inc. common stockholders (as adjusted in 2015 to remove the impact of the fair value adjustments for any currently exercisable warrants in which the number of shares are included in the weighted average number of common stock outstanding) by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed by giving effect to all potentially dilutive securities, including stock options, restricted stock units and common stock warrants, using the treasury stock method or the as converted method, as applicable. For the years ended December 31, 2013 and 2015, basic net loss per share was the same as diluted net loss per share because the inclusion of all potentially dilutive securities outstanding was anti-dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss were the same for those years. The following table presents the calculation of basic and diluted net loss per share of common stock attributable to Amyris, Inc. common stockholders (in thousands, except share and per share amounts): Years Ended December 31, 2015 2014 2013 Numerator: Net income (loss) attributable to Amyris, Inc. common stockholders $ (217,952 ) $ 2,286 $ (235,111 ) Adjustment to exclude fair value gain on liability classified warrants (1) (3,825 ) — — Net income (loss) attributable to Amyris, Inc. common stockholders (for basic income (loss) per share) (221,777 ) 2,286 (235,111 ) Interest on convertible debt — 9,365 — Accretion of debt discount — 5,597 — Gain from change in fair value of derivative instruments — (127,109 ) — Net loss attributable to Amyris, Inc. common stockholders after assumed conversion $ (221,777 ) $ (109,861 ) $ (235,111 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 126,961,576 78,400,098 75,472,770 Basic income (loss) per share $ (1.75 ) $ 0.03 $ (3.12 ) Weighted average shares of common stock outstanding 126,961,576 78,400,098 75,472,770 Effect of dilutive securities: Convertible promissory notes — 43,459,343 — Weighted common stock equivalents — 43,459,343 — Diluted weighted-average common shares 126,961,576 121,859,441 75,472,770 Diluted loss per share $ (1.75 ) $ (0.90 ) $ (3.12 ) (1) The amount represents a net gain related to a change in the fair value of a liability classified

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Financial Instruments Disclosure [Text Block]	3. Fair Value of Financial Instruments The inputs to the valuation techniques used to measure fair value are classified into the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. As of December 31, 2015, the Company’s financial assets and financial liabilities are presented below at fair value and were classified within the fair value hierarchy as follows (in thousands): Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 2,078 $ — $ — $ 2,078 Certificates of deposit 1,520 — — 1,520 Total financial assets $ 3,598 $ — $ 0 $ 3,598 Financial Liabilities Loans payable (1) $ — $ 9,541 $ — $ 9,541 Credit facilities (1) — 34,893 — 34,893 Convertible notes (1) — — 96,291 96,291 Compound embedded derivative liabilities — — 46,430 46,430 Currency interest rate swap derivative liability — 5,009 — 5,009 Total financial liabilities $ — $ 49,443 $ 142,721 $ 192,164 _________ (1) The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The fair values of money market funds and certificates of deposit are based on fair values of identical assets. The fair values of the loans payable, convertible notes, credit facilities and currency interest rate swaps are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The method of determining the fair value of the compound embedded derivative liabilities is described subsequently in this note. Market risk associated with the fixed and variable rate long-term loans payable, credit facilities and convertible notes relates to the potential reduction in fair value and negative impact to future earnings, from an increase in interest rates. Market risk associated with the compound embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates. The carrying amounts of certain financial instruments, such as cash equivalents, short term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. As of December 31, 2014, the Company’s financial assets and financial liabilities are presented below at fair value and were classified within the fair value hierarchy as follows (in thousands): Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 20,160 $ — $ — $ 20,160 Certificates of deposit 1,375 — — 1,375 Loans to affiliate — — 1,745 1,745 Total financial assets $ 21,535 $ — $ 1,745 $ 23,280 Financial Liabilities Loans payable (1) $ — $ 16,720 $ — $ 16,720 Credit facilities (1) — 39,332 — 39,332 Convertible notes (1) — — 222,031 222,031 Compound embedded derivative liabilities — — 56,026 56,026 Currency interest rate swap derivative liability — 3,710 — 3,710 Total financial liabilities $ — $ 59,762 $ 278,057 $ 337,819 (1) The following table provides a reconciliation of the beginning and ending balances for the convertible notes disclosed at fair value using significant unobservable inputs (Level 3) (in thousands): 2015 2014 Balance at January 1 $ 222,031 $ 131,952 Additions to convertible notes 31,984 123,273 Conversion/extinguishment of convertible notes (127,583 ) (13,539 ) Change in fair value of convertible notes (30,141 ) (19,655 ) Balance at December 31 $ 96,291 $ 222,031 Derivative Instruments The following table provides a reconciliation of the beginning and ending balances for the compound embedded derivative liabilities measured at fair value using significant unobservable inputs (Level 3) (in thousands): 2015 2014 Balance at January 1 $ 56,026 $ 131,117 Additions to Level 3 40,359 90,174 Derecognition on conversion/extinguishment (30,806 ) (1,104 ) Gain from change in fair value of derivative liabilities (1) (19,149 ) (164,161 ) Balance at December 31 $ 46,430 $ 56,026 (1) The compound embedded derivative liabilities, represent the fair value of the equity conversion options and "make-whole" provisions, down round conversion price adjustments or conversion rate adjustments to provisions of the R&D Notes, the Tranche I Notes, the Tranche II Notes, the 2014 144A Notes and the 2015 144A Notes (see Note 5, "Debt"). There is no current observable market for these types of derivatives and, as such, the Company determined the fair value of the embedded derivatives using a Monte Carlo simulation valuation model for the R&D Notes and the binomial lattice model for the Tranche I Notes, the Tranche II Notes, the 2014 144A Notes and the 2015 144A Notes (collectively, the Convertible Notes). A Monte Carlo simulation valuation model combines expected cash outflows with market-based assumptions regarding risk-adjusted yields, stock price volatility, probability of a change of control and the trading information of the Company's common stock into which the notes are or may be convertible. A binomial lattice model generates two probable outcomes - one up and another down - arising at each point in time, starting from the date of valuation until the maturity date. A lattice model was used to determine if the Convertible Notes would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the Convertible Notes will be converted early if the conversion value is greater than the holding value and (ii) the Convertible Notes will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the Convertible Notes are called, then the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the Convertible Notes. Using this lattice method, the Company valued the embedded derivatives using the "with-and-without method", where the fair value of the Convertible Notes including the embedded derivative is defined as the "with", and the fair value of the Convertible Notes excluding the embedded derivatives is defined as the "without". This method estimates the fair value of the embedded derivatives by looking at the difference in the values between the Convertible Notes with the embedded derivatives and the fair value of the Convertible Notes without the embedded derivatives. The lattice model uses the stock price, conversion price, maturity date, risk-free interest rate, estimated stock volatility and estimated credit spread. The Company marks the compound embedded derivatives to market due to the conversion price not being indexed to the Company's own stock. Except for the "make-whole interest" provision included in the conversion option, which is only required to be settled in cash upon a change of control at the noteholder's option, the compound embedded derivatives will be settled in either cash or shares. As of December 31, 2015 and 2014, included in "Derivative Liabilities" on the consolidated balance sheet are the Company's compound embedded derivative liabilities of $46.4 million and $56.0 million, respectively. The market-based assumptions and estimates used in valuing the compound embedded derivative liabilities include amounts in the following ranges/amounts: December 31, 2015 December 31, 2014 Risk-free interest rate 1.26% - 1.40% 0.75% - 1.51% Risk-adjusted yields 35.80% - 45.93% 21.40% - 31.50% Stock-price volatility 45% 45% Probability of change in control 5% 5% Stock price $1.62 $2.06 Credit spread 34.48% - 44.55% 19.97% - 29.99% Estimated conversion dates 2016 - 2019 2017 - 2019 Changes in valuation assumptions can have a significant impact on the valuation of the embedded derivative liabilities. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. The conversion price of certain of the Convertible Notes also include conversion price adjustment features and for, example, issuances of common stock by the Company at prices lower than the conversion price result in a reset of the conversion price of certain notes, which increases the value of the embedded derivative liabilities. See Note 5, "Debt" for further details of conversion price adjustment features. In June 2012, the Company entered into a loan agreement with Banco Pine S.A. (or Banco Pine) under which Banco Pine provided the Company with a loan (or the Banco Pine Bridge Loan) (see Note 5, "Debt"). At the time of the Banco Pine Bridge Loan, the Company also entered into a currency interest rate swap arrangement with Banco Pine with respect to the repayment of R$22.0 million (approximately US$5.6 million based on the exchange rate as of December 31, 2015) of the Banco Pine Bridge Loan. The swap arrangement exchanges the principal and interest payments under the Banco Pine Bridge Loan for alternative principal and interest payments that are subject to adjustment based on fluctuations in the foreign exchange rate between the U.S. dollar and Brazilian real. The swap has a fixed interest rate of 3.94%. Changes in the fair value of the swap are recognized in “Gain (loss) from change in fair value of derivative instruments" in the consolidated statements of operations are as follows (in thousands): Income Years Ended December 31, Type of Derivative Contract Statement Classification 2015 2014 2013 Gain (Loss) Recognized Currency interest rate swap (1) Gain (loss) from change in fair value of derivative instruments $ (3,367 ) $ (480 ) $ (2,404 ) The Company granted a warrant to Temasek to purchase the Company’s common stock, (the “Temasek Funding Warrant”), as part of the Exchange transaction completed on July 29, 2015. The terms of the Temasek Funding Warrant provide for an adjustment to the number of shares issuable in the future based on the number of any additional shares for which certain other outstanding convertible promissory notes may become exercisable as a result of a reduction to the conversion price of such notes, including down-round provisions. As a result of the future adjustment feature (for reduction to the conversion price of outstanding convertible notes), the Company determined the Temasek Funding Warrant would not meet the conditions in ASC 815-40-15 to be considered indexed to the Company’s own equity. Consequently the Temasek Funding Warrant is a derivative and is marked to market each reporting period. The Temasek Funding Warrant is valued using a Black-Scholes valuation model with the following assumptions (in addition to the Company’s share price): Initial recognition Expected dividend yield 0 Risk-free interest rate 2 % Expected term (in years) 10.0 Expected volatility 74 % The Company recognized a derivative liability for the Temasek Funding Warrant of $19.4 million on July 29, 2015. On December 15, 2015, Temasek exercised the Temasek Funding Warrant for cash of $0.1 million. At the day of exercise, the Temasek Funding Warrant was valued at $18.9 million, being the fair value of the 12.7 million shares issued upon exercise of the warrant. Derivative instruments measured at fair value as of December 31, 2015 and 2014, and their classification on the consolidated balance sheets are as follows (in thousands): December 31, 2015 2014 Fair market value of swap obligation $ 5,009 $ 3,710 Fair value of compound embedded derivative liabilities 46,430 56,026 Total derivative liabilities $ 51,439 $ 59,736

Note 4 - Balance Sheet Componen

Note 4 - Balance Sheet Components	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Supplemental Balance Sheet Disclosures [Text Block]	4. Balance Sheet Components Inventories, net Inventories are stated at the lower of cost or market and consist of the following (in thousands): December 31, 2015 2014 Raw materials $ 2,204 $ 2,665 Work-in-process 3,583 5,269 Finished goods 5,099 6,572 Inventories, net $ 10,886 $ 14,506 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are comprised of the following (in thousands): December 31, 2015 2014 Maintenance $ 124 $ 399 Prepaid insurance 581 701 Manufacturing catalysts 2,698 1,166 Recoverable VAT and other taxes — 2,411 Debt issuance costs 1,357 — Other 1,112 1,857 Prepaid expenses and other current assets $ 5,872 $ 6,534 Property, Plant and Equipment, net Property, plant and equipment, net is comprised of the following (in thousands): December 31, 2015 2014 Leasehold improvements $ 38,519 $ 39,132 Machinery and equipment 72,876 90,657 Computers and software 9,117 8,946 Furniture and office equipment 2,234 2,445 Buildings 3,922 6,321 Vehicles 215 353 Construction in progress 5,736 38,815 132,619 186,669 Less: accumulated depreciation and amortization (72,822 ) (67,689 ) Property, plant and equipment, net $ 59,797 $ 118,980 The Company's first, purpose-built, large-scale Biofene production plant in southeastern Brazil commenced operations in December 2012. This plant is located at Brotas in the state of São Paulo, Brazil and is adjacent to an existing sugar and ethanol mill, Tonon Bioenergia S.A. (or “Tonon”) (formerly Paraíso Bioenergia) with which the Company has an agreement to purchase a certain number of tons of sugarcane per year, along with specified water and vapor volumes. In July 2015, the Company announced that it was in discussions with São Martinho S.A. (“SMSA”) regarding the continuation of its joint venture with SMSA. In December 2015, the Company and SMSA agreed to terminate the joint venture. Pursuant to the Termination Agreement, the Company is required to remove the existing assets of the joint venture, which are currently situated on land owned by SMSA (the “SMSA site”). As a result of the above developments, the Company recorded an impairment charge of $27.6 million (included in ‘Loss on purchase commitments, impairment of property, plant and equipment and other asset allowances’), related to the assets at the SMSA site with no alternative future use, for the year ended December 31, 2015 related to the SMSA site. The Company also recorded a $3.6 million reserve for moving and dismantling costs for the SMSA site and wrote-off $1.2 million of irrecoverable Brazilian VAT related to the assets at the SMSA site, both of which are included in 'Loss on purchase commitments, impairment of property, plant and equipment and other asset allowances'. If the Company's plans or estimate of the value of the remaining assets change, additional impairment charges may arise in future periods. Property, plant and equipment, net includes $2.7 million and $4.1 million of machinery and equipment under capital leases as of December 31, 2015 and 2014, respectively. Accumulated amortization of assets under capital leases totaled $0.5 million and $2.3 million as of December 31, 2015 and 2014, respectively. Depreciation and amortization expense, including amortization of assets under capital leases, was $12.8 million, $15.0 million and $16.6 million for the years ended December 31, 2015, 2014 and 2013, respectively. Other Assets Other assets are comprised of the following (in thousands): December 31, 2015 2014 Deposits on property and equipment, including taxes $ 243 $ 1,738 Recoverable taxes from Brazilian government entities 8,887 9,747 Debt issuance costs 2,806 851 Other 1,214 1,299 Total other assets $ 13,150 $ 13,635 Accrued and Other Current Liabilities Accrued and other current liabilities are comprised of the following (in thousands): December 31, 2015 2014 Professional services $ 4,017 $ 2,015 Accrued vacation 2,023 2,213 Payroll and related expenses 3,122 5,393 Tax-related liabilities 2,505 277 Withholding tax related to conversion of related party notes 4,723 — Deferred rent, current portion 1,111 1,111 Accrued interest 1,984 1,308 SMA relocation accrual 3,641 — Other 1,142 1,248 Total accrued and other current liabilities $ 24,268 $ 13,565

Note 5 - Debt

Note 5 - Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	5. Debt Debt is comprised of the following (in thousands): December 31, 2015 2014 FINEP credit facility $ 840 $ 1,614 BNDES credit facility 1,956 4,314 Hercules loan facility 31,653 29,779 Total credit facilities 34,449 35,707 Convertible notes 64,603 60,418 Related party convertible notes 43,029 115,239 Loans payable 13,975 21,097 Total debt 156,056 232,461 Less: current portion (37,570 ) (17,100 ) Long-term debt $ 118,486 $ 215,361 FINEP Credit Facility In November 2010, the Company entered into a credit facility with Financiadora de Estudos e Projetos (or the FINEP Credit Facility). The FINEP Credit Facility was extended to partially fund expenses related to the Company’s research and development project on sugarcane-based biodiesel (or the FINEP Project) and provides for loans of up to an aggregate principal amount of R$6.4 million (approximately US$1.6 million based on the exchange rate as of December 31, 2015) which is secured by a chattel mortgage on certain equipment of Amyris Brasil as well as by bank letters of guarantee. All available credit under this facility is fully drawn. Interest on loans drawn under the FINEP Credit Facility is fixed at 5% per annum. In case of default under or non-compliance with the terms of the agreement, the interest on loans will be dependent on the long-term interest rate as published by the Central Bank of Brazil (such rate, the TJLP). If the TJLP at the time of default is greater than 6%, then the interest will be 5% plus a TJLP adjustment factor, otherwise the interest will be at 11% per annum. In addition, a fine of up to 10% shall apply to the amount of any obligation in default. Interest on late balances will be 1% interest per month, levied on the overdue amount. Payment of the outstanding loan balance is being made in 81 monthly installments, which commenced in July 2012 and extends through March 2019. Interest on loans drawn and other charges are paid on a monthly basis and commenced in March 2011. As of December 31, 2015 and 2014, the total outstanding loan balance under this credit facility was R$3.4 million (approximately US$0.9 million based on the exchange rate as of December 31, 2015) and R$4.3 million (approximately US$1.6 million based on exchange rate as of December 31, 2014), respectively. BNDES Credit Facility In December 2011, the Company entered into a credit facility with the Brazilian Development Bank (or BNDES and such credit facility is the BNDES Credit Facility) in the amount of R$22.4 million (approximately US$5.7 million based on the exchange rate as of December 31, 2015). This BNDES Credit Facility was extended as project financing for a production site in Brazil. The credit line is divided into an initial tranche for up to approximately R$19.1 million and an additional tranche of approximately R$3.3 million that becomes available upon delivery of additional guarantees. The credit line was cancelled in 2013. The principal of the loans under the BNDES Credit Facility is required to be repaid in 60 monthly installments, with the first installment due in January 2013 and the last due in December 2017. Interest will be due initially on a quarterly basis with the first installment due in March 2012. From and after January 2013, interest payments are due on a monthly basis together with principal payments. The loaned amounts carry interest of 7% per annum. Additionally, there is a credit reserve charge of 0.1% on the unused balance from each credit installment from the day immediately after it is made available through its date of use, when it is paid. The BNDES Credit Facility is collateralized by a first priority security interest in certain of the Company's equipment and other tangible assets totaling R$24.9 million (approximately US$6.4 million based on the exchange rate as of December 31, 2015). The Company is a parent guarantor for the payment of the outstanding balance under the BNDES Credit Facility. Additionally, the Company was required to provide a bank guarantee equal to 10% of the total approved amount (R$22.4 million in total debt, approximately US$5.7 million based on the exchange rate as of December 31, 2015) available under the BNDES Credit Facility. For advances of the second tranche (above R$19.1 million, approximately US$4.9 million based on the exchange rate as of December 31, 2015), the Company is required to provide additional bank guarantees equal to 90% of each such advance, plus additional Company guarantees equal to at least 130% of such advance. The BNDES Credit Facility contains customary events of default, including payment failures, failure to satisfy other obligations under this credit facility or related documents, defaults in respect of other indebtedness, bankruptcy, insolvency and inability to pay debts when due, material judgments, and changes in control of Amyris Brasil. If any event of default occurs, BNDES may terminate its commitments and declare immediately due all borrowings under the facility. As of December 31, 2015 and 2014, the Company had R$7.6 million (approximately US$1.9 million based on the exchange rate as of December 31, 2015) and R$11.5 million (approximately US$4.3 million based on the exchange rate as of December 31, 2014), respectively, in outstanding advances under the BNDES Credit Facility. Hercules Loan Facility In March 2014, the Company entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. (or Hercules) to make available to Amyris a loan in the aggregate principal amount of up to $25.0 million (or the Hercules Loan Facility). The original Hercules Loan Facility accrues interest at a rate per annum equal to the greater of either the prime rate reported in the Wall Street Journal plus 6.25% or 9.50%. The Company may repay the loaned amounts before the maturity date (generally February 1, 2017) if it pays an additional fee of 3% of the outstanding loans (1% if after the initial twelve-month period of the loan). The Company was also required to pay a 1% facility charge at the closing of the transaction, and is required to pay a 10% end of term charge. In connection with the original Hercules Loan Facility, Amyris agreed to certain customary representations and warranties and covenants, as well as certain covenants that were subsequently amended (as described below). The total available credit of $25.0 million under this facility was fully drawn down by the Company. In June 2014, the Company and Hercules entered into a first amendment (or the "First Hercules Amendment") of the Loan and Security Agreement entered into in March 2014. Pursuant to the First Hercules Amendment, the parties agreed to adjust the term loan maturity date from May 31, 2015 to February 1, 2017 and remove (i) a requirement for the Company to pay a forbearance fee of $10.0 million in the event certain covenants were not satisfied, (ii) a covenant that the Company maintain positive cash flow commencing with the fiscal quarter beginning October 1, 2014, (iii) a covenant that, beginning with the fiscal quarter beginning July 1, 2014, the Company and its subsidiaries achieve certain projected cash product revenues and projected cash product gross profits, and (iv) an obligation for the Company to file a registration statement on Form S-3 with the SEC by no later than June 30, 2014 and complete an equity financing of more than $50.0 million by no later than September 30, 2014. The Company further agreed to include a new covenant requiring the Company to maintain unrestricted, unencumbered cash in an amount equal to at least 50% of the principal amount then outstanding under the Hercules Loan Facility and borrow an additional $5.0 million. The additional $5.0 million borrowing was completed in June 2014, and accrues interest at a rate per annum equal to the greater of either the prime rate reported in the Wall Street Journal plus 5.25% or 8.5%. The Hercules Loan Facility is secured by liens on the Company's assets, including on certain Company intellectual property. The Hercules Loan Facility includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events cross defaults and judgments, and insolvency. If an event of default occurs, Hercules may require immediate repayment of all amounts due. In March 2015, the Company and Hercules entered into a second amendment (or the “Second Hercules Amendment”) of the Hercules Loan Facility. Pursuant to the Second Hercules Amendment, the parties agreed to, among other things, establish an additional credit facility in the principal amount of up to $15.0 million, which would be available to be drawn by the Company through the earlier of March 31, 2016 or such time as the Company raised an aggregate of at least $20.0 million through the sale of new equity securities. Under the terms of the Second Hercules Amendment, the Company agreed to pay Hercules a 3.0% facility availability fee on April 1, 2015. If the facility was not canceled, and any outstanding borrowings were not repaid, before June 30, 2015, an additional 5.0% facility fee became payable on June 30, 2015. The Company did not pay the additional facility fee and thereafter received a waiver from Hercules with respect thereto. The Company had the ability to cancel the additional facility at any time prior to June 30, 2015 at its own option, and the additional facility would terminate upon the Company securing a new equity financing of at least $20.0 million. The additional facility was cancelled undrawn upon the completion of the Company’s private offering of common stock and warrants in July 2015. In November 2015, the Company and Hercules entered into a third amendment (or the “Third Hercules Amendment”) of the Hercules Loan Facility. Pursuant to the Third Hercules Amendment, the Company borrowed $10,960,000 (or the “Third Hercules Amendment Borrowed Amount”) from Hercules on November 30, 2015. As of December 1, 2015, after the funding of the Third Hercules Amendment Borrowed Amount (and including repayment of $9.1 million of principal that had occurred prior to the Third Hercules Amendment), the aggregate principal amount outstanding under the Loan Facility was approximately $31.7 million. The Third Hercules Amendment Borrowed Amount accrues interest at a rate per annum equal to the greater of (i) 9.5% and (ii) the prime rate reported in the Wall Street Journal plus 6.25%, and, like the previous loans under the Hercules Loan Facility, has a maturity date of February 1, 2017. Upon the earlier of the maturity date, prepayment in full or such obligations otherwise becoming due and payable, in addition to repaying the outstanding Third Hercules Amendment Borrowed Amount (and all amounts owed under the Original Hercules Agreement, as amended), the Company is also required to pay Hercules an end-of-term charge of $767,200. Pursuant to the Third Hercules Amendment, the Company also paid Hercules fees of $1.0 million, $750,000 of which was owed in connection with the expired $15.0 million facility under the Second Hercules Amendment and $250,000 of which was related to the Third Hercules Amendment Borrowed Amount. Under the Third Hercules Amendment, the parties agreed that the Company would, commencing on December 1, 2015, be required to pay only the interest accruing on all outstanding loans under the Loan Facility until February 29, 2016. Commencing on March 1, 2016, the Company would be required to begin repaying principal of all loans under the Loan Facility, in addition to the applicable interest. However, pursuant to the Third Hercules Amendment, the Company could, by achieving certain cash inflow targets in 2016, extend the interest-only period to December 1, 2016. If the achievement of those targets occurs after March 1, 2016, the Company could, after commencing the repayment of principal, revert to interest-only payments once the applicable target is achieved. Upon the issuance by the Company of $20.0 million of unsecured promissory notes and warrants in a private placement in February 2016 for aggregate cash proceeds of $20.0 million, the Company satisfied the conditions for extending the interest-only period to May 31, 2016. The Third Hercules Amendment Borrowed Amount is secured by the same liens provided for in the Original Hercules Agreement and the First Amendment, including a lien on certain Company intellectual property, and the preexisting covenants under the Loan Facility (including a covenant requiring the Company to maintain a minimum cash balance equal to at least 50% of the principal amount then outstanding) apply to the Loan Facility as amended. As of December 31, 2015, $31.7 million was outstanding under the Hercules Loan Facility, net of discount of $0.3 million. The Hercules Loan Facility requires the Company to maintain unrestricted, unencumbered cash in certain U.S. bank accounts in an amount equal to at least 50% of the principal amount outstanding under such facility. In February 2016, the Company received a waiver from Hercules with respect to non-compliance with such covenants as of December 31, 2015. As disclosed in footnote 1, there is substantial doubt about the Company’s ability to continue as a going concern. It is probable that the Company will breach the minimum cash covenant required by Hercules during the twelve months following the balance sheet date. Consequently all obligations under the Hercules Loan Facility agreements are classified as current liabilities at December 31, 2015. If Hercules accelerates repayment of the amounts due to it, this would trigger a cross default under other loan agreements of the Company, resulting in those amounts also falling immediately due and payable. Convertible Notes Fidelity In February 2012, the Company completed the sale of senior unsecured convertible promissory notes in an aggregate principal amount of $25.0 million pursuant to a securities purchase agreement (or the Fidelity Securities Purchase Agreement), between the Company and certain investment funds affiliated with FMR LLC. The offering consisted of the sale of 3% senior unsecured convertible promissory notes with a March 1, 2017 maturity date and an initial conversion price equal to $7.0682 per share of the Company's common stock, subject to proportional adjustment for adjustments to outstanding common stock and anti-dilution provisions in case of dividends and distributions (or the Fidelity Notes). The note holders have a right to require repayment of 101% of the principal amount of the Fidelity Notes in an acquisition of the Company, and the notes provide for payment of unpaid interest on conversion following such an acquisition if the note holders do not require such repayment. The Fidelity Securities Purchase Agreement and Fidelity Notes include covenants regarding payment of interest, maintaining the Company's listing status, limitations on debt, maintenance of corporate existence, and filing of SEC reports. The Fidelity Notes include standard events of default resulting in acceleration of indebtedness, including failure to pay, bankruptcy and insolvency, cross-defaults, material adverse effect clauses and breaches of the covenants in the Fidelity Securities Purchase Agreement and Fidelity Notes, with default interest rates and associated cure periods applicable to the covenant regarding SEC reporting. Furthermore, the Fidelity Notes include restrictions on the amount of debt the Company is permitted to incur. With exceptions for certain existing debt, refinancing of such debt and certain other exclusions and waivers, the Fidelity Notes provide that the Company's total outstanding debt at any time cannot exceed the greater of $200.0 million or 50% of its consolidated total assets and its secured debt cannot exceed the greater of $125.0 million or 30% of its consolidated total assets. In connection with the Company’s closing of a short-term bridge loan for $35.0 million in October 2013 (or the Temasek Bridge Note) and the August 2013 Financing (defined below), holders of the Fidelity Notes waived compliance with the debt limitations outlined above as to such transactions. In consideration for such waiver, the Company granted to holders of the Fidelity Notes or their affiliates, the right to purchase up to an aggregate of $7.6 million worth of convertible promissory notes in the first tranche of the August 2013 Financing. Pursuant to a Securities Purchase Agreement among the Company, Maxwell (Mauritius) Pte Ltd (or Temasek) and Total, dated as of August 8, 2013 (or the August 2013 SPA), as amended in October 2013 to include certain entities affiliated with FMR LLC (or the Fidelity Entities) the Company sold and issued certain senior convertible notes (or the Tranche I Notes) pursuant to the financing (or the August 2013 Financing) exempt from registration under the Securities Act of 1933, as amended, (or the Securities Act) with an aggregate principal amount of $7.6 million of Tranche I Notes sold to the Fidelity Entities. See "Related Party Convertible Notes" in Note 5, "Debt." 2014 Rule 144A Convertible Note Offering In May 2014, the Company entered into a Purchase Agreement with Morgan Stanley & Co. LLC, as the initial purchaser (or the “Initial Purchaser”), relating to the sale of $75.0 million aggregate in principal amount of its 6.50% Convertible Senior Notes due 2019 (or the "2014 144A Notes") to the Initial Purchaser in a private placement, and for initial resale by the Initial Purchaser to certain qualified institutional buyers (or the "2014 144A Convertible Note Offering"). In addition, the Company granted the Initial Purchaser an option to purchase up to an additional $15.0 million aggregate principal amount of 2014 144A Notes, which option expired according to its terms. Under the terms of the purchase agreement for the 2014 144A Notes, the Company agreed to customary indemnification of the Initial Purchaser against certain liabilities. The Notes were issued pursuant to an Indenture, dated as of May 29, 2014 (or the “2014 Indenture”), between the Company and Wells Fargo Bank, National Association, as trustee. The net proceeds from the offering of the 2014 144A Notes were approximately $72.0 million after payment of the Initial Purchaser’s discounts and offering expenses. In addition, in connection with obtaining a waiver from Total of its preexisting contractual right to exchange certain senior secured convertible notes previously issued by the Company for new notes issued in the offering, the Company used approximately $9.7 million of the net proceeds to repay previously issued notes (representing the amount of 2014 144A Notes purchased by Total from the Initial Purchaser). Certain of the Company's affiliated entities purchased $24.7 million in aggregate principal amount of 2014 144A Notes from the Initial Purchaser (described further below under "Related Party Convertible Notes"). The 2014 144A Notes bear interest at a rate of 6.50% per year, payable semiannually in arrears on May 15 and November 15 of each year, beginning November 15, 2014. The 2014 144A Notes mature on May 15, 2019, unless earlier converted or repurchased. The 2014 144A Notes are convertible into shares of the Company's common stock at any time prior to the close of business day on May 15, 2019. The 2014 144A Notes have an initial conversion rate of 267.037 shares of Common Stock per $1,000 principal amount of 2014 144A Notes (subject to adjustment in certain circumstances). This represents an initial effective conversion price of approximately $3.74 per share of common stock. For any conversion on or after May 15, 2015, in the event that the last reported sale price of the Company’s common stock for 20 or more trading days (whether or not consecutive) in a period of 30 consecutive trading days ending within five trading days immediately prior to the date the Company receives a notice of conversion exceeds the conversion price of $3.74 per share on each such trading day, the holders, in addition to the shares deliverable upon conversion, noteholders will be entitled to receive a cash payment equal to the present value of the remaining scheduled payments of interest that would have been made on the 2014 144A Notes being converted from the conversion date to the earlier of the date that is three years after the date the Company receives such notice of conversion and maturity (May 15, 2019), which will be computed using a discount rate of 0.75%. In the event of a fundamental change, as defined in the 2014 Indenture, holders of the 2014 144A Notes may require the Company to purchase all or a portion of the 2014 144A Notes at a price equal to 100% of the principal amount of the 2014 144A Notes, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, holders of the 2014 144A Notes who convert their 2014 144A Notes in connection with a make-whole fundamental change will, under certain circumstances, be entitled to an increase in the conversion rate. Refer to the “Exchange” and “Maturity Treatment Agreement” sections of this Note 5, "Debt", for details of the impact of the Maturity Treatment and Exchange agreements on the 2014 144A Notes. 2015 Rule 144A Convertible Note Offering On October 14, 2015, the Company entered into a purchase agreement with certain qualified institutional buyers relating to the sale of $57.6 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2019 (or the “2015 144A Notes”) to the purchasers in a private placement (or the “2015 144A Offering”). The Notes were issued pursuant to an Indenture, dated as of October 20, 2015 (or the “2015 Indenture”), between the Company and Wells Fargo Bank, National Association, as trustee. The net proceeds from the offering of the 2015 144A Notes were approximately $54.4 million after payment of the estimated offering expenses and placement agent fees. The Company used approximately $18.3 million of the net proceeds to repurchase $22.9 million aggregate principal amount of outstanding 2014 144A Notes and approximately $8.8 million to repurchase $9.7 million aggregate principal amount of outstanding Fidelity Notes, in each case held by purchasers of the 2015 144A Notes. The 2015 144A Notes bear interest at a rate of 9.50% per year, payable semiannually in arrears on April 15 and October 15 of each year, with the first such interest payment to be made on April 15, 2016. Interest may be payable, at the Company’s option, entirely in cash or entirely in common stock. The 2015 144A Notes will mature on April 15, 2019 unless earlier converted or repurchased. The 2015 144A Notes are convertible into shares of the Company's common stock at any time prior to the close of business on April 15, 2019. The 2015 144A Notes have an initial conversion rate of 443.6557 shares of Common Stock per $1,000 principal amount of 2015 144A Notes (subject to adjustment in certain circumstances). This represents an initial effective conversion price of approximately $2.25 per share of common stock. Following the issuance by the Company of warrants to purchase common stock in a private placement transaction in February 2016, as described below, the conversion rate of the 2015 144A Notes was adjusted to 445.2252 shares of Common Stock per $1,000 principal amount of 2015 144A Notes. For any conversion on or after November 27, 2015, in addition to the shares deliverable upon conversion, will be entitled to receive a payment equal to the present value of the remaining scheduled payments of interest that would have been made on the 2015 144A Notes being converted from the conversion date to the earlier of the date that is three years after the date the Company receives such notice of conversion and maturity (April 15, 2019), which will be computed using a discount rate of 0.75%. The Company may make such payment (the “Early Conversion Payment”) either in cash or in common stock, at its election, provided that it may only make such payment in common stock if such common stock is not subject to restrictions on transfer under the Securities Act by persons other than the Company’s affiliates. If the Company elects to pay an Early Conversion Payment in common stock, then the stock will be valued at 92.5% of the simple average of the daily volume-weighted average price per share for the 10 trading days ending on and including the trading day immediately preceding the conversion date. In the event of a fundamental change, as defined in the 2015 Indenture, holders of the 2015 144A Notes may require the Company to purchase all or a portion of the 2015 144A Notes at a price equal to 100% of the principal amount of the 2015 144A Notes, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, holders of the 2015 144A Notes who convert their 2015 144A Notes in connection with a make-whole fundamental change will, under certain circumstances, be entitled to an increase in the conversion rate. The issuance of shares of common stock upon conversion of the 2015 144A Notes, upon the Company’s election to pay interest on the 2015 144A Notes in shares of common stock and upon the Company’s election to pay the Early Conversion Payment in shares of common stock in an aggregate amount in excess of Related Party Convertible Notes Total R&D Convertible Notes In July 2012 and December 2013, the Company entered into a series of agreements with Total (or the "Total Fuel Agreements") that expanded Total's investment in the Biofene collaboration with the Company, provided a new structure for a joint venture (or the "Fuels JV") to commercialize the products encompassed by the diesel and jet fuel research and development program (or the "Program"), and established a convertible debt structure for the collaboration funding from Total. The purchase agreement for the notes related to the funding from Total (or the “Total Purchase Agreement”) provided for the sale of an aggregate of $105.0 million in 1.5% Senior Unsecured Convertible Notes due March 2017 (the “Unsecured R&D Notes”) as follows: • As part of an initial closing under the purchase agreement (which was completed in two installments), (i) on July 30, 2012, the Company sold an Unsecured R&D Note with a principal amount of $38.3 million, including $15.0 million in new funds and $23.3 million in previously-provided diesel research and development funding by Total, and (ii) on September 14, 2012, the Company sold another Unsecured R&D Note for $15.0 million in new funds from Total. • At a second closing under the Total Purchase Agreement (also completed in two installments) the Company sold additional Unsecured R&D Notes for an aggregate of $30.0 million in new funds from Total ($10.0 million in June 2013 and $20.0 million in July 2013). • At a third closing under the Total Purchase Agreement (also completed in two installments) the Company sold additional Unsecured R&D Notes for an aggregate of $21.7 million in new funds from Total ($10.85 million in July 2014 and $10.85 million in January 2015) (or the “Third Closing Notes”). The Unsecured R&D Notes have a maturity date of March 1, 2017, an initial conversion price equal to $7.0682 per share for the Unsecured R&D Notes issued under the initial closing, an initial conversion price equal to $3.08 per share for the Unsecured R&D Notes issued under the second closing and an initial conversion price equal to $4.11 per share for the Unsecured R&D Notes issued in the third closing. The Unsecured R&D Notes bear interest of 1.5% per annum (with a default rate of 2.5%), accruing from the date of funding and payable at maturity or on conversion or a change of control where Total exercises the right to require the Company to repay the notes. Accrued interest is partially or fully cancelled if the Unsecured R&D Notes are cancelled based on a final decision by Total to go forward with the fuels collaboration (either partially with respect to jet fuel or fully with respect to jet fuel and diesel (a “Go” decision) (see Note 8, "Significant Agreements"). The agreements contemplate that the research and development efforts under the Program may extend through 2016, with a series of “Go/No Go” decisions (see Note 8, "Significant Agreements") by Total through such date tied to funding by Total. The Unsecured R&D Notes become convertible into the Company's common stock (i) within 10 trading days prior to maturity (if they are not cancelled as described above prior to their maturity date), (ii) on a change of control of the Company, (iii) if Total is no longer the largest stockholder of the Company following a “No-Go” decision (subject to a six-month lock-up with respect to any shares of common stock issued upon conversion), and (iv) on a default by the Company. If Total makes a final “Go” decision with respect to the full fuels collaboration, then the Unsecured R&D Notes will be exchanged by Total for equity interests in the Fuels JV, after which the Unsecured R&D Notes will not be convertible and any obligation to pay principal or interest on the Unsecured R&D Notes will be extinguished. In case of a “Go” decision only with respect to jet fuel, the parties would form an operational joint venture only for jet fuel (and the rights associated with diesel would terminate), 70% of the outstanding Unsecured R&D Notes would remain outstanding and become payable by the Company, and 30% of the outstanding Unsecured R&D Notes would be cancelled. If Total makes a “No-Go” decision, outstanding Unsecured R&D Notes will remain outstanding and become payable at maturity. In March 2013, the Company entered into a letter agreement with Total (or the March 2013 Letter Agreement) under which Total agreed to waive its right to cease its participation in the parties' fuels collaboration at the July 2013 decision point and committed to proceed with the July 2013 funding tranche of $30.0 million (subject to the Company's satisfaction of the relevant closing conditions for such funding in the Total Purchase Agreement). As consideration for this waiver and commitment, the Company agreed to: • reduce the conversion price for the $30.0 million in principal amount of Unsecured R&D Notes to be issued in connection with the second closing of the Unsecured R&D Notes (as described above) from $7.0682 per share to a price per share equal to the greater of (i) the consolidated closing bid price of the Company's common stock on the date of the March 2013 Letter Agreement, plus $0.01, and (ii) $3.08 per share, provided that the conversion price would not be reduced by more than the maximum possible amount permitted under the rules of The NASDAQ Stock Market (or “NASDAQ”) such that the new conversion price would require the Company to obtain stockholder consent; and • grant Total a senior security interest in the Company's intellectual property, subject to certain exclusions and subject to release by Total when the Company and Total enter into final documentation regarding the establishment of the Fuels JV. In addition to the waiver by Total described above, Total also agreed that, at the Company's request and contingent upon the Company meeting its obligations described above, it would pay advance installments of the amounts otherwise payable at the second closing. In June 2013, the Company sold and issued $10.0 million in principal amount of Unsecured R&D Notes to Total pursuant to the second closing of the Unsecured R&D Notes as discussed above. In accordance with the March 2013 Letter Agreement, this Unsecured R&D Note had an initial conversion price equal to $3.08 per share of the Company's common stock. In July 2013, the Company sold and issued $20.0 million in principal amount of Unsecured R&D Notes to Total pursuant to the Total second closing of the Unsecured R&D Notes as discussed above. This purchase and sale completed Total's commitment to purchase $30.0 million of the Unsecured R&D Notes in the second closing by July 2013. In accordance with the March 2013 Letter Agreement, this Unsecured R&D Note has an initial conversion price equal to $3.08 per share of the Company's common stock. The conversion prices of the Unsecured R&D Notes were subject to adjustment for proportional adjustments to outstanding common stock and under anti-dilution provisions in case of certain dividends and distributions. Total had a right to require repayment of 101% of the principal amount of the Unsecured R&D Notes in the event of a change of control of the Company and the Unsecured R&D Notes provided for payment of unpaid interest on conversion following such a chang

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Commitments Contingencies and Guarantees [Text Block]	6. Commitments and Contingencies Lease Obligations The Company leases certain facilities and finances certain equipment under operating and capital leases, respectively. Operating leases include leased facilities and capital leases include leased equipment (see Note 4, "Balance Sheet Components"). The Company recognizes rent expense on a straight-line basis over the non-cancellable lease term and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Where leases contain escalation clauses, rent abatements, and/or concessions, such as rent holidays and landlord or tenant incentives or allowances, the Company applies them as straight-line rent expense over the lease term. The Company has non-cancellable operating lease agreements for office, research and development, and manufacturing space that expire at various dates, with the latest expiration in February 2031. Rent expense under operating leases was $5.5 million, $5.4 million and $4.8 million, for the years ended December 31, 2015, 2014 and 2013, respectively. In December 2011, the Company executed an equipment financing agreement for $3.0 million for certain qualifying manufacturing and laboratory equipment. Pursuant to the equipment financing agreement, the Company financed the equipment with transactions representing capital leases. This sales/leaseback transaction resulted in a $1.3 million unrealized loss which is being amortized over the life of the assets under lease. Accordingly, a capital lease liability was recorded at the present value of the future lease payments of $0.3 million and $1.2 million during the years ended December 31, 2014 and 2013, respectively. The incremental borrowing rate used to determine the present values of the future lease payments was 6.5%. The lease obligations expired on January 1, 2015. In connection with the capital lease entered into in 2011, the Company issued a warrant to purchase shares of the Company's common stock (see Note 10, "Stockholder's Equity"). In 2007, the Company entered into an operating lease for its headquarters in Emeryville, California, with a term of ten years commencing in May 2008. As part of the operating lease agreement, the Company received a tenant improvements allowance of $11.4 million. The Company recorded the allowance as deferred rent and associated expenditures as leasehold improvements that are being amortized over the shorter of their estimated useful life or the term of the lease. In connection with the operating lease, the Company elected to defer a portion of the monthly base rent due under the lease and entered into notes payable agreements with the lessor for the purchase of certain tenant improvements. In October 2010, the Company amended its lease agreement with the lessor of its headquarters, to lease up to approximately 22,000 square feet of research and development and office space. In return for the removal of the early termination clause in its amended lease agreement, the Company received approximately $1.0 million from the lessor in December 2010. In April 2013, the Company amended its lease agreement for its headquarters in Emeryville, California (or the Lease Amendment). The Lease Amendment provided for an extension of the lease term to May 2023, a modification of the base rent and elimination of the Company's loans and notes payable to the lessor of approximately $1.6 million (see Note 5, "Debt"). In addition, per the terms of the Lease Amendment, the Company also received a rent credit of approximately $71,000 per month for the period of June 2013 through December 2013 and a rent credit of approximately $42,000 per month for the full year of 2014. In March 2011, the Company entered into an operating lease on real property owned by Tonon in Brazil. In conjunction with a supply agreement (see Note 8, "Significant Agreements") with the same entity, the land is being used by the Company for its Biofene production plant in Brotas. This lease has a term of 15 years commencing in March 2011 with an estimated annual rent payment of approximately $61,463. In August 2011, the Company notified the lessor of its leased office facilities in Brazil of the Company's termination of its existing lease effective November 30, 2011. At the same time, the Company entered into an operating lease for new office facilities in Campinas, Brazil. The new lease has a term of 5 years commencing in November 2011 with an estimated annual rent payment of approximately $153,504. Future minimum payments under the Company's lease obligations as of December 31, 2015, are as follows (in thousands): Years ending December 31: Capital Operating Total Lease 2016 $ 565 $ 6,724 $ 7,289 2017 188 6,644 6,832 2018 — 6,701 6,701 2019 — 6,749 6,749 2020 — 6,985 6,985 Thereafter — 18,047 18,047 Total future minimum lease payments 753 $ 51,850 $ 52,603 Less: amount representing interest (54 ) Present value of minimum lease payments 699 Less: current portion (523 ) Long-term portion $ 176 Guarantor Arrangements The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or directors are serving in their official capacities. The indemnification period remains enforceable for the officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of December 31, 2015 and 2014. The Company entered into the FINEP Credit Facility to finance a research and development project on sugarcane-based biodiesel (see Note 5, "Debt"). The FINEP Credit Facility is guaranteed by a chattel mortgage on certain equipment of the Company. The Company's total acquisition cost for the equipment under this guarantee is approximately R$6.0 million (approximately US$1.5 million based on the exchange rate as of December 31, 2015). The Company entered into the BNDES Credit Facility to finance a production site in Brazil (see Note 5, "Debt").The BNDES Credit Facility is collateralized by a first priority security interest in certain of the Company's equipment and other tangible assets with a total acquisition cost of R$24.9 million (approximately US$6.4 million based on the exchange rate as of December 31, 2015). The Company is a parent guarantor for the payment of the outstanding balance under the BNDES Credit Facility. Additionally, the Company is required to provide certain bank guarantees under the BNDES Credit Facility. Accordingly, the Company had zero and $0.6 million restricted cash as of December 31, 2015 and 2014, respectively. The Company entered into loan agreements and security agreement where the Company pledged certain farnesene production assets as collateral (the fiduciary conveyance of movable goods) with each of Nossa Caixa and Banco Pine (see Note 5, "Debt"). The Company's total acquisition cost for the farnesene production assets pledged as collateral under these agreements is approximately R$68.0 million (approximately US$17.4 million based on the exchange rate as of December 31, 2015). The Company is also a parent guarantor for the payment of the outstanding balance under these loan agreements. The Company had an export financing agreement with ABC for approximately $2.2 million for a one-year term to fund exports through March 2015. As of December 31, 2015, the loan was fully paid. On April 8, 2015, the Company entered into another export financing agreement with the same bank for approximately $1.6 million for a one year term to fund exports through March 2016. This loan is collateralized by future exports from Amyris Brasil. The Company is also a parent guarantor for the payment of the outstanding balance under these loan agreements. In October 2013, the Company entered into a letter agreement with Total relating to the Temasek Bridge Note and to the closing of the August 2013 Financing (or the "Amendment Agreement") (see Note 5, "Debt"). In the August 2013 Financing, the Company was required to provide the purchasers under the August 2013 SPA with a security interest in the Company’s intellectual property if Total still held such security interest as of the initial closing of the August 2013 Financing. Under the terms of a previous Intellectual Property Security Agreement by and between the Company and Total (or the "Security Agreement"), the Company had previously granted a security interest in favor of Total to secure the obligations of the Company under the R&D Notes issued and issuable to Total under the Total Purchase Agreement. The Security Agreement provided that such security interest would terminate if Total and the Company entered into certain agreements relating to the formation of the Fuels JV. In connection with Total’s agreement to (i) permit the Company to grant the security interest under the Temasek Bridge Note and the August 2013 Financing and (ii) waive a secured debt limitation contained in the outstanding R&D Notes issued pursuant to the Total Purchase Agreement and held by Total, the Company entered into the Amendment Agreement. Under the Amendment Agreement, the Company agreed to reduce, effective December 2, 2013, the conversion price for the R&D Notes issued in 2012 (approximately $5.0 million of which are outstanding as of the date hereof) from $7.0682 per share to $2.20, the market price per share of the Company’s common stock as of the signing of the Amendment Agreement, as determined in accordance with applicable NASDAQ rules, unless the Company and Total entered into the JV Documents on or prior to December 2, 2013. The Company and Total entered into the JV agreements on December 2, 2013 and the Amendment Agreement and all security interests thereunder were automatically terminated and the conversion price of such R&D Notes remained at $7.0682 per share. In December 2013, in connection with the execution of JV Documents entered into by and among Amyris, Total and TAB relating to the establishment of TAB (see Note 5, "Debt" and Note 7, "Joint Venture and Noncontrolling Interests"), the Company agreed to exchange the $69.0 million outstanding R&D Notes issued pursuant to the Total Purchase Agreement and issue replacement 1.5% Senior Secured Convertible Notes due March 2017, in principal amounts equal to the principal amount of each R&D Note and grant a security interest to Total in and lien on all the Company’s rights, title and interest in and to the Company’s shares in the capital of TAB. Following execution of the JV Documents, all Unsecured R&D Notes that had been issued were exchanged for Secured R&D Notes. Further, the $10.85 million in principal amount of such notes issued in the initial tranche of the third closing under the Total Purchase Agreement in July 2014 and the $10.85 million in principal amount of such notes issued in the second tranche of the third closing were Secured R&D Notes instead of Unsecured R&D Notes. "See Note 5,"Debt" for the impact of the Exchange and Maturity Treatment Agreement on the R&D Notes. The Hercules Loan Facility (see Note 5, "Debt") is collateralized by liens on the Company's assets, including certain Company intellectual property. Purchase Obligations As of December 31, 2015, the Company had $1.3 million in purchase obligations which included $0.5 million in non-cancellable contractual obligations and construction commitments. Other Matters Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but will only be recorded when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed. The Company has levied indirect taxes on sugarcane-based biodiesel sales by Amyris Brasil to customers in Brasil based on advice from external legal counsel. In the absence of definitive rulings from the Brazilian tax authorities on the appropriate indirect tax rate to be applied to such product sales, the actual indirect rate to be applied to such sales could differ from the rate we levied. The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may arise in the ordinary course of business are subject to many uncertainties and outcomes are not predictable with reasonable assurance and therefore an estimate of all the reasonably possible losses cannot be determined at this time. Therefore, if one or more of these legal disputes or claims resulted in settlements or legal proceedings that were resolved against the Company for amounts in excess of management’s expectations, the Company’s consolidated financial statements for the relevant reporting period could be materially adversely affected.

Note 7 - Joint Ventures and Non

Note 7 - Joint Ventures and Noncontrolling Interest	12 Months Ended
	Dec. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	7. Joint Ventures and Noncontrolling Interest Novvi LLC In September 2011, the Company and Cosan US, Inc. (or “Cosan U.S.”) formed Novvi LLC (or “Novvi”), a U.S. entity that is jointly owned by the Company and Cosan U.S.. In March 2013, the Company and Cosan U.S. entered into agreements to (i) expand their base oils joint venture to also include additives and lubricants and (ii) operate their joint venture exclusively through Novvi. Specifically, the parties entered into an Amended and Restated Operating Agreement for Novvi (or the “Operating Agreement”), which sets forth the governance procedures for Novvi and the parties' initial contribution. The Company also entered into an IP License Agreement with Novvi (or, as amended, the “IP License Agreement”) under which the Company granted Novvi (i) an exclusive (subject to certain limited exceptions for the Company), worldwide, royalty-free license to develop, produce and commercialize base oils, additives, and lubricants derived from Biofene for use in automotive and industrial lubricants markets, and (ii) a non-exclusive, royalty free license, subject to certain conditions, to manufacture Biofene solely for its own products. In addition, both the Company and Cosan U.S. granted Novvi certain rights of first refusal with respect to alternative base oil and additive technologies that may be acquired by the Company or Cosan U.S. during the term of the IP License Agreement. Under these agreements, the Company and Cosan U.S. each own 50% of Novvi and each party shares equally in any costs and any profits ultimately realized by the joint venture. Novvi is governed by a six member Board of Managers (or the “Board of Managers”), with three managers represented by each investor. The Board of Managers appoints the officers of Novvi, who are responsible for carrying out the daily operating activities of Novvi as directed by the Board of Managers. The IP License Agreement has an initial term of 20 years from the date of the agreement, subject to standard early termination provisions such as uncured material breach or a party's insolvency. Under the terms of the Operating Agreement, Cosan U.S. was obligated to fund its 50% ownership share of Novvi in cash in the amount of $10.0 million and the Company was obligated to fund its 50% ownership share of Novvi through the granting of an IP License to develop, produce and commercialize base oils, additives, and lubricants derived from Biofene for use in the automotive, commercial and industrial lubricants markets, which Cosan U.S. and Amyris agreed was valued at $10.0 million. In March 2013, the Company measured its initial contribution of intellectual property to Novvi at the Company's carrying value of the licenses granted under the IP License Agreement, which was zero. Additional funding requirements to finance the ongoing operations of Novvi are expected to happen through revolving credit or other loan facilities provided by unrelated parties (i.e., such as financial institutions); cash advances or other credit or loan facilities provided by the Company and Cosan U.S. or their affiliates; or additional capital contributions by the Company and Cosan U.S. In April 2014, the Company purchased additional membership units of Novvi for an aggregate purchase price of $0.2 million. Also in April 2014, the Company contributed $2.1 million in cash in exchange for receiving additional membership units in Novvi. Each member owns 50% of Novvi's issued and outstanding membership units. In September 2014, the Company and Cosan U.S. entered into a member senior loan agreement to grant Novvi a loan amounting to approximately $3.7 million. The loan is due on September 1, 2017 and bears interest at a rate of 0.36% per annum. Interest accrues daily and is due and payable in arrears on September 1, 2017. The Company and Cosan U.S. each agreed to provide 50% of the loan. The Company's share of approximately $1.8 million was disbursed in two installments. The first installment of $1.2 million was made in September 2014 and the second installment of $0.6 million was made in October 2014. In November 2014, the Company and Cosan U.S. entered into a second member senior loan agreement to grant Novvi a loan of approximately $1.9 million on the same terms as the loan issued in September 2014. The Company and Cosan U.S. each agreed to provide 50% of the loan. The Company disbursed its share of approximately $1.0 million in November 2014. In May 2015, the Company and Cosan U.S. entered into a third member senior loan agreement to grant Novvi a loan of approximately $1.1 million on the same terms as the loan issued in September 2014, except that the due date is May 14, 2018. As of December 31, 2015 and 2014, total loans to Novvi were $2.7 million and $1.7 million, respectively, net of imputation of interest of $1.6 million and $1.0 million, respectively, as result of the below market interest rate on the loans. In the fourth quarter of 2015, the Company and Cosan U.S. entered into several senior loan agreements to grant Novvi a loan of approximately $1.6 million on the same terms as the loan issued in September 2014, except that the due date is August 19, 2018. In December, 2015, the Company determined that the investments in Novvi to date are not expected to be recoverable because the decline in oil prices and the prolonged delays in Novvi raising external finance for its commercial scale plant have adversely impacted the prospects for the business. Consequently, an impairment charge of $1.7 million was recognized in the fourth quarter of 2015. The Company also recorded an allowance of $0.5 million related to various receivables due from Novvi. The following table is a reconciliation of our equity and loans in Novvi: December 31, (In thousands) 2015 2014 Balance at January 1 $ 2,192 $ — Loans to affiliate 1,579 1,745 Capital contribution (cash) — 2,312 Share in net loss offset to equity investment (848 ) (2,910 ) Share in net loss offset to loans to affiliate (1,743 ) — Accretion of imputed interest 413 1,045 Impairment (1,593 ) — Balance at December 31 $ — $ 2,192 The Company has identified Novvi as a VIE and determined that the power to direct activities, which most significantly impact the economic success of the joint venture (i.e., continuing research and development, marketing, sales, distribution and manufacturing of Novvi products), is equally shared between the Company and Cosan U.S. Accordingly, the Company is not the primary beneficiary and therefore accounts for its investment in Novvi under the equity method of accounting. The Company will continue to reassess its primary beneficiary analysis of Novvi if there are changes in events and circumstances impacting the power to direct activities that most significantly affect Novvi's economic success. Under the equity method, the Company's share of profits and losses and impairment charges on investments in affiliates are included in “Loss from investments in affiliates” in the consolidated statements of operations. The Company recorded $2.6 million and $2.9 million for its share of Novvi's net loss for the years ended December 31, 2015 and 2014, respectively, and an impairment charge of $1.6 million for the year ended December 31, 2015. The carrying amount of the Company's equity investment in Novvi was zero and $2.2 million as of December 30, 2015 and 2014, respectively. Total Amyris BioSolutions B.V. In November 2013, the Company and Total formed TAB. As of December 31, 2015, the common equity of TAB was jointly owned (50%/50%) by the Company and Total, and the preferred equity of TAB was 100% owned by the Company. Prior to the restructuring of TAB in March 2016 as described below, TAB’s purpose was limited to executing the License Agreement dated December 2, 2013 between the Company, Total and TAB and maintaining such licenses under it, unless and until either (i) Total elects to go forward with either the full (diesel and jet fuel) TAB commercialization program or the jet fuel component of the TAB commercialization program (or a “Go Decision”), (ii) Total elects to not continue its participation in the R&D Program and TAB (or a “No-Go Decision”), or (iii) Total exercises any of its rights to buy out the Company’s interest in TAB. Following a Go Decision, the articles and shareholders’ agreement of TAB would be amended and restated to be consistent with the shareholders’ agreement contemplated by the Total Fuel Agreements (see Note 5, "Debt", Note 8, "Significant Agreements" and Note 16, “Subsequent Events”). TAB has an initial capitalization of €0.1 million (approximately US$0.1 million based on the exchange rate as of December 31, 2015). The Company has identified TAB as a VIE and determined that the Company is not the primary beneficiary and therefore accounts for its investment in TAB under the equity method of accounting. Under the equity method, the Company's share of profits and losses are included in “Loss from investment in affiliate” in the consolidated statements of operations. In July 2015, the Company and Total entered into a Letter Agreement (or, as amended in February 2016, the “JVCO Letter Agreement”) regarding the restructuring of the ownership and rights of TAB (or the “Restructuring”), pursuant to which the parties agreed to enter into an Amended & Restated Jet Fuel License Agreement between the Company and TAB (or the “Jet Fuel Agreement”), a License Agreement regarding Diesel Fuel in the European Union (or the “EU”) between the Company and Total (or the “EU Diesel Fuel Agreement”, and together with the Jet Fuel Agreement, the “Commercial Agreements”), and an Amended and Restated Shareholders’ Agreement among the Company, Total and TAB (or, together with the Commercial Agreements, the “Restructuring Agreements”), and file a Deed of Amendment of Articles of Association of TAB, all in order to reflect certain changes to the ownership structure of TAB and license grants and related rights pertaining to TAB Additionally, in connection with the proposed Restructuring, in July 2015 the Company and Total entered into Amendment #1 (or the "Pilot Plant Agreement Amendment") to that certain Pilot Plant Services Agreement dated as of April 4, 2014 (or, as amended, the "Pilot Plant Agreement") whereby the Company and Total agreed to restructure the payment obligations of Total under the Pilot Plant Agreement. Under the original Pilot Plant Agreement, for a five year period, the Company is providing certain fermentation and downstream separations scale-up services and training to Total and receives an aggregate annual fee payable by Total for all services in the amount of up to approximately $900,000 per annum. Such annual fee is due in three equal installments payable on March 1, July 1 and November 1 each year during the term of the Pilot Plant Agreement. Under the Pilot Plant Agreement Amendment, in connection with the restructuring of TAB discussed above, the Company agreed to waive a portion of these fees up to approximately $2.0 million, over the term of the Pilot Plant Agreement. On March 21, 2016, the Company, Total and TAB closed the Restructuring and entered into the Restructuring Agreements. Under the Jet Fuel Agreement, (a) the Company granted exclusive (excluding its Brazil jet fuel business), world-wide, royalty-free rights to TAB for the production and commercialization of farnesene- or farnesane-based jet fuel, (b) the Company granted TAB the option, until March 1, 2018, to purchase the Company’s Brazil jet fuel business at a price based on the fair value of the commercial assets and on the Company’s investment in other related assets, (c) the Company granted TAB the right to purchase farnesene or farnesane for its jet fuel business from the Company on a “most-favored” pricing basis and (d) all rights to farnesene- or farnesane-based diesel fuel previously granted to TAB by the Company reverted back to the Company. Upon all farnesene- or farnesane-based diesel fuel rights reverting back to the Company, the Company granted to Total, pursuant to the EU Diesel Fuel Agreement, (a) an exclusive, royalty-free license to offer for sale and sell farnesene- or farnesane-based diesel fuel in the EU, (b) the right to make farnesene or farnesane anywhere in the world, provided Total must (i) use such farnesene or farnesane to produce diesel fuel to offer for sale or sell in the EU and (ii) pay the Company a to-be-negotiated, commercially reasonable, “most-favored” basis royalty and (c) the right to purchase farnesene or farnesane for its EU diesel fuel business from the Company on a “most-favored” pricing basis. In addition, as part of the closing of the Restructuring and pursuant the JVCO Letter Agreement, on March 21, 2016, the Company sold to Total one half of the Company’s ownership stake in TAB (giving Total an aggregate ownership stake of 75% of TAB and giving the Company an aggregate ownership stake of 25% of TAB) in exchange for Total cancelling (i) approximately $1.3 million of R&D Notes, plus all paid-in-kind and accrued interest under all outstanding R&D Notes (including all such interest that was outstanding as of July 29, 2015) and (ii) a note in the principal amount of Euro 50,000, plus accrued interest, issued to Total in connection with the original TAB capitalization. To satisfy its purchase obligation above, Total surrendered to the Company the remaining R&D Note of approximately $5 million in principal amount, and the Company executed and delivered to Total a new, senior convertible note, containing substantially similar terms and conditions other than it is unsecured and its payment terms are severed from TAB’s business performance, in the principal amount of $3.7 million. As a result of, and in order to reflect, the changes to the ownership structure of TAB described above, on March 21, 2016, (a) the Company, Total and TAB entered into an Amended and Restated Shareholders’ Agreement and filed a Deed of Amendment of Articles of Association of TAB and (b) the Company and Total terminated the Amended and Restated Master Framework Agreement, dated December 2, 2013 and amended on April 1, 2015, between the Company and Total. SMA Indústria Química S.A. In April 2010, the Company established SMA Indústria Química (or "SMA"), a joint venture with São Martinho S.A. (or "SMSA"), to build a production facility in Brazil. SMA is located at the SMSA mill in Pradópolis, São Paulo state. The joint venture agreements establishing SMA have a 20 year initial term. SMA was initially managed by a three member executive committee, of which the Company appointed two members, one of whom is the plant manager who is the most senior executive responsible for managing the construction and operation of the facility. SMA was initially governed by a four member board of directors, of which the Company and SMSA each appointed two members. The board of directors had certain protective rights which include final approval of the engineering designs and project work plan developed and recommended by the executive committee. The joint venture agreements required the Company to fund the construction costs of the new facility and SMSA would reimburse the Company up to R$61.8 million (approximately US$15.8 million based on the exchange rate as of December 31, 2015) of the construction costs after SMA commences production. After commercialization, the Company would market and distribute Amyris renewable products produced by SMA and SMSA would sell feedstock and provide certain other services to SMA. The cost of the feedstock to SMA would be a price that is based on the average return that SMSA could receive from the production of its current products, sugar and ethanol. The Company would be required to purchase the output of SMA for the first four years at a price that guarantees the return of SMSA’s investment plus a fixed interest rate. After this four year period, the price would be set to guarantee a break-even price to SMA plus an agreed upon return. Under the terms of the joint venture agreements, if the Company became controlled, directly or indirectly, by a competitor of SMSA, then SMSA would have the right to acquire the Company’s interest in SMA. If SMSA became controlled, directly or indirectly, by a competitor of the Company, then the Company would have the right to sell its interest in SMA to SMSA. In either case, the purchase price would be determined in accordance with the joint venture agreements, and the Company would continue to have the obligation to acquire products produced by SMA for the remainder of the term of the supply agreement then in effect even though the Company would no longer be involved in SMA’s management. The Company initially had a 50% ownership interest in SMA. The Company has identified SMA as a VIE pursuant to the accounting guidance for consolidating VIEs because the amount of total equity investment at risk is not sufficient to permit SMA to finance its activities without additional subordinated financial support, as well as because the related commercialization agreement provides a substantive minimum price guarantee. Under the terms of the joint venture agreement, the Company directed the design and construction activities, as well as production and distribution. In addition, the Company had the obligation to fund the design and construction activities until commercialization was achieved. Subsequent to the construction phase, both parties equally would fund SMA for the term of the joint venture. Based on those factors, the Company was determined to have the power to direct the activities that most significantly impact SMA’s economic performance and the obligation to absorb losses and the right to receive benefits. Accordingly, the financial results of SMA are included in the Company’s consolidated financial statements and amounts pertaining to SMSA’s interest in SMA are reported as noncontrolling interests in subsidiaries. The Company completed a significant portion of the construction of the new facility in 2012. The Company suspended construction of the facility in 2013 in order to focus on completing and operating the Company's smaller production facility in Brotas, Brazil. In February 2014, the Company entered into an amendment to the joint venture agreement with SMSA which updated and documented certain preexisting business plan requirements related to the recommencement of construction at the joint venture operated plant and sets forth, among other things, (i) the extension of the deadline for the commencement of operations at the joint venture operated plant to no later than 18 months following the construction of the plant no later than March 31, 2017, and (ii) the extension of an option held by SMSA to build a second large-scale farnesene production facility to no later than December 31, 2018 with the commencement of operations at such second facility to occur no later than April 1, 2019. On July 1, 2015 SMSA filed a material fact document with CVM, the Brazilian securities regulator, that announced that certain contractual targets undertaken by the Company have not been achieved, which affects the feasibility of the project. Therefore, SMSA decided not to approve continuing construction of the plant for the joint venture with the Company and its Brazilian subsidiary Amyris Brasil Ltda. (“AB”). In July 2015, the Company announced that it was in discussions with SMSA regarding the continuation of the joint venture. In December 2015, the Company and SMSA entered into a Termination Agreement and a Share Purchase and Sale Agreement (SPA) relating to the termination of the joint venture. Under the Termination Agreement, the parties agreed that the joint venture would be terminated effective upon the closing of a purchase by AB of SMSA’s shares of SMA. Under the SPA, AB agreed to purchase, for R$50,000 (approximately US$12,805 based on the exchange rate as of December 31, 2015), 50,000 shares of SMA (representing all the outstanding shares of SMA held by SMSA), which purchase and sale was consummated on January 11, 2016. The Share Purchase and Sale Agreement also provides that Amyris and AB will have 12 months following the closing of the share purchase to remove assets from SMSA’s site, and enter into an extension of the lease for such 12 month period for monthly rental payments of R$9,853 (approximately US$2,523 based on the exchange rate as of December 31, 2015). The SPA also clarified that the Company and AB would not be required to demolish or remove the foundations of the plant at the SMSA site. Refer to Note 4 “Balance Sheet Components” for details of the impact of these developments. Glycotech In January 2011, the Company entered into a production service agreement (or the "Glycotech Agreement") with Glycotech, Inc. (or "Glycotech"), under which Glycotech provides process development and production services for the manufacturing of various Company products at its leased facility in Leland, North Carolina. The Company products manufactured by Glycotech are owned and distributed by the Company. Pursuant to the terms of the Glycotech Agreement, the Company is required to pay the manufacturing and operating costs of the Glycotech facility, which is dedicated solely to the manufacture of Amyris products. The initial term of the Glycotech Agreement was for a two year period commencing on February 1, 2011 and the Glycotech Agreement renews automatically for successive one-year terms, unless terminated by the Company. Concurrent with the Glycotech Agreement, the Company also entered into a Right of First Refusal Agreement with the lessor of the facility and site leased by Glycotech (or the "ROFR Agreement"). Per conditions of the ROFR Agreement, the lessor agreed not to sell the facility and site leased by Glycotech during the term of the Glycotech Agreement. In the event that the lessor is presented with an offer to sell or decides to sell an adjacent parcel, the Company has the right of first refusal to acquire it. The Company has determined that the arrangement with Glycotech qualifies as a VIE. The Company determined that it is the primary beneficiary of this arrangement since it has the power through the management committee over which it has majority control to direct the activities that most significantly impact Glycotech's economic performance. In addition, the Company is required to fund 100% of Glycotech's actual operating costs for providing services each month while the facility is in operation under the Glycotech Agreement. Accordingly, the Company consolidates the financial results of Glycotech. As of December 31, 2015 and 2014, the carrying amounts of Glycotech's assets and liabilities were not material to the Company's consolidated financial statements. The table below reflects the carrying amount of the assets and liabilities of the two consolidated VIEs for which the Company is the primary beneficiary. As of December 31, 2015, the assets include $5.2 million in property, plant and equipment, $0.3 million in other assets and $1.5 million in current assets. The liabilities include $1.1 million in accounts payable and accrued current liabilities and $0.1 million in loan obligations by Glycotech to its shareholders that are non-recourse to the Company. The creditors of each consolidated VIE have recourse only to the assets of that VIE. December 31, (In thousands) 2015 2014 Assets * $ 6,993 $ 22,812 Liabilities $ 1,221 $ 290 *Net of impairment at December 31, 2015 of $28.5 million related to SMA assets (see Note 4 “Balance Sheet Components” for details). The change in noncontrolling interest for the years ended December 31, 2015 and 2014 is summarized below (in thousands): 2015 2014 Balance at January 1 $ 611 $ 584 Foreign currency translation adjustment (320 ) (92 ) Income attributable to noncontrolling interest 100 119 Balance at December 31 $ 391 $ 611

Note 8 - Significant Agreements

Note 8 - Significant Agreements	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	8. Significant Agreements Research and Development Activities Total Collaboration Agreement In June 2010, the Company entered into a technology license, development, research and collaboration agreement (or the “Collaboration Agreement”) with Total Gas & Power USA Biotech, Inc., an affiliate of Total. This agreement provided for joint collaboration on the development of products through the use of the Company’s synthetic biology platform. In November 2011, the Company entered into an amendment of the Collaboration Agreement with respect to development and commercialization of Biofene for fuels. This represented an expansion of the initial collaboration with Total, and established a global, exclusive collaboration for the development of Biofene for fuels and a framework for the creation of a joint venture to manufacture and commercialize Biofene for diesel. In addition, a limited number of other potential products were subject to development by the joint venture on a non-exclusive basis. The Amendment provided for an exclusive strategic collaboration for the development of renewable diesel products and contemplated that the parties would establish a joint venture (or the “JV”) for the production and commercialization of such renewable diesel products on an exclusive, worldwide basis. In addition, the Amendment contemplated providing the JV with the right to produce and commercialize certain other chemical products on a non-exclusive basis. The amendment further provided that definitive agreements to form the JV had to be in place by March 31, 2012 or such other date as agreed to by the parties or the renewable diesel program, including any further collaboration payments by Total related to the renewable diesel program, would terminate. In the second quarter of 2012, the parties extended the deadline to June 30, 2012, and, through June 30, 2012, the parties were engaged in discussions regarding the structure of future payments related to the program, until the amendment was superseded by a further amendment in July 2012 (as further described below). Pursuant to the Amendment, Total agreed to fund the following amounts: (i) the first $30.0 million in research and development costs related to the renewable diesel program incurred since August 1, 2011, which amount would be in addition to the $50.0 million in research and development funding contemplated by the Collaboration Agreement, and (ii) for any research and development costs incurred following the JV formation date that were not covered by the initial $30.0 million, an additional $10.0 million in 2012 and up to an additional $10.0 million in 2013, which amounts would be considered part of the $50.0 million contemplated by the Collaboration Agreement. In addition to these payments, Total further agreed to fund 50% of all remaining research and development costs for the renewable diesel program under the Amendment. In July 2012, the Company entered into a further amendment of the Collaboration Agreement that expanded Total’s investment in the Biofene collaboration, incorporated the development of certain JV products for use in diesel and jet fuel into the scope of the collaboration, and changed the structure of the funding from Total for the collaboration by establishing a convertible debt structure for the collaboration funding (see Note 5, “Debt”). In connection with such additional amendment Total and the Company also executed certain other related agreements. Under these agreements (collectively referred to as the “Total Fuel Agreements”), the parties would grant exclusive manufacturing and commercial licenses to the JV for the JV products (diesel and jet fuel from Biofene) when the JV was formed. The licenses to the JV were to be consistent with the principle that development, production and commercialization of the JV products in Brazil would remain with Amyris unless Total elected, after formation of the operational JV, to have such business contributed to the joint venture (see below for additional detail). Further, as part of the Total Fuel Agreements, Total's royalty option contingency related to diesel was removed and the jet fuel collaboration was combined with the expanded Biofene collaboration. As a result, $46.5 million of payments previously received from Total that had been recorded as an advance from Total were no longer contingently repayable. Of this amount, $23.3 million was treated as a repayment by the Company and included as part of the senior unsecured convertible promissory note issued to Total in July 2012 and the remaining $23.2 million was recorded as a contract to perform research and development services, which was offset by the reduction of the capitalized deferred charge asset of $14.4 million resulting in the Company recording revenue from a related party of $8.9 million in 2012. See Note 5, "Debt" for details of the Exchange and Maturity Treatment Agreements and Note 7," Joint Ventures and Noncontrolling Interest" and Note 16 “Subsequent Events” for further details of the relationship with Total. F&F Collaboration Partner Master Collaboration and Joint Development Agreement In November 2010, the Company entered into a Master Collaboration and Joint Development Agreement with a collaboration partner. Under the agreement, the collaboration partner was to fund technical development at the Company to produce an ingredient for the flavors and fragrances market. The Company agreed to manufacture the ingredient and the collaboration partner would market it, and the parties would share in any resulting economic value. The agreement also grants exclusive worldwide flavors and fragrances commercialization rights to the collaboration partner for the ingredient. Under further agreements, the collaboration partner has an option to collaborate with the Company to develop additional ingredients. These agreements continue in effect until the later of the expiration or termination of the development agreements or the supply agreements. The Company is also eligible to receive potential total payments of $6.0 million upon the achievement of certain performance milestones towards which the Company will be required to make a contributory performance. The Company concluded that these milestone payments were substantive. All performance milestones under this agreement were achieved in 2013. In March 2013, the Company entered into a Master Collaboration Agreement (or the “March 2013 Agreement”) with the collaboration partner to establish a collaboration arrangement for the development and commercialization of multiple renewable flavors and fragrances compounds. Under this agreement, except for rights granted under preexisting collaboration relationships, the Company granted the collaboration partner exclusive access for such compounds to specified Company intellectual property for the development and commercialization of flavors and fragrances products in exchange for research and development funding and a profit sharing arrangement. The agreement superseded and expanded the prior collaboration agreement between the Company and the collaboration partner. The agreement provided for annual, up-front funding to the Company by the collaboration partner of $10.0 million for each of the first three years of the collaboration. Payments of $10.0 million were received by the Company in each of March 2015, 2014 and 2013. The Company recognized collaboration revenues under the March 2013 Agreement with the collaboration partner of $11.0 million and $10.0 million for the year ended December 31, 2015 and 2014, respectively. The agreement contemplated additional funding by the collaboration partner of up to $5.0 million under three potential milestone payments, as well as additional funding by the collaboration partner on a discretionary basis. Through 2015, the Company achieved the second performance milestone under the Master Collaboration Agreement and recognized collaboration revenues of $1.0 million for the year ended December 31, 2015. In addition, the March 2013 Agreement contemplated that the parties will mutually agree on a supply price for each compound and share product margins from sales of each compound on a 70/30 basis (70% for the collaboration partner) until the collaboration partner receives $15.0 million more than the Company in the aggregate, after which the parties will share 50/50 in the product margins on all compounds. The Company also agreed to pay a one-time success bonus of up to $2.5 million to the collaboration partner's for outperforming certain commercialization targets. The collaboration partner eligibility to receive the one-time success bonus commences upon the first sale of the collaboration partner's product. The March 2013 Agreement does not impose any specific research and development commitments on either party after year six, but if the parties mutually agree to perform development after year six, the agreement provides that the parties will fund it equally. Under the March 2013 Agreement, the parties agreed to jointly select target compounds, subject to final approval of compound specifications by the collaboration partner. During the development phase, the Company would be required to provide labor, intellectual property and technology infrastructure and the collaboration partner would be required to contribute downstream polishing expertise and market access. The March 2013 Agreement provided that the Company would own research and development and strain engineering intellectual property, and the collaboration partner would own blending and, if applicable, chemical conversion intellectual property. Under certain circumstances such as the Company's insolvency, the collaboration partner would gain expanded access to the Company's intellectual property. Following development of flavors and fragrances compounds under the March 2013 Agreement, the March 2013 Agreement contemplated that the Company would manufacture the initial target molecules for the compounds and the collaboration partner will perform any required downstream polishing and distribution, sales and marketing. In September 2014, the Company entered into a supply agreement with the collaboration partner to provide target compounds to make a certain finished ingredient and market and sell such finished ingredient and/or products to the flavors and fragrances market. The Company recognized $1.4 million revenues from product sales under this agreement for the year ended December 31, 2015. Michelin and Braskem Collaboration Agreements In September 2011, the Company entered into a collaboration agreement with Manufacture Francaise de Pnematiques Michelin (or “Michelin”). Under the terms of the September 2011 collaboration agreement, the Company and Michelin agreed to collaborate on the development, production and worldwide commercialization of isoprene or isoprenol, generally for tire applications, using the Company's technology. Under the agreement, Michelin made an upfront payment to the Company of $5.0 million. In June 2014, the Company entered into a collaboration agreement with Braskem S.A. (or “Braskem”) and Michelin to collaborate to develop the technology to produce and possibly commercialize renewable isoprene. The term of the collaboration agreement commenced on June 30, 2014 and will continue, unless earlier terminated in accordance with the agreement, until the first to occur of (i) the date that is three years following the actual date on which a work plan is completed, which date is estimated to occur on or about December 30, 2020, or (ii) the date of the commencement of commissioning of a production plant for the production of renewable isoprene. The June 2014 collaboration agreement terminated and supersedes the September 2011 collaboration agreement with Michelin, and, as a result of the signing of the June 2014 collaboration agreement, the upfront payment by Michelin of $5.0 million is being rolled into the new collaboration agreement between Michelin, Braskem and the Company as Michelin's collaboration funding towards the research and development activities to be performed. As of December 31, 2014, the Company accrued a total contribution from Braskem to the collaboration of $4.0 million, of which $2.0 million was received in July 2014 and $2.0 million was received in January 2015. The Company recognized collaboration revenues of $2.2 million and $0.9 million for the years ended December 31, 2015 and 2014 under this agreement, respectively. Kuraray Collaboration Agreement and Securities Purchase Agreement In March 2014, the Company entered into the Second Amended and Restated Collaboration Agreement with Kuraray Co., Ltd (or “Kuraray”) in order to extend the term of the original agreement dated July 21, 2011 for an additional two years and add additional fields and products to the scope of development. In consideration for the Company’s agreement to extend the term of the original collaboration agreement and add additional fields and products, Kuraray agreed to pay the Company $4.0 million in two equal installments of $2.0 million. The first installment was paid on April 30, 2014 and the second installment was due on April 30, 2015. In connection with the collaboration agreement, Kuraray signed a Securities Purchase Agreement in March 2014 to purchase 943,396 shares of the Company's common stock at a price per share of $4.24 per share. The Company issued 943,396 shares of its common stock at a price per share of $4.24 in April 2014 for aggregate cash proceeds of $4.0 million. In March 2015, the Company entered into the First Amendment to the Second Amended and Restated Collaboration Agreement with Kuraray Co., Ltd (or Kuraray) to extend the term of the original agreement until December 31, 2016 and accelerate payment to the Company of the second installment of $2.0 million to March 31, 2015. The Company recognized collaboration revenues of $1.6 million and $0.9 million, respectively, for the years ended December 31, 2015 and 2014 under this agreement. DARPA In September 2015, the Company entered into a Technology Investment Agreement (the “2015 TIA”) with The Defense Advanced Research Projects Agency (“DARPA”), under which the Company, with the assistance of five specialized subcontractors, will work to create new research and development tools and technologies for strain engineering and scale-up activities. The program that is the subject of the 2015 TIA will be performed and funded on a milestone basis, where DARPA, upon the Company’s successful completion of each milestone event in the 2015 TIA, pays the Company the amount in the 2015 TIA corresponding to such milestone event. Under the 2015 TIA, the Company and its subcontractors could collectively receive DARPA funding of up to $35.0 million over the program’s four year term if all of the program’s milestones are achieved. In conjunction with DARPA’s funding, the Company and its subcontractors are obligated to collectively contribute approximately $15.5 million toward the program over its four year term (primarily by providing specified labor and/or purchasing certain equipment). The Company can elect to retain title to the patentable inventions it produces in the program, but DARPA receives certain data rights as well as a government purposes license to certain of such inventions. Either party may, upon written notice and subject to certain consultation obligations, terminate the 2015 TIA upon a reasonable determination that the program will not produce beneficial results commensurate with the expenditure of resources. Financing Agreements Nomis Bay Ltd. Common Stock Purchase Agreement In February 2015, the Company entered into a Common Stock Purchase Agreement (or the “Common Stock Purchase Agreement”) and a Registration Rights Agreement (or the “Registration Rights Agreement”) with Nomis Bay Ltd. (or “Nomis Bay”) under which the Company may from time to time sell up to $50.0 million of its common stock to Nomis Bay over a 24-month period. In connection with such Common Stock Purchase Agreement and Registration Rights Agreement, the Company also entered into a Placement Agent Letter Agreement (or the “Placement Agent Agreement”) with Financial West Group (or “FWG”, the Common Stock Purchase Agreement, the Registration Rights Agreement and the Placement Agent Agreement are collectively referred to as the “Committed Equity Facility Agreements”). The equity commitment arrangement entered into under the Committed Equity Facility Agreements is sometimes referred to as a committed equity line financing facility. Subject to customary covenants and conditions, from time to time over the 24-month term, and in the Company’s sole discretion, the Company may present Nomis Bay with up to 24 draw down notices requiring Nomis Bay to purchase a specified dollar amount of shares of the Company’s common stock, based on the volume weighted average price of our common stock over 10 consecutive trading days prior to the date the Company delivers a draw down notice (or the “10-Day VWAP”). The per share purchase price for these shares equals the daily volume weighted average price of the Company’s common stock on each date during the 10 consecutive trading days following delivery of the draw down notice (or a “Draw Down Period”) on which shares are purchased, less a discount ranging from 3.0% to 6.25%, which discount is based on the 10-Day VWAP. The maximum amount of shares that may be sold in any Draw Down Period ranges from shares having aggregate purchase prices of $325,000 to $3,250,000, based on the 10-Day VWAP. Alternatively, in the Company’s sole discretion, but subject to certain limitations, the Company may require Nomis Bay to purchase a percentage of the daily trading volume of the Company’s common stock for each trading day during the Draw Down Period. The Company will not sell under the Common Stock Purchase Agreement a number of shares of voting common stock which, when aggregated with all other shares of voting common stock then beneficially owned by Nomis Bay and its affiliates, would result in the beneficial ownership by Nomis Bay or any of its affiliates of more than 9.9% of the then issued and outstanding shares of common stock. Under the Committed Equity Facility Agreements, the Company agreed to pay up to $35,000 of Nomis Bay’s legal fees and expenses. The Company also agreed to pay Nomis Bay a commitment fee of $0.1 million which was paid at the signing of the Purchase Agreement, and $0.3 million paid in May 2015. The issuance of the shares of common stock to Nomis Bay would be exempt from registration under the Securities Act pursuant to the exemption for transactions by an issuer not involving a public offering. The Company agreed to indemnify Nomis Bay and its affiliates for losses related to a breach of the representations and warranties by the Company under the Committed Equity Facility Agreements and the other transaction documents, or any action instituted against Nomis Bay or its affiliates due to the transactions contemplated by the Committed Equity Facility Agreements or other transaction documents, subject to certain limitations. Under the Registration Rights Agreement, the Company granted to Nomis Bay certain registration rights related to the resale of the maximum shares of common stock issuable pursuant to the Common Stock Purchase Agreement. On May 12, 2015 the Company filed the registration statement required by the Registration Rights Agreement and such registration statement was declared effective on May 20, 2015. Under the Placement Agent Agreement, the Company agreed to pay Financial West Group ("FWG") a fee not to exceed $15,000 in the aggregate for FWG’s reasonable attorney’s fees and expenses incurred in connection with the transaction . Naxyris Securities Purchase Agreement In March, 2015, the Company entered into a Securities Purchase Agreement (or the “Naxyris SPA”) for the sale of up to $10.0 million in principal amount of an unsecured convertible note of the Company (or the “Naxyris Note”) to Naxyris, S.A. (or “Naxyris”), a beneficial owner of more than 5% of the Company's outstanding common stock at the time of the transaction and an affiliate of director Carole Piwnica, who was designated to serve on the Company’s Board of Directors by Naxyris pursuant to a February 2012 letter agreement between the Company, Naxyris and the other parties thereto. The Naxyris SPA contemplated that the Naxyris Note may be issued in one closing to occur at the option of the Company at any time prior to the earlier of March 31, 2016 or the Company completing a new financing (or series of financings) of equity, debt or similar instruments in the amount of at least $10.0 million in the aggregate (excluding amounts that may be raised under existing commitments and agreements in existence as of March 30, 2015), following the satisfaction of certain closing conditions, including the receipt of certain third party consents, and required that the Company pay a commitment availability fee of $0.2 million to Naxyris on April 1, 2015. The agreement expired in July 2015 following the Company’s private placement of shares of its common stock, as described below. July 2015 Private Offering In July 2015, the Company sold and issued 16,025,642 shares of the Company’s common stock at a price per share of $1.56, under a Securities Purchase Agreement, dated as of July 24, 2015, by and among the Company and the purchasers named therein. The purchasers include existing beneficial owners of more than 5% of the Company's outstanding shares of common stock: Foris Ventures, LLC (an entity affiliated with director John Doerr of Kleiner Perkins Caufield & Byers, a current stockholder), which purchased 9,615,384 shares; Total, which purchased 1,282,051 shares; and Naxyris S.A., which purchased 2,243,594 shares. Pursuant to the Securities Purchase Agreement, the Company granted to the purchasers warrants for the purchase of an aggregate of 1,602,562 shares of the Company’s common stock, with a term of five years exercisable at an exercise price of $0.01 per share. The exercisability of the warrants was subject to stockholder approval, which was obtained on September 17, 2015. Second Hercules Amendment In March 2015, the Company and Hercules entered into the Second Hercules Amendment. Pursuant to the Second Hercules Amendment, the parties agreed to, among other things, establish an additional credit facility in the principal amount of up to $15.0 million, which would be available to be drawn by the Company through the earlier of March 31, 2016 or such time as the Company raised an aggregate of at least $20.0 million through the sale of new equity securities. The additional credit facility expired in July 2015 following the Company’s private placement of shares of its common stock, as described above. Third Hercules Amendment In November 2015, the Company and Hercules entered into a third amendment (or the “Third Hercules Amendment”) of the Hercules Loan Facility. Pursuant to the Third Hercules Amendment, the Company borrowed another $10,960,000 (or the “Third Hercules Amendment Borrowed Amount”) from Hercules on November 30, 2015. As of December 1, 2015, after the funding of the Third Hercules Amendment Borrowed Amount (and including repayment of principal that had occurred prior to the Third Hercules Amendment), the aggregate principal amount outstanding under the Loan Facility was approximately $30.7 million. The Third Hercules Amendment Borrowed Amount accrues interest at a rate per annum equal to the greater of (i) 9.5% and (ii) the prime rate reported in the Wall Street Journal plus 6.25%, and, like the previous loans under the Loan Facility, has a maturity date of February 1, 2017. Upon the earlier of the maturity date, prepayment in full or such obligations otherwise becoming due and payable, in addition to repaying the outstanding Third Hercules Amendment Borrowed Amount (and all amounts owed under the Original Hercules Agreement, as amended), the Company is also required to pay Hercules an end-of-term charge of $767,200. Pursuant to the Third Hercules Amendment, the Company also paid Hercules fees of $1.0 million, $750,000 of which was owed in connection with the expired $15.0 million facility under the Second Amendment and $250,000 of which was related to the Third Hercules Amendment Borrowed Amount. Under the Third Hercules Amendment, the parties agreed that the Company would, commencing on December 1, 2015, be required to pay only the interest accruing on all outstanding loans under the Loan Facility until February 29, 2016. Commencing on March 1, 2016, the Company have been required to begin repaying principal of all loans under the Loan Facility, in addition to the applicable interest. However, pursuant to the Third Hercules Amendment, the Company could, by achieving certain cash inflow targets in 2016, extend the interest-only period to December 1, 2016. If the achievement of those targets occurs after March 1, 2016, the Company could, after commencing the repayment of principal, revert to interest-only payments once the applicable target is achieved. Upon the issuance by the Company of $20.0 million of unsecured promissory notes and warrants in a private placement in February 2016 for aggregate cash proceeds of $20.0 million, the Company satisfied the conditions for extending the interest-only period to May 31, 2016. The Third Hercules Amendment Borrowed Amount is secured by the same liens provided for in the Original Hercules Agreement and the First Amendment, including a lien on certain Company intellectual property, and the preexisting covenants under the Loan Facility (including a covenant requiring the Company to maintain a minimum cash balance equal to at least 50% of the principal amount then outstanding) apply to the Loan Facility as amended. 2015 144A Convertible Notes Offering In October 2015, the Company entered into a purchase agreement with certain qualified institutional buyers relating to the sale of $57.6 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2019 (or the “2015 144A Notes”) to the purchasers in a private placement (or the “2015 144A Offering”). The Notes were issued pursuant to an Indenture, dated as of October 20, 2015 (or the “2015 Indenture”), between the Company and Wells Fargo Bank, National Association, as trustee. The net proceeds from the offering of the 2015 144A Notes were approximately $54.4 million after payment of the estimated offering expenses and placement agent fees. The Company used approximately $18.3 million of the net proceeds to repurchase $22.9 million aggregate principal amount of its outstanding 6.50% convertible senior notes due 2019 and approximately $8.8 million to repurchase $9.7 million aggregate principal amount of its outstanding 3% convertible senior notes due 2017, in each case held by purchasers of the 2015 144A Notes. The 2015 144A Notes bear interest at a rate of 9.50% per year, payable semiannually in arrears on April 15 and October 15 of each year, with the first such interest payment made on April 15, 2016. Interest may be payable, at the Company’s option, entirely in cash or entirely in common stock. The 2015 144A Notes will mature on April 15, 2019 unless earlier converted or repurchased. The 2015 144A Notes are convertible into shares of the Company's common stock at any time prior to the close of business on April 15, 2019. The 2015 144A Notes have an initial conversion rate of 443.6557 shares of Common Stock per $1,000 principal amount of 2015 144A Notes (subject to adjustment in certain circumstances). This represents an initial effective conversion price of approximately $2.25 per share of common stock. Following the issuance by the Company of warrants to purchase common stock in a private placement transaction in February 2016, the conversion rate of the 2015 144A Notes was adjusted to 445.2252 shares of Common Stock per $1,000 principal amount of 2015 144A Notes. For any conversion on or after November 27, 2015, the holders, in addition to the shares deliverable upon conversion, will be entitled to receive a payment equal to the present value of the remaining scheduled payments of interest that would have been made on the 2015 144A Notes being converted from the conversion date to the earlier of the date that is three years after the date the Company receives such notice of conversion and maturity (April 15, 2019), which will be computed using a discount rate of 0.75%. The Company may make such payment (the “Early Conversion Payment”) either in cash or in common stock, at its election, provided that it may only make such payment in common stock if such common stock is not subject to restrictions on transfer under the Securities Act by persons other than the Company’s affiliates. If the Company elects to pay an Early Conversion Payment in common stock, then the stock will be valued at 92.5% of the simple average of the daily volume-weighted average price per share for the 10 trading days ending on and including the trading day immediately preceding the conversion date. In the event of a fundamental change, as defined in the 2015 Indenture, holders of the 2015 144A Notes may require the Company to purchase all or a portion of the 2015 144A Notes at a price equal to 100% of the principal amount of the 2015 144A Notes, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, holders of the 2015 144A Notes who convert their 2015 144A Notes in connection with a make-whole fundamental change will, under certain circumstances, be entitled to an increase in the conversion rate. The issuance of shares of common stock upon conversion of the 2015 144A Notes, upon the Company’s election to pay interest on the 2015 144A Notes in shares of common stock and upon the Company’s election to pay the Early Conversion Payment in shares of common stock in an aggregate amount in excess of In conjunction with the closing of the 2015 144A Notes and repurchase of $22.9 million of outstanding 6.5% convertible senior notes and $9.7 million of outstanding 3% convertible senior notes, a $5.3 million gain on extinguishment was recognized in 2015. In addition, $1.3 million of the principal amount of the 2015 144A Notes converted to equity in 2015, which gave rise to a $0.5 million loss on extinguishment.

Note 9 - Goodwill and Intangibl

Note 9 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	9. Goodwill and Intangible Assets The following table presents the components of the Company's goodwill and intangible assets (in thousands): December 31, 2015 December 31, 2014 Useful Life Gross Accumulated Net Gross Accumulated Net In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (3,035 ) $ 5,525 Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (3,807 ) $ 6,085 The following table presents the activity of goodwill and intangible assets for the year ended December 31, 2015 (in thousands): December 31, 2014 December 31, 2015 Net Carrying Value Impairment Net Carrying Value In-process research and development $ 5,525 $ (5,525 ) $ — Acquired licenses and permits — — — Goodwill 560 — 560 $ 6,085 $ (5,525 ) $ 560 The in-process research and development (IPR&D) of $8.6 million was acquired through the acquisition of Draths in October 2011 and were treated as indefinite lived intangible assets pending completion or abandonment of the projects to which the IPRD related. If the carrying amount of the assets is greater than the measures of fair value, impairment is considered to have occurred and a write-down of the asset is recorded in the income statement. During 2014, the Company updated its ongoing analysis of the technical and commercial viability of the IPR&D. The complex scientific and significant funding requirements of certain potential products, caused the Company to re-focus its research and development efforts on a narrower range of potential products. During the fourth quarter of 2015, the Company determined that there were expected to be significant delays in the timetable for completion of the IPR&D and the forecast prices for the product expected to be produced upon completion of the IPR&D declined significantly. As a result of the assessment using the estimated discounted future cash flows of the IPR&D, the Company recorded an impairment charge of $5.5 million to write-off all of its IPR&D assets in 2015. The impairment charges are recognized in "Impairment of intangible assets" in the consolidated statements of operations. Acquired licenses and permits are amortized using a straight-line method over their estimated useful lives. Amortization expense for this intangible was zero, zero and $32,000 for the years ended December 31, 2015, 2014 and 2013, respectively. As of December 31, 2015, acquired licenses and permits were fully amortized. The Company has a single reportable segment (see Note 15, Reporting Segments" for further details). Consequently, all of the Company's goodwill is attributable to the single reportable segment.

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Deficit Private Placement December 2012 Private Placement In December 2012, the Company completed a private placement of 14,177,849 shares of its common stock at a price of $2.98 per share for aggregate proceeds of $37.2 million and the cancellation of $5.0 million worth of outstanding senior unsecured convertible promissory notes previously issued to Total by the Company. The Company issued 1,677,852 shares to Total in exchange for this note cancellation. Net cash received for this private placement as of December 31, 2012 was $22.2 million and the remaining $15.0 million of proceeds was received in January 2013. In connection with this, the Company entered into a letter of agreement with an investor under which the Company acknowledged that the investor's initial investment of $10.0 million in December 2012 represented partial satisfaction of the investor's preexisting contractual obligation to fund $15.0 million by March 31, 2013 upon satisfaction by the Company of criteria associated with the commissioning of the Company's production plant in Brotas, Brazil. In January 2013, the Company received $15.0 million in proceeds from the private placement offering that closed in December 2012. Consequently, the Company issued 5,033,557 shares of the 14,177,849 shares of the Company's common stock. March 2013 Private Placement In March 2013, the Company completed a private placement of 1,533,742 shares of its common stock at a price of $3.26 per share for aggregate proceeds of $5.0 million. This private placement represented the final tranche of an investor’s preexisting contractual obligation to fund $15.0 million upon satisfaction by the Company of certain criteria associated with the commissioning of a production plant in Brotas, Brazil. April 2014 Private Placement In April 2014, the Company completed a private placement of 943,396 shares of its common stock at a price of $4.24 per share for aggregate proceeds of $4.0 million (see Note 8, "Significant Agreements"). Evergreen Shares for 2010 Equity Plan and 2010 ESPP In January 2015, the Company's Board of Directors (or Board) approved an increase to the number of shares available for issuance under the Company's 2010 Equity Incentive Plan (or Equity Plan) and the 2010 Employee Stock Purchase Plan (or ESPP). These shares represent an automatic annual increase in the number of shares available for issuance under the Equity Plan and the ESPP of 3,961,094 and 792,219, respectively. These increases are equal to 5% and 1%, respectively, of 79,221,883 shares, the total outstanding shares of the Company’s common stock as of December 31, 2014. This automatic increase was effective as of January 1, 2015. Shares available for issuance under the Equity Plan and ESPP were initially registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission on October 1, 2010 (Registration No. 333-169715). The Company filed a registration statement on Form S-8 on April 2, 2015 (Registration No. 333-203213) with respect to the shares added by the automatic increase on January 1, 2015. Common Stock As of December 31, 2015 and 2014, the Company was authorized to issue 400,000,000 and 300,000,000 shares of common stock, respectively, pursuant to the Company’s certificate of incorporation, as amended and restated (in September 2015, the Company filed an amended and restated certificate of incorporation to increase the shares of common stock authorized by the Company from 300,000,000 to 400,000,000 in connection with the approval by the Company's stockholders at the special meeting of the Company’s stockholders held in September 2015). Holders of the Company’s common stock are entitled to dividends as and when declared by the Board, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. Preferred Stock Pursuant to the Company’s amended and restated certificate of incorporation, the Company is authorized to issue 5,000,000 shares of preferred stock. The Board has the authority, without action by its stockholders, to designate and issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. As of December 31, 2015 and December 31, 2014, the Company had zero shares of convertible preferred stock outstanding. Common Stock Warrants In December 2011, in connection with a capital lease agreement, the Company issued warrants to purchase 21,087 shares of the Company's common stock at an exercise price of $10.67 per share. The Company estimated the fair value of these warrants as of the issuance date to be $0.2 million and recorded these warrants as other assets, amortizing them subsequently over the term of the lease. The fair value was based on the contractual term of the warrants of 10 years, risk free interest rate of 2%, expected volatility of 86% and zero expected dividend yield. These warrants remain unexercised and outstanding as of December 31, 2015. In October 2013, in connection with the issuance of the Tranche I Notes (see Note 5, "Debt"), the Company issued to Temasek contingently exercisable warrants to purchase 1,000,000 shares of the Company's common stock at an exercise price of $0.01 per share. The Company estimated the fair value of these warrants as of the issuance date at $1.3 million and recorded these warrants as debt issuance cost to be amortized over the term of the Tranche I Notes. The fair-value was calculated using a Monte Carlo simulation valuation model based on the contractual term of the warrants of 3.4 years, risk free interest rate of 0.77%, expected volatility of 45% and zero expected dividend yield. These warrants have been exercised as of December 31, 2015. Each of these warrants includes a cashless exercise provision which permits the holder of the warrant to elect to exercise the warrant without paying the cash exercise price, and receive a number of shares determined by multiplying (i) the number of shares for which the warrant is being exercised by (ii) the difference between the fair market value of the stock on the date of exercise and the warrant exercise price, and dividing such by (iii) the fair market value of the stock on the date of exercise. During the years ended December 31, 2015 and 2014, no warrants were exercised through the cashless exercise provision. The Temasek Exchange Warrant and Total Funding Warrant issued under the Exchange Agreement were recognized in equity at fair value on July 29, 2015. The fair value was calculated using a Black-Scholes valuation model based on the contractual term of the warrants, risk free interest rate of 2%, expected volatility of 74% and zero expected dividend yield. See Note 5, "Debt," for further details. In July 2015, in connection with a private offering of the Company’s common stock, the Company issued warrants to purchase a total of 1,602,562 of shares of common stock to the investors in the private offering. The warrants have an exercise price of $0.01 per share and, as of December 31, 2015, 1,442,307 of these warrants remain unexercised and outstanding. As of December 31, 2015 and 2014, the Company had 4,343,733 and 1,021,087 of unexercised common stock warrants, respectively.

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. Stock-Based Compensation Plans 2010 Equity Incentive Plan The Company's 2010 Equity Incentive Plan (or 2010 Equity Plan) became effective on September 28, 2010 and will terminate in 2020. Pursuant to the 2010 Equity Plan, any shares of the Company’s common stock (i) issued upon exercise of stock options granted under the Company's 2005 Stock Option/Stock Issuance Plan (or the 2005 Plan) that cease to be subject to such option and (ii) issued under the 2005 Plan that are forfeited or repurchased by the Company at the original purchase price will become part of the 2010 Equity Plan. Subsequent to the effective date of the 2010 Equity Plan, an additional 2,148,585 shares that were forfeited under the 2005 Plan were added to the shares reserved for issuance under the 2010 Equity Plan. The number of shares reserved for issuance under the 2010 Equity Plan increase automatically on January 1 st st As of December 31, 2015 and 2014, options to purchase 11,321,194 and 8,692,818 shares, respectively, of the Company's common stock granted from the 2010 Equity Plan were outstanding. As of December 31, 2015 and 2014, 1,833,004 and 5,133,576 shares, respectively, of the Company’s common stock remained available for future awards that may be granted from the 2010 Equity Plan. The options outstanding as of December 31, 2015 and 2014 had a weighted-average exercise price of approximately $4.27 per share and $5.72 per share, respectively. 2005 Stock Option/Stock Issuance Plan In 2005, the Company established its 2005 Plan which provided for the granting of common stock options, restricted stock units, restricted stock and stock purchase rights awards to employees and consultants of the Company. The 2005 Plan allowed for time-based or performance-based vesting for the awards. Options granted under the 2005 Plan were ISOs or NSOs. ISOs were granted only to Company employees (including officers and directors who are also employees). NSOs were granted to Company employees, non-employee directors, and consultants. All options issued under the 2005 Plan had a ten year life. The exercise prices of ISOs and NSOs granted under the 2005 Plan were not less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. The exercise price of an ISO and NSO granted to a 10% stockholder could not be less than 110% of the estimated fair value of the underlying stock on the date of grant as determined by the Board. The options generally vested over 5 years. As of December 31, 2015 and 2014, options to purchase 1,548,918 and 1,787,160 shares, respectively, of the Company’s common stock granted from the 2005 Stock Option/Stock Issuance Plan remained outstanding and as a result of the adoption of the 2010 Equity Incentive Plan discussed above, zero shares of the Company’s common stock remained available for future awards issuance under the 2005 Plan. The options outstanding under the 2005 Plan as of December 31, 2015 and 2014 had a weighted-average exercise price of approximately $8.46 per share and $8.04 per share, respectively. 2010 Employee Stock Purchase Plan The 2010 Employee Stock Purchase Plan (or the 2010 ESPP) became effective on September 28, 2010. The 2010 ESPP is designed to enable eligible employees to purchase shares of the Company’s common stock at a discount. Each offering period is for one year and consists of two six-month purchase periods. Each twelve-month offering period generally commences on May 16 th th st st During the year ended December 31, 2015 and 2014, 385,892 and 352,816 shares, respectively, of the Company's common stock were purchased under the 2010 ESPP. At December 31, 2015 and 2014, 1,221,896 and 815,569 shares, respectively, of the Company’s common stock remained available for issuance under the 2010 ESPP. Stock Option Activity The Company’s stock option activity and related information for the year ended December 31, 2015 was as follows: Number Weighted- Weighted- Aggregate (in thousands) Outstanding - December 31, 2014 10,539,978 $ 6.10 7.22 $ 50 Options granted 4,720,278 $ 1.84 — — Options exercised (13,250 ) $ 1.38 — — Options cancelled (2,316,894 ) $ 4.89 — — Outstanding - December 31, 2015 12,930,112 $ 4.77 7.39 $ 22 Vested and expected to vest after December 31, 2015 11,967,864 $ 4.98 7.21 $ 20 Exercisable at December 31, 2015 6,226,620 $ 7.43 5.57 $ 12 The aggregate intrinsic value of options exercised under all option plans was $0.0 million, $0.6 million and $0.6 million for the years ended December 31, 2015, 2014 and 2013, respectively, determined as of the date of option exercise. The Company’s restricted stock units (or RSUs) and restricted stock activity and related information for the year ended December 31, 2015 was as follows: RSUs Weighted- Weighted Average Outstanding - December 31, 2014 1,975,503 $ 3.28 0.93 Awarded 4,988,539 $ 1.82 — Vested (1,046,468 ) $ 3.10 — Forfeited (362,730 ) $ 2.90 — Outstanding - December 31, 2015 5,554,844 $ 2.03 1.61 Expected to vest after December 31, 2015 4,698,610 $ 2.05 1.47 The following table summarizes information about stock options outstanding as of December 31, 2015: Options Outstanding Options Exercisable Exercise Price Number of Options Weighted- Weighted-Average Exercise Price Number of Options Weighted-Average Exercise Price $0.28—$1.67 1,363,293 9.43 $ 1.62 65,593 $ 1.44 $1.69—$1.75 1,338,225 9.64 $ 1.73 — $ — $1.78—$1.80 121,000 9.33 $ 1.79 437 $ 1.80 $1.96—$1.96 1,390,783 9.44 $ 1.96 — $ — $1.98—$2.79 1,661,324 7.41 $ 2.62 930,882 $ 2.71 $2.81—$3.05 1,322,620 7.23 $ 2.94 902,484 $ 2.94 $3.08—$3.44 323,669 7.55 $ 3.33 192,283 $ 3.30 $3.51—$3.51 1,922,290 8.06 $ 3.51 829,483 $ 3.51 $3.55—$3.93 1,481,696 4.89 $ 3.87 1,324,343 $ 3.88 $4.08—$30.17 2,005,212 4.07 $ 16.16 1,981,115 $ 16.30 $0.28—$30.17 12,930,112 7.39 $ 4.77 6,226,620 $ 7.43 Stock-Based Compensation Expense Stock-based compensation expense related to options and restricted stock units granted to employees and nonemployees was allocated to research and development expense and sales, general and administrative expense as follows (in thousands): Years Ended December 31, 2015 2014 2013 Research and development $ 2,306 $ 3,508 $ 4,281 Sales, general and administrative 6,828 10,597 13,766 Total stock-based compensation expense $ 9,134 $ 14,105 $ 18,047 During the years ended December 31, 2015, 2014 and 2013, the Company granted options to purchase 4,720,278 shares, 3,683,791 shares, and 2,849,919 shares of its common stock, respectively, with weighted-average grant date fair values of $1.21, $2.31, and $1.98 per share, respectively. Compensation expense of $6.0 million, $10.1 million, and $13.1 million was recorded for the years ended December 31, 2015, 2014 and 2013, respectively, for stock-based options granted. As of December 31, 2015, 2014 and 2013, there were unrecognized compensation costs of $8.0 million, $11.4 million, and $15.0 million, respectively, related to these stock options. The Company expects to recognize those costs over a weighted-average period of 3.0 years and 2.8 years as of December 31, 2015 and 2014, respectively. Future option grants will increase the amount of compensation expense to be recorded in these periods. During the years ended December 31, 2015, 2014 and 2013, 4,988,539, 1,083,300 and 1,222,250 of restricted stock units, respectively, were granted with a weighted-average service-inception date fair value of $1.82, $3.51 and $2.85 per unit, respectively. The Company recognized a total of $2.8 million, $3.3 million and $4.1 million, respectively, in December 31, 2015, 2014 and 2013 in stock-based compensation expense for restricted stock units granted. As of December 31, 2015, 2014 and 2013, there were unrecognized compensation costs of $7.7 million, $3.6 million and $3.6 million, respectively, related to these restricted stock units. During the years ended December 31, 2015, 2014 and 2013, the Company also recognized stock-based compensation expense related to its 2010 ESPP of $0.3 million, $0.5 million, and $0.6 million, respectively. Employee stock-based compensation expense recognized for the years ended December 31, 2015, 2014 and 2013 included zero, $0.1 million and $1.0 million, respectively, related to option modifications. As part of separation agreements with certain former senior employees, the Company agreed to accelerate the vesting of options for zero, zero and 458,424 shares of common stock and extend the exercise period for certain grants in the years ended December 31, 2015, 2014 and 2013, respectively. Stock-based compensation cost for RSUs is measured based on the closing fair market value of the Company's common stock on the date of grant. Stock-based compensation expense for stock options and employee stock purchase plan rights is estimated at the grant date and offering date, respectively, based on the fair-value using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions: Years Ended December 31, 2015 2014 2013 Expected dividend yield — % — % — % Risk-free interest rate 1.8 % 1.9 % 1.4 % Expected term (in years) 6.08 6.10 6.10 Expected volatility 74 % 75 % 82 % Expected Dividend Yield Risk-Free Interest Rate - Expected Term Expected Volatility Forfeiture Rate Each of the inputs discussed above is subjective and generally requires significant management and director judgment.

Note 12 - Employee Benefit Plan

Note 12 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	12. Employee Benefit Plan The Company established a 401(k) Plan to provide tax deferred salary deductions for all eligible employees. Participants may make voluntary contributions to the 401(k) Plan up to 90% of their eligible compensation, limited by certain Internal Revenue Service (or IRS) restrictions. Effective January 2014, the Company implemented a discretionary employer match plan whereby the Company matches employee contributions for the year ended December 31, 2014 onwards up to the IRS limit or 90% of compensation, with a minimum one year of service required for vesting. The total matching amount for the years ended December 31, 2015 and 2014, was $0.5 million and $0.4 million, respectively.

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	13. Related Party Transactions Letter Agreements with Total In March 2013 and April 2014, respectively, the Company entered into letter agreements with Total that reduced the respective conversion prices of certain convertible promissory notes issuable under the Total Purchase Agreement, as described under “Related Party Convertible Notes” in Note 5, "Debt." Related Party Financings In March 2013, the Company completed a private placement of 1,533,742 shares of its common stock to an existing stockholder, Biolding SA, at a price of $3.26 per share for aggregate proceeds of $5.0 million. This private placement represented the final tranche of Biolding's preexisting contractual obligation to fund $15.0 million upon satisfaction by the Company of certain criteria associated with the commissioning of a production plant in Brotas, Brazil. In June 2013, the Company sold and issued a 1.5% Senior Unsecured Convertible Note to Total with a principal amount of $10.0 million with a March 1, 2017 maturity date pursuant to the Total Purchase Agreement as discussed above under “Related Party Convertible Notes” in Note 5, “Debt." In July 2013, the Company sold and issued a 1.5% Senior Unsecured Convertible Note to Total with a principal amount of $20.0 million with a March 1, 2017 maturity date pursuant to the Total Purchase Agreement as discussed above under “Related Party Convertible Notes” in Note 5, “Debt." In August 2013, the Company entered into a securities purchase agreement by and among the Company, Total and Temasek, each a beneficial owner of more than 5% of the Company's outstanding common stock at the time of the transaction and each affiliated with members of our Board of Directors, for a private placement of convertible promissory notes in an aggregate principal amount of $73.0 million. The initial closing of the August 2013 Financing was completed in October 2013 for the sale of approximately $42.6 million of the Tranche I Notes and the second closing of the August 2013 Financing for the sale of approximately $30.4 million of the Tranche II Notes was completed in January 2014 (the Company issued to Temasek $25.0 million of Tranche II Notes for cash and Total purchased approximately $6.0 million of Tranche II Notes through cancellation of the same amount of principal of previously outstanding convertible promissory notes held by Total (in respect of Total's preexisting contractual right to maintain its pro rata ownership position through such cancellation)). See “Related Party Convertible Notes” in Note 5, "Debt." In September 2013, the Company entered into a bridge loan agreement with an existing investor to provide additional cash availability of up to $5.0 million as needed before the initial closing of the August 2013 Financing. The Company did not use this facility and it expired in October 2013 in accordance with its terms. In October 2013, the Company sold and issued a senior secured promissory note to Temasek for a bridge loan of $35.0 million. The note was due on February 2, 2014 and accrued interest at a rate of 5.5% each four months from October 4, 2013 (with a rate of 2% per month if a default occurred). The note was cancelled as payment for the investor’s purchase of Tranche I Notes in the August 2013 Financing. See "Related Party Convertible Notes" in Note 5, "Debt." In October 2013, the Company completed the closing of the first tranche of the August 2013 Financing, which resulted in the exchange and cancellation of the $35.0 million Temasek Bridge Note and the $9.2 million Total convertible note, as a result of the exchange and cancellation the Company recorded a loss from extinguishment of debt of $19.9 million (see Note 5, "Debt"). In December 2013, the Company agreed (i) to exchange the $69.0 million outstanding 1.5% Senior Unsecured Convertible Notes due March 2017 and issue replacement 1.5% Senior Secured Convertible Notes due March 2017, in principal amounts equal to the principal amount of each cancelled note and (ii) that all notes issued in connection with a third closing under the Total Purchase Agreement would be senior secured convertible notes instead of senior unsecured convertible notes (see "Related Party Convertible Notes" in Note 5, "Debt"). In December 2013, the Company agreed to issue to Temasek $25.0 million of the second tranche of convertible promissory notes for cash. Total purchased approximately $6.0 million of the second tranche of convertible promissory notes through cancellation of the same amount of principal of previously outstanding convertible promissory notes held by Total (in respect of Total’s preexisting contractual right to maintain its pro rata ownership position through such cancellation). Such financing transactions closed in January 2014 (see Note 5, "Debt"). In April 2014, the Company and Total entered into the March 2014 Total Letter Agreement under which the Company agreed to, (i) amend the conversion price of the convertible notes to be issued in the third closing under the Total Purchase Agreement from $7.0682 per share to $4.11 per share subject to stockholder approval at the Company's 2014 annual meeting (which was obtained in May 2014), (ii) extend the period during which Total may exchange for other Company securities certain outstanding convertible promissory notes issued under the Total Fuel Agreements from June 30, 2014 to the later of December 31, 2014 and the date on which the Company shall have raised $75.0 million of equity and/or convertible debt financing (excluding any convertible promissory notes issued pursuant to the Total Purchase Agreement), (iii) eliminate the Company’s ability to qualify, in a disclosure letter to Total, certain of the representations and warranties that the Company must make at the closing of any third closing sale, and (iv) beginning on March 31, 2014, provide Total with monthly reporting on the Company’s cash, cash equivalents and short-term investments. In consideration of these agreements, Total agreed to waive its right not to consummate the closing of the issuance of the third closing notes if it had decided not to proceed with the collaboration and made a "No-Go" decision with respect thereto. In May 2014, the Company sold and issued 2014 144A Notes pursuant to the 2014 144A Offering. In connection with obtaining a waiver from one of its existing investors, Total, of its preexisting contractual right to exchange certain senior secured convertible notes previously issued by Amyris for new notes issued in the 2014 144A Offering, Amyris used approximately $9.7 million of the net proceeds of the 2014 144A Offering to repay such amount of notes previously issued to Total (representing the amount of notes purchased by Total in the 144A Offering). Additionally, Foris Ventures, LLC (a fund affiliated with John Doerr) (“Foris”) and Temasek each participated in the 2014 Rule 144A Convertible Note Offering and purchased $5.0 million and $10.0 million, respectively, of the convertible promissory notes sold thereunder (see "Related Party Convertible Notes" in Note 5, “Debt"). In July 2014 and January 2015, the Company sold and issued 1.5% Senior Secured Convertible Notes to Total with an aggregate principal amount of $21.70 million with a March 1, 2017 maturity date pursuant to the Total Purchase Agreement as discussed under "Related Party Convertible Notes" in Note 5, "Debt." These convertible notes (each with a principal amount of $10.85 million) had an initial conversion price equal to $4.11 per share of the Company's common stock. In July 2015, the Company sold and issued 16,025,642 shares of the Company’s common stock at a price per share of $1.56, under a Securities Purchase Agreement, dated as of July 24, 2015, by and among the Company, and the purchasers named therein. The purchasers included existing stockholders: Foris, which purchased 9,615,384 shares; Total, which purchased 1,282,051 shares; and Naxyris S.A. (an investment vehicle owned by Naxos Capital Partners SCA Sicar; director Carole Piwnica is Director of NAXOS UK, which is affiliated with Naxos Capital Partners SCA Sicar, and was designated to serve on our Board by Naxyris S.A. pursuant to a letter agreement between us, Naxyris S.A. and the other parties thereto), which purchased 2,243,594 shares. Pursuant to the Securities Purchase Agreement, the Company agreed to grant to each of the purchasers a warrant with a term of five years exercisable at an exercise price of $0.01 per share for the purchase of a number of shares of the Company’s common stock equal to 10% of the shares purchased by such investor. The exercisability of the warrants was subject to stockholder approval, which was obtained on September 17, 2015. Refer to Note 5, "Debt", for details of the related party transactions under the Exchange and Maturity Treatment agreements. As of December 31, 2015 and 2014, convertible notes with related parties were outstanding in an aggregate principal amount of $43.0 million and $115.2 million, respectively, net of debt discount of $1.6 million and $53.8 million, respectively. The Company recorded losses of $5.9 million, $10.5 million and $19.9 million from extinguishment of debt from the settlement, exchange and/or cancellation of related party convertible notes for the years ended December 31, 2015, 2014 and 2013, respectively (see "Related Party Convertible Notes" in Note 5, "Debt" for details). The fair value of derivative liabilities related to the related party convertible notes as of December 31, 2015 and 2014 were $7.9 million and $39.8 million, respectively. The Company recognized a gain from change in fair value of the derivative instruments of $10.5 million and $141.2 million for the years ended December 31, 2015 and 2014, and a loss from change in fair value of the derivative instruments of $76.2 million for the year ended December 31, 2013, related to these derivative liabilities (see Note 3, "Fair Value of Financial Instruments"). Related Party Revenues The Company recognized related party revenues from product sales to Total of $0.9 million, $0.6 million and $0.2 million for the years ended December 31, 2015, 2014 and 2013, respectively. Related party accounts receivable from Total as of December 31, 2015 and 2014, were $1.2 million and $0.3 million, respectively. Loans to Related Parties See Note 7, "Joint Ventures and Noncontrolling Interest" for details of the Company's loans to its affiliate, Novvi LLC. Joint Venture with Total In November 2013, the Company and Total formed TAB as discussed above under Note 7, "Joint Ventures and Noncontrolling Interest." Pilot Plant Agreements In May 2014, the Company received the final consents necessary for the Pilot Plant Services Agreement (or Pilot Plant Services Agreement) and a Sublease Agreement (or the Sublease Agreement), each dated as of April 4, 2014 (collectively the Pilot Plant Agreements), between the Company and Total. The Pilot Plant Agreements generally have a term of five years. Under the terms of the Pilot Plant Services Agreement, the Company agreed to provide certain fermentation and downstream separations scale-up services and training to Total and receives an aggregate annual fee payable by Total for all services in the amount of up to approximately $0.9 million per annum. In July 2015, Total and the Company entered into Amendment #1 (the "Pilot Plant Agreement Amendment") to the Pilot Plant Services Agreement whereby the Company agreed to waive a portion of these fees, up to approximately $2.0 million, over the term of the Pilot Plant Services Agreement in connection with the restructuring of TAB discussed above. Under the Sublease Agreement, the Company receives an annual base rent payable by Total of approximately $0.1 million per annum. As of December 31, 2015, the Company had received $1.7 million in cash under the Pilot Plant Agreements from Total. In connection with these arrangements, sublease payments and service fees of $0.9 million and $0.7 million were offset against cost and operating expenses for the year ended December 31, 2015 and 2014, respectively. As of December 31, 2015 and 2014, zero and $0.2 million, respectively, of cash received under the Pilot Plant Agreements from Total was recorded as "Accrued and other current liabilities" on the consolidated balance sheet. See the Naxyris Securities Purchase Agreement Significant Agreements

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. Income Taxes For each of the years ended December 31, 2015 and 2014, the Company recorded a provision from income taxes of $0.5 million and for the year ended December 31, 2013, the Company recorded a benefit for income taxes of $0.8 million. The provision for income taxes for the years ended December 31, 2015 and 2014, generally relates to accrued withholding taxes that would be due in connection with the payment of interest on intercompany loans. In the year ended December 31, 2013, the recorded tax benefit was associated with the conversion of certain loans to equity, which reduces the accrual of the interest from the Company's subsidiary and will correspondingly eliminate the withholding tax obligation. Other than the above mentioned provision for income tax, no additional provision for income taxes has been made, net of the valuation allowance, due to cumulative losses since the commencement of operations. The components of income (loss) before income taxes, loss from investment in affiliate and noncontrolling interest are as follows for the years ended December 31, 2015, 2014 and 2013 (in thousands): Years Ended December 31, 2015 2014 2013 United States $ (193,128 ) $ 10,847 $ (216,583 ) Foreign (24,457 ) (5,275 ) (19,171 ) Income (loss) before income taxes and loss from investment in affiliate $ (217,585 ) $ 5,572 $ (235,754 ) The components of the provision for (benefit from) income taxes are as follows for the years ended December 31, 2015, 2014 and 2013 (in thousands): Years Ended December 31, 2015 2014 2013 Current: Federal $ — $ — $ — State — — — Foreign 468 495 (847 ) Total current provision (benefit) 468 495 (847 ) Deferred: Federal — — — State — — — Foreign — — — Total deferred provision (benefit) — — — Total provision (benefit) for income taxes $ 468 $ 495 $ (847 ) A reconciliation between the statutory federal income tax and the Company’s effective tax rates as a percentage of income (loss) before income taxes is as follows: Years Ended December 31, 2015 2014 2013 Statutory tax rate (34.0 )% (34.0 )% (34.0 )% State tax rate, net of federal benefit (0.3 )% 23.3 % (0.7 )% Stock-based compensation 0.1 % (2.8 )% 0.1 % Federal R&D credit (0.6 )% 31.0 % (0.8 )% Derivative liabilities 3.6 % 541.5 % 13.9 % Non-Deductible Interest 5.5 % — % 0.0 % Other 0.1 % (7.8 )% (0.6 )% Foreign losses (1.2 )% 32.3 % (1.4 )% Change in valuation allowance 27.1 % (592.4 )% 23.1 % Effective income tax rate 0.3 % (8.9 )% (0.4 )% Temporary differences and carryforwards that gave rise to significant portions of deferred taxes are as follows (in thousands): December 31, 2015 2014 2013 Net operating loss carryforwards $ 207,241 $ 195,536 $ 167,354 Fixed assets 10,519 1,299 822 Research and development credits 16,612 14,701 11,654 Foreign Tax Credit 1,899 1,431 935 Accruals and reserves 26,366 16,425 17,893 Stock-based compensation 19,048 18,773 17,521 Capitalized start-up costs 9,568 13,095 15,133 Capitalized research and development costs 63,339 56,880 45,968 Other 9,999 6,700 6,741 Total deferred tax assets 364,591 324,840 284,021 Fixed assets — — — Debt discount and derivative (4,402 ) (12,517 ) — Total deferred tax liabilities (4,402 ) (12,517 ) — Net deferred tax asset prior to valuation allowance 360,189 312,323 284,021 Less: Valuation allowance (360,189 ) (312,323 ) (284,021 ) Net deferred tax assets (liabilities) $ — $ — $ — Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. Based upon the weight of available evidence, especially the uncertainties surrounding the realization of deferred tax assets through future taxable income, the Company believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets as of December 31, 2015, 2014 and 2013. The valuation allowance increased by $47.9 million, $28.3 million, and $47.7 million, during the years ended December 31, 2015, 2014 and 2013, respectively. On November 20, 2015, the FASB issued Accounting Standards Update 2015-17, Balance Sheet Classification of Deferred Taxes. The ASU is part of the Board’s simplification initiative aimed at reducing complexity in accounting standards and requires companies to classify all deferred tax assets and liabilities, along with any related valuation allowance, as noncurrent on the balance sheet. Although ASU 2015-17 isn’t required for public companies to implement until fiscal years beginning after December 15, 2016, early adoption is allowed. The Company decided to adopt early and has classified all of its deferred tax assets and liabilities, along with its valuation allowance as noncurrent on the balance sheet. The Company early adopted ASU 2015-17 as the Company considers this change an improvement in the usefulness of information provided to users of the Company’s financial statements. The Company applied the standard prospectively and did not retrospectively adjust any prior periods. As of December 31, 2015 and 2014, the Company had federal net operating loss carryforwards of approximately $570.3 million and $525.6 million, respectively, and state net operating loss carryforwards $200.3 million and $200.7 million, respectively, available to reduce future taxable income, if any. As of December 31, 2015 and 2014, approximately $27.1 million and $27.1 million, respectively, of the federal loss carryforwards and $12.9 million and $13.8 million, respectively, of state net operating loss carryforwards, resulted from exercises of employee stock options and vesting of restricted stock units and have not been included in the Company’s gross deferred tax assets. In accordance with ASC 718, such unrealized tax benefits will be accounted for as a credit to additional paid-in capital if and when realized through a reduction in income taxes payable. During the year ended December 31, 2015, unrecognized tax benefits of $8.5 million were resolved in connection with the outcome of a California Supreme Court case, involving another taxpayer, that concluded on a methodology which follows that certain of the Company’s net operating losses cannot be sustained. The decision had no impact on the Company’s gross deferred tax assets as presented, as the Company’s deferred tax asset for net operating losses was previously reported, net of a reserve for this same item The Company also has federal research and development credits of $9.8 million and $8.5 million and California research and development credit carryforwards of $10.4 million and $9.4 million, at December 31, 2015 and 2014, respectively. The Tax Reform Act of 1986 (or the TRA) and similar state provisions limit the use of net operating loss and credit carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event the Company has experienced an ownership change, as defined in the TRA, utilization of its federal and state net operating loss and credit carryforwards could be limited. If not utilized, the federal net operating loss carryforward begins expiring in 2025, and the California net operating loss carryforward begins expiring in 2015. The federal research and development credit carryforwards will expire starting in 2024 if not utilized. The California tax credits can be carried forward indefinitely. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: Balance at December 31, 2012 $ 3,918 Increases in tax positions for prior period 469 Increases in tax positions during current period 1,693 Balance at December 31, 2013 $ 6,080 Increases in tax positions for prior period 4,736 Increases in tax positions during current period 6,265 Balance at December 31, 2014 $ 17,081 Decreases in tax positions for prior period (9,404 ) Increases in tax positions during current period 957 Balance at December 31, 2015 $ 8,634 The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the provision for taxes. The Company determined that no accrual for interest and penalties was required as of December 31, 2015 or December 31, 2014. None of the tax benefits, if recognized, would affect the effective income tax rate for any of the above years due to the valuation allowance that currently offsets deferred tax assets. The Company does not anticipate the total amount of unrecognized income tax benefits will significantly increase or decrease in the next 12 months. The Company’s primary tax jurisdiction is the United States. For United States federal and state tax purposes, returns for tax years 2004 and forward remain open and subject to tax examination by the appropriate federal or state taxing authorities. Brazil tax years 2009 through the current remain open and subject to examination. As of December 31, 2015, the US Internal Revenue Service (or the IRS) has completed its audit of the Company for tax year 2008 which concluded that there were no adjustments resulting from the audit. While the statutes are closed for tax year 2008, the US federal tax carryforwards (net operating losses and tax credits) may be adjusted by the IRS in the year in which the carryforward is utilized.

Note 15 - Reporting Segments

Note 15 - Reporting Segments	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	15. Reporting Segments The chief operating decision maker for the Company is the chief executive officer. The chief executive officer reviews financial information presented on a consolidated basis, accompanied by information about revenues by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity comprised of research and development and sales of fuels and farnesene-derived products and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable segment and operating segment structure. Revenues by geography are based on the location of the customer. The following tables set forth revenues and long-lived assets by geographic area (in thousands): Revenues Years Ended December 31, 2015 2014 2013 United States $ 20,897 $ 21,331 $ 21,235 Brazil 5,070 5,961 4,071 Europe 3,557 9,738 10,340 Asia 4,629 6,244 5,473 Total $ 34,153 $ 43,274 $ 41,119 Long-Lived Assets December 31, 2015 2014 United States $ 18,401 $ 44,418 Brazil 41,093 74,197 Europe 303 365 Total $ 59,797 $ 118,980

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	16. Subsequent Events February 2016 Private Placement On February 12, 2016, the Company entered into a Note and Warrant Purchase Agreement (the “February 2016 Purchase Agreement”) with the purchasers named therein for the sale of $18.0 million in aggregate principal amount of unsecured promissory notes (the “2016 Notes”) to the purchasers, as well as warrants to purchase 2,571,428 shares of the Company’s common stock at an exercise price of $0.01 per share, representing aggregate proceeds to the Company of $18 million (the “Initial Sale”). On February 15, 2016, an additional purchaser joined the Purchase Agreement and purchased $2.0 million in aggregate principal amount of the 2016 Notes, as well as warrants to purchase 285,714 shares of the Company’s common stock at an exercise price of $0.01 per share, representing aggregate proceeds to the Company of $2 million (the “Subsequent Sale” and together with the Initial Sale, the “February 2016 Private Placement”). The 2016 Notes are unsecured obligations of the Company and are subordinate to the Company’s obligations under its Hercules Loan Facility pursuant to a Subordination Agreement, dated as of February 12, 2016, by and among the Company, the purchasers and the administrative agent under the Hercules Loan Facility. Interest will accrue on the 2016 Notes from and including, with respect to the Initial Sale, February 12, 2016, and with respect to the Subsequent Sale, February 15, 2016, at a rate of 13.50% per annum and is payable on May 15, 2017, the maturity date of the 2016 Notes, unless the Notes are prepaid in accordance with their terms prior to such date. The February 2016 Purchase Agreement and the 2016 Notes contain customary terms, provisions, representations and warranties, including certain events of default after which the 2016 Notes may be due and payable immediately, as set forth in the Notes. The exercisability of the warrants sold in the February 2016 Private Placement, which each have a term of five years, will be subject to stockholder approval. The Company intends to solicit such approval at its 2016 annual meeting of stockholders. Novvi Capital Contribution In February 2016, the Company purchased additional membership units of Novvi for an aggregate purchase price of $0.6 million in the form of forgiveness of existing receivables due from Novvi related to rent and other services performed by the Company. Cosan, the other member of Novvi, purchased an equal number of additional membership units in Novvi in cash. Each member owns 50% of Novvi's issued and outstanding membership units. At Market Issuance Sales Agreement On March 8, 2016, the Company entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with FBR Capital Markets & Co. and MLV & Co. LLC (the “Agents”) under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time through the Agents, acting as its sales agents, under the Company’s Registration Statement on Form S-3 (File No. 333-203216), effective April 9, 2015. Sales of the Company’s common stock through the Agents, if any, will be made by any method that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act, including by means of ordinary brokers’ transactions at market prices, in block transactions, or as otherwise agreed by the Company and the Agents. The Agents will use commercially reasonable efforts consistent with their normal trading and sales practices. Each time that the Company wishes to issue and sell the Company’s common stock under the ATM Sales Agreement, the Company will notify one of the Agents of the number of shares to be issued, the dates on which such sales are anticipated to be made, any minimum price below which sales may not be made and other sales parameters as the Company deems appropriate. The Company will pay the designated Agent a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock sold through such Agent as agent under the ATM Sales Agreement. The ATM Sales Agreement contains customary terms, provisions, representations and warranties. TAB Restructuring In July 2015, the Company and Total entered into a Letter Agreement (as amended in February 2016, the “JVCO Letter Agreement”) regarding the restructuring of the ownership and rights of TAB (the “Restructuring”), pursuant to which the parties agreed to enter into an Amended & Restated Jet Fuel License Agreement between the Company and TAB (the “Jet Fuel Agreement”), a License Agreement regarding Diesel Fuel in the European Union (the “EU”) between the Company and Total (the “EU Diesel Fuel Agreement”, and together with the Jet Fuel Agreement, the “Commercial Agreements”), and an Amended and Restated Shareholders’ Agreement among the Company, Total and TAB (together with the Commercial Agreements, the “Restructuring Agreements”), and file a Deed of Amendment of Articles of Association of TAB, all in order to reflect certain changes to the ownership structure of TAB and license grants and related rights pertaining to TAB. On February 12, 2016, the Company and Total entered into an amendment to the JVCO Letter Agreement, pursuant to which the parties agreed that, upon the closing of the Restructuring, Total would cancel R&D Notes in an aggregate principal amount of approximately $1.3 million, plus all paid-in-kind and accrued interest as of the closing of the Restructuring under all outstanding R&D Notes (including all such interest that was outstanding as of July 29, 2015), and a note in the principal amount of Euro 50,000, plus accrued interest, issued by the Company to Total in connection with the existing TAB capitalization, in exchange for an additional 25% ownership interest of TAB (giving Total an aggregate ownership stake of 75% of TAB and giving the Company an aggregate ownership stake of 25% of TAB). In connection therewith, Total would surrender to the Company the remaining R&D Notes and the Company would provide to Total a new unsecured senior convertible note, containing substantially similar terms and conditions, in the principal amount of $3.7 million (collectively, the “TAB Share Purchase”). On March 21, 2016, the Company, Total and TAB closed the Restructuring and entered into the Restructuring Agreements. Under the Jet Fuel Agreement, (a) the Company granted exclusive (excluding its Brazil jet fuel business), world-wide, royalty-free rights to TAB for the production and commercialization of farnesene- or farnesane-based jet fuel, (b) the Company granted TAB the option, until March 1, 2018, to purchase the Company’s Brazil jet fuel business at a price based on the fair value of the commercial assets and on the Company’s investment in other related assets, (c) the Company granted TAB the right to purchase farnesene or farnesane for its jet fuel business from the Company on a “most-favored” pricing basis and (d) all rights to farnesene- or farnesane-based diesel fuel previously granted to TAB by the Company reverted back to the Company. Upon all farnesene- or farnesane-based diesel fuel rights reverting back to the Company, the Company granted to Total, pursuant to the EU Diesel Fuel Agreement, (a) an exclusive, royalty-free license to offer for sale and sell farnesene- or farnesane-based diesel fuel in the EU, (b) the right to make farnesene or farnesane anywhere in the world, provided Total must (i) use such farnesene or farnesane to produce diesel fuel to offer for sale or sell in the EU and (ii) pay the Company a to-be-negotiated, commercially reasonable, “most-favored” basis royalty and (c) the right to purchase farnesene or farnesane for its EU diesel fuel business from the Company on a “most-favored” pricing basis. In addition, on March 21, 2016, the Company sold one half of the Company’s ownership stake in TAB to Total pursuant to the TAB Share Purchase (giving Total an aggregate ownership stake of 75% of TAB and giving the Company an aggregate ownership stake of 25% of TAB), and executed and delivered to Total a new, senior convertible note (the “March 2016 R&D Note”) in the principal amount of $3.7 million. Other than it is unsecured and its payment terms are severed from TAB’s business performance, the March 2016 R&D Note contains substantially similar terms and conditions to the R&D Notes. The March 2016 R&D Note has a March 1, 2017 maturity date and an initial conversion price equal to $3.08 per share of the Company’s common stock, which is subject to adjustment for proportional adjustments to the Company’s outstanding common stock and under anti-dilution provisions in case of certain dividends and distributions. The March 2016 R&D Note becomes convertible into the Company’s common stock (i) within 10 trading days prior to maturity, (ii) on a change of control of the Company, and (iii) on a default by the Company. The March 2016 R&D Note bears interest at a rate of 1.5% per year (with a default rate of 2.5% per year), accruing from March 21, 2016 and payable at maturity or on conversion of the March 2016 R&D Note or a change of control of the Company where Total exercises its right to require the Company to repurchase the March 2016 R&D Note at a price equal to 101% of the principal amount of the March 2016 R&D Note. The Total Purchase Agreement and March 2016 R&D Note include covenants regarding, among other things, payment of interest, maintenance of the Company’s listing status, limitations on debt and liens, maintenance of corporate existence, and filing of SEC reports. The March 2016 R&D Note contains standard events of default, including failure to pay, bankruptcy and insolvency, cross-defaults, and breaches of the covenants in the Total Purchase Agreement and the March 2016 R&D Note (and other notes issued under the Total Purchase Agreement), with added default interest rates and associated cure periods applicable to the covenant regarding SEC reporting. As a result of, and in order to reflect, the changes to the ownership structure of TAB described above, on March 21, 2016, (a) the Company, Total and TAB entered into an Amended and Restated Shareholders’ Agreement and filed a Deed of Amendment of Articles of Association of TAB and (b) the Company and Total terminated the Amended and Restated Master Framework Agreement, dated December 2, 2013 and amended on April 1, 2015, between the Company and Total.

Supplementary Financial Data -

Supplementary Financial Data - Selected Quarterly Financial Data	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	SUPPLEMENTARY FINANCIAL DATA Selected Quarterly Financial Data (unaudited) The following table presents selected unaudited consolidated financial data for each of the eight quarters in the two-year periods ended December 31, 2015. In the Company’s opinion, this unaudited information has been prepared on the same basis as the audited information and includes all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of the financial information for the periods presented. Net income (loss) per share—basic and diluted, for the four quarters of each fiscal year may not sum to the total for the fiscal year because of the different number of shares outstanding during each period. Quarter First Second Third Fourth (In thousands, except share and per share amounts) Year Ended December 31, 2015 Total revenues $ 7,872 $ 7,843 $ 8,591 $ 9,847 Product sales $ 2,095 $ 3,340 $ 4,228 $ 5,233 Gross profit (loss) from product sales $ (4,548 ) $ (7,619 ) $ (4,227 ) $ (6,084 ) Net income (loss) attributable to common stockholders (for basic income (loss) per share) (1) $ (52,240 ) $ (47,130 ) $ (76,664 ) $ (48,352 ) Net income (loss) attributable to common stockholders (for diluted income (loss) per share) $ (52,240 ) $ (54,527 ) $ (76,664 ) $ (68,316 ) Net income (loss) per share: Basic (1) $ (0.66 ) $ (0.59 ) $ (0.55 ) $ (0.23 ) Diluted $ (0.66 ) $ (0.62 ) $ (0.55 ) $ (0.30 ) Shares used in calculation: Basic 79,222,051 80,041,152 140,374,297 206,661,506 Diluted 79,222,051 87,421,439 140,374,297 231,014,248 Year Ended December 31, 2014 Total revenues $ 6,041 $ 9,307 $ 16,341 $ 11,585 Product sales $ 2,845 $ 4,410 $ 11,480 $ 4,704 Gross profit (loss) from product sales $ (3,391 ) $ (3,101 ) $ 1,334 $ (4,605 ) Net income (loss) attributable to common stockholders $ 16,385 $ (35,479 ) $ (36,641 ) $ 58,021 Net income (loss) per share: Basic $ 0.21 $ (0.45 ) $ (0.46 ) $ 0.73 Diluted $ (0.34 ) $ (0.45 ) $ (0.46 ) $ (0.21 ) Shares used in calculation: Basic 76,830,388 78,604,692 78,980,402 79,148,281 Diluted 117,097,976 78,604,692 78,980,402 146,804,047 (1)

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED DECEMBER 31, 2015, 2014 and 2013 (in thousands) Balance at Beginning of Additions Write-off Balance at Deferred Tax Assets Valuation Allowance: Year ended December 31, 2015 $ 312,323 $ 47,866 $ — $ 360,189 Year ended December 31, 2014 $ 284,021 $ 28,302 $ — $ 312,323 Year ended December 31, 2013 $ 236,288 $ 47,733 $ — $ 284,021 Balance at Additions Write-off Balance at Allowance for Doubtful Accounts: Year ended December 31, 2015 $ 479 $ 490 $ — $ 969 Year ended December 31, 2014 $ 479 $ — $ — $ 479 Year ended December 31, 2013 $ 481 $ — $ (2 ) $ 479

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (or GAAP) and with the instructions for Form 10-K and Regulations S-X. The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method to account for investments in companies, if its investments provide it with the ability to exercise significant influence over operating and financial policies of the investee. Consolidated net income or loss includes the Company’s proportionate share of the net income or loss of these companies. Judgments made by the Company regarding the level of influence over each equity method investment include considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements of the Company include the accounts of Amyris, Inc., its subsidiaries and two consolidated variable interest entities (or “VIEs”), with respect to which the Company is considered the primary beneficiary, after elimination of intercompany accounts and transactions. Disclosure regarding the Company’s participation in the VIEs is included in Note 7, "Joint Ventures and Noncontrolling Interest."
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	Variable Interest Entities The Company has interests in joint venture entities that are VIEs. Determining whether to consolidate a VIE requires judgment in assessing (i) whether an entity is a VIE and (ii) if the Company is the entity’s primary beneficiary and thus required to consolidate the entity. To determine if the Company is the primary beneficiary of a VIE, the Company evaluates whether it has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company’s evaluation includes identification of significant activities and an assessment of its ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding and financing and other applicable agreements and circumstances. The Company’s assessment of whether it is the primary beneficiary of its VIEs requires significant assumptions and judgment.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates In preparing the consolidated financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short term investments and accounts receivable. The Company places its cash equivalents and investments (primarily certificates of deposits) with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and short-term investments. The Company performs ongoing credit evaluation of its customers, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary. Customers representing 10% or greater of accounts receivable were as follows: December 31, Customers 2015 2014 Customer H 23 % ** Customer C 26 % 19 % Customer G 10 % ** Customer I * 23 % Customer E ** 28 % * No outstanding balance ** Less than 10% Customers representing 10% or greater of revenues were as follows: Years Ended December 31, Customers 2015 2014 2013 Customer B ** ** 15 % Customer C ** 10 % 10 % Customer E 37 % 47 % 20 % Customer F ** ** 12 % Customer J 10 % ** * * Not a customer ** Less than 10%
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not available, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments’ complexity. The carrying amounts of certain financial instruments, such as cash equivalents, short term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The fair values of the loans payable, convertible notes and credit facility are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The loans payable, convertible notes and credit facility are carried on the consolidated balance sheet on a historical cost basis, because the Company has not elected to recognize the fair value of these liabilities. However, the Remaining Notes subject to the Maturity Treatment Agreement were revalued to fair value on July 29, 2015 (see Note 5 “Debt” for details). The Company estimates the fair value of the compound embedded derivatives for the convertible promissory notes to Total Energies Nouvelles Activités USA (formerly known as Total Gas & Power USA, SAS, or Total) (refer to Note 5, "Debt" for further details) using the Monte Carlo simulation valuation model that combines expected cash outflows with market-based assumptions regarding risk-adjusted yields, stock price volatility, probability of a change of control and the trading information of the Company's common stock into which the notes are or may become convertible. The Company estimates the fair value of the compound embedded derivatives for the first and second tranches of the August 2013 Financing (or, Tranche I Notes and Tranche II Notes, respectively) and the 2014 and 2015 144A Notes (as defined in Note 5, "Debt" and collectively, Convertible Notes) using the binomial lattice model in order to estimate the fair value of the embedded derivatives. A binomial lattice model generates two probable outcomes - one up and another down - arising at each point in time, starting from the date of valuation until the maturity date. A lattice model was used to determine if the Convertible Notes would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the Convertible Notes will be converted early if the conversion value is greater than the holding value and (ii) the Convertible Notes will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the Convertible Notes are called, then the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the Convertible Notes. Using this lattice method, the Company valued the embedded derivatives using the "with-and-without method", where the fair value of the Convertible Notes including the embedded derivatives is defined as the "with", and the fair value of the Convertible Notes excluding the embedded derivatives is defined as the "without". This method estimates the fair value of the embedded derivatives by looking at the difference in the values between the Convertible Notes with the embedded derivatives and the fair value of the Convertible Notes without the embedded derivatives. The lattice model uses the stock price, conversion rate, conversion price, maturity date, risk-free interest rate, estimated stock volatility and estimated credit spread. Changes in the inputs into these valuation models have a significant impact on the estimated fair value of the embedded derivatives. For example, a decrease (increase) in the estimated credit spread for the Company results in an increase (decrease) in the estimated fair value of the embedded derivatives. Conversely, a decrease (increase) in the stock price results in a decrease (increase) in the estimated fair value of the embedded derivatives. The changes during 2015, 2014 and 2013 in the fair values of the bifurcated compound embedded derivatives are primarily related to the change in price of the Company's underlying common stock and are reflected in the consolidated statements of operations as “Gain (loss) from change in fair value of derivative instruments.”
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents All highly liquid investments purchased with an original maturity date of 90 days or less at the date of purchase are considered to be cash equivalents. Cash and cash equivalents consist of money market funds and certificates of deposit.
Investment, Policy [Policy Text Block]	Short Term Investments Investments with original maturities greater than 90 days that mature less than 1 year from the consolidated balance sheet date are classified as short-term investments. The Company classifies investments as short-term or long-term based upon whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. The Company invests its excess cash balances primarily in certificates of deposit. Certificates of deposits that have maturities greater than 90 days that mature less than one year from the consolidated balance sheet date are classified as short term investments. The Company classifies all of its investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity (deficit). Debt securities are adjusted for amortization of premiums and accretion of discounts and such amortization and accretion are reported as a component of interest income. Realized gains and losses and declines in value that are considered to be other-than-temporary are recognized in the statements of operations. The cost of securities sold is determined on the specific identification method. There were no significant realized gains or losses from sales of debt securities during the years ended December 31, 2015, 2014 and 2013. As of December 31, 2015 and 2014, the Company did not have any other-than-temporary declines in the fair value of its debt securities.
Receivables, Policy [Policy Text Block]	Accounts Receivable The Company maintains an allowance for doubtful accounts receivable for estimated losses resulting from the inability of its customers to make required payments. The Company determines this allowance based on specific doubtful account identification and management judgment on estimated exposure. The Company writes off accounts receivable against the allowance when it determines a balance is uncollectible and no longer actively pursues collection of the receivable.
Inventory, Policy [Policy Text Block]	Inventories Inventories, which consist of farnesene-derived products and flavor and fragrances ingredients are stated at the lower of cost or market and categorized as finished goods, work-in-process or raw material inventories. The Company evaluates the recoverability of its inventories based on assumptions about expected demand and net realizable value. If the Company determines that the cost of inventories exceeds its estimated net realizable value, the Company records a write-down equal to the difference between the cost of inventories and the estimated net realizable value. If actual net realizable values are less favorable than those projected by management, additional inventory write-downs may be required that could negatively impact the Company's operating results. If actual net realizable values are more favorable, the Company may have favorable operating results when products that have been previously written down are sold in the normal course of business. The Company also evaluates the terms of its agreements with its suppliers and establishes accruals for estimated losses on adverse purchase commitments as necessary, applying the same lower of cost or market approach that is used to value inventory. Cost is computed on a first-in, first-out basis. Inventory costs include transportation costs incurred in bringing the inventory to its existing location.
Equity Method Investments, Policy [Policy Text Block]	Investments in Affiliates We use the equity method to account for our investments in affiliates. We include our proportionate share of earnings and/or losses of our equity method investees in the loss from investments in affiliates in the consolidated statements of operations. The carrying value of our investments in affiliates includes loans to affiliates. Investments in affiliates are carried at cost less impairment, as adjusted for market rates of interest imputed to non-market interest rate loans advanced to affiliates.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash Cash accounts that are restricted to withdrawal or usage are presented as restricted cash. As of
Derivatives, Policy [Policy Text Block]	Derivative Instruments The Company makes limited use of derivative instruments, which includes currency interest rate swap agreements, to manage the Company's exposure to foreign currency exchange rate fluctuations and interest rate fluctuations related to the Company's Banco Pine S.A. loan (discussed below under Note 5, "Debt"). Changes in the fair value of the derivative contracts are recognized immediately in the consolidated statements of operations. Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e. host) are accounted for and valued as separate financial instruments. The Company evaluated the terms and features of its convertible notes payable and identified compound embedded derivatives requiring bifurcation and accounting at fair value because the economic and contractual characteristics of the embedded derivatives met the criteria for bifurcation and separate accounting due to the conversion options containing “make-whole interest” provisions, down round conversion price adjustment provisions and conversion rate adjustments,.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment, net Property, plant and equipment, net are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the related assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. Depreciation and amortization periods for the Company’s property, plant and equipment are as follows: Machinery and equipment (in years) 7 - 15 Buildings (in years) 15 Computers and software (in years) 3 - 5 Furniture and office equipment (in years) 5 Vehicles (in years) 5 Buildings and leasehold improvements are amortized on a straight-line basis over the terms of the lease, or the useful life of the assets, whichever is shorter. Computers and software includes internal-use software that is acquired to meet the Company’s needs. Amortization commences when the software is ready for its intended use and the amortization period is the estimated useful life of the software, generally 3 to 5 years. Capitalized costs primarily include contract labor costs of the individuals dedicated to the development and installation of internal-use software.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable or the estimated useful life is no longer appropriate. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the assets down to their estimated fair values. Fair value is estimated based on discounted future cash flows. There were $28.5 million, $1.8 million, and $7.7 million, of impairment charges recorded during the years ended December 31, 2015, 2014 and 2013, respectively.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Intangible Assets Goodwill represents the excess of the cost over the fair value of net assets acquired from business combinations. Intangible assets are comprised primarily of in-process research and development (or IPR&D). The goodwill and IPR&D were recognized on an acquisition completed in 2011. Goodwill and intangible assets with indefinite useful lives are assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such a review. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. The Company makes significant judgments in relation to the valuation of goodwill and intangible assets resulting from business combinations. There are several methods that can be used to determine the estimated fair value of the IPR&D acquired in a business combination. We used the "income method," which applies a probability weighting that considers the risk of development and commercialization, to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets will be amortized over the remaining useful life or written off, as appropriate. Amounts recorded as IPR&D will begin being amortized upon the completion of development activities over the estimated useful life of the technology. The development activities have not been completed, and therefore the amortization of the acquired IPR&D has not begun. Factors that could trigger an impairment review include significant under-performance relative to expected historical or projected future operating results, significant changes in the manner of use of the acquired assets or the strategy for the Company's overall business or significant negative industry or economic trends. If this evaluation indicates that the value of the intangible asset may be impaired, we make an assessment of the recoverability of the net carrying value of the asset. If this assessment indicates that the intangible asset is not recoverable, based on the estimated discounted future cash flows of the technology over its expected life, we reduce the net carrying value of the related intangible asset to fair value. As a result of the impairment assessment of IPR&D, the Company recognized an impairment of its IPR&D asset of $5.5 million and $3.0 million for the years ended December 31, 2015 and 2014, respectively, and zero for the year ended December 31 2013. As of December 31, 2015, the Company's intangible assets had a carrying amount of zero.
Combination of Entities under Common Control, Policy [Policy Text Block]	Noncontrolling Interest Changes in noncontrolling interest ownership that do not result in a change of control and where there is a difference between fair value and carrying value are accounted for as equity transactions. In April 2010, the Company entered into a joint venture with São Martinho S.A. (or São Martinho). The carrying value of the noncontrolling interest from this joint venture is recorded in the equity section of the consolidated balance sheets (see Note 7, "Joint Ventures and Noncontrolling Interest"). In January 2011, the Company entered into a production service agreement with Glycotech, Inc. (or Glycotech). The Company has determined that the arrangement with Glycotech qualifies as a VIE. The Company determined that it is the primary beneficiary. The carrying value of the noncontrolling interest from this VIE is recorded in the equity section of the consolidated balance sheets (see Note 7, "Joint Ventures and Noncontrolling Interest").
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of renewable products, delivery of research and development services, and from governmental grants. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and collectability is reasonably assured. If sales arrangements contain multiple elements, the Company evaluates whether the components of each arrangement represent separate units of accounting. Product Sales The Company's renewable product sales do not include rights of return. Returns are only accepted if the product does not meet product specifications and such nonconformity is communicated to the Company within a set number of days of delivery. The Company offers a two year standard warranty provision for squalane products sold after March 31, 2012, if the products do not meet Company-established criteria as set forth in the Company's trade terms. The Company bases its return reserve on a historical rate of return for the Company's squalane products. Revenues are recognized, net of discounts and allowances, once passage of title and risk of loss has occurred and contractually specified acceptance criteria have been met, provided all other revenue recognition criteria have also been met. Grants and Collaborative Revenue Revenue from collaborative research services is recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research services fluctuate over the research term, the Company recognizes revenue using the proportionate performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by the Company. When up-front payments are received and the planned levels of research services do not fluctuate over the research term, revenue is recorded on a ratable basis over the arrangement term, up to the amount of cash received. When up-front payments are received and the planned levels of research services fluctuate over the research term, revenue is recorded using the proportionate performance method, up to the amount of cash received. Where arrangements include milestones that are determined to be substantive and at risk at the inception of the arrangement, revenue is recognized upon achievement of the milestone and is limited to those amounts whereby collectability is reasonably assured. Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met and only perfunctory obligations are outstanding.
Cost of Sales, Policy [Policy Text Block]	Cost of Products Sold Cost of products sold includes production costs of renewable products, which include cost of raw materials, amounts paid to contract manufacturers and period costs including inventory write-downs resulting from applying lower-of-cost-or-market inventory valuation. Cost of products sold also includes certain costs related to the scale-up in production of such products. Shipping and handling costs charged to customers are recorded as revenues. Shipping costs are included in cost of products sold. Such charges were not significant in any of the periods presented.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements and government grants, including internal research. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to others that conduct certain research activities on the Company’s behalf.
Debt, Policy [Policy Text Block]	Debt Extinguishment The Company accounts for the income or loss from extinguishment of debt in accordance with ASC 470, "Debt", which indicates that for all extinguishment of debt, the difference between the reacquisition price and the net carrying amount of the debt being extinguished should be recognized as gain or loss when the debt is extinguished. The gain or loss from debt extinguishment is recorded in the consolidated statements of operations under "other income (expense)" as "gain (loss) from extinguishment of debt".
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized. The Company recognizes and measures uncertain tax positions in accordance with Income Taxes subtopic 05-6 of ASC 740, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken in a tax return, in the consolidated financial statements. Additionally, the guidance also prescribes treatment for the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Currency Translation The Company considers the local currency to be the functional currency of the Company’s wholly-owned subsidiary in Brazil and of the Company's consolidated joint venture in Brazil. Accordingly, asset and liability accounts of those operations are translated into United States dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into United States dollars using historical rates. The revenues and expenses are translated using the exchange rates in effect when the transactions occur. Gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income (loss) on the consolidated balance sheets. Foreign currency differences arising from the translation of intercompany loans from a foreign currency into the functional currency of an entity, which are of a long-term investment nature (that is, settlement is not planned or anticipated in the foreseeable future) are recorded in “Accumulated other comprehensive income (loss)” on our Consolidated Balance Sheets. Foreign currency differences arising from the translation of other intercompany loans are recorded in “Other income (expense)” on our Consolidated Statements of Operations.
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The Company uses the Black-Scholes option pricing model to estimate the fair value of options granted, which is expensed on a straight-line basis over the vesting period. The Company accounts for restricted stock unit awards issued to employees based on the fair market value of the Company’s common stock. The Company accounts for stock options issued to nonemployees based on the estimated fair value of the awards using the Black-Scholes option pricing model. The Company accounts for restricted stock units issued to nonemployees based on the fair market value of the Company’s common stock. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in the Company’s consolidated statements of operations during the period the related services are rendered.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) Comprehensive income (loss) represents all changes in stockholders’ deficit except those resulting from investments or contributions by stockholders. The Company’s foreign currency translation adjustments represent the components of comprehensive income (loss) excluded from the Company’s net income (loss) and have been disclosed in the consolidated statements of comprehensive loss for all periods presented. The components of accumulated other comprehensive loss are as follows (in thousands): December 31, 2015 2014 Foreign currency translation adjustment, net of tax $ (47,198 ) $ (29,977 ) Total accumulated other comprehensive loss $ (47,198 ) $ (29,977 )
Earnings Per Share, Policy [Policy Text Block]	Net Loss Attributable to Common Stockholders and Net Loss per Share The Company computes net loss per share in accordance with ASC 260, “Earnings per Share.” Basic net loss per share of common stock is computed by dividing the Company’s net loss attributable to Amyris, Inc. common stockholders (as adjusted in 2015 to remove the impact of the fair value adjustments for any currently exercisable warrants in which the number of shares are included in the weighted average number of common stock outstanding) by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed by giving effect to all potentially dilutive securities, including stock options, restricted stock units and common stock warrants, using the treasury stock method or the as converted method, as applicable. For the years ended December 31, 2013 and 2015, basic net loss per share was the same as diluted net loss per share because the inclusion of all potentially dilutive securities outstanding was anti-dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss were the same for those years. The following table presents the calculation of basic and diluted net loss per share of common stock attributable to Amyris, Inc. common stockholders (in thousands, except share and per share amounts): Years Ended December 31, 2015 2014 2013 Numerator: Net income (loss) attributable to Amyris, Inc. common stockholders $ (217,952 ) $ 2,286 $ (235,111 ) Adjustment to exclude fair value gain on liability classified warrants (1) (3,825 ) — — Net income (loss) attributable to Amyris, Inc. common stockholders (for basic income (loss) per share) (221,777 ) 2,286 (235,111 ) Interest on convertible debt — 9,365 — Accretion of debt discount — 5,597 — Gain from change in fair value of derivative instruments — (127,109 ) — Net loss attributable to Amyris, Inc. common stockholders after assumed conversion $ (221,777 ) $ (109,861 ) $ (235,111 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 126,961,576 78,400,098 75,472,770 Basic income (loss) per share $ (1.75 ) $ 0.03 $ (3.12 ) Weighted average shares of common stock outstanding 126,961,576 78,400,098 75,472,770 Effect of dilutive securities: Convertible promissory notes — 43,459,343 — Weighted common stock equivalents — 43,459,343 — Diluted weighted-average common shares 126,961,576 121,859,441 75,472,770 Diluted loss per share $ (1.75 ) $ (0.90 ) $ (3.12 ) (1) The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company’s consolidated statement of operations for the year ended December 31, 2015. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company’s common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive: Years Ended December 31, 2015 2014 2013 Period-end stock options to purchase common stock 12,930,112 10,539,978 8,409,605 Convertible promissory notes (1) 72,537,306 26,887,005 42,905,005 Period-end common stock warrants 2,901,926 1,021,087 1,021,087 Period-end restricted stock units 5,554,844 1,975,503 2,316,437 Total 93,924,188 40,423,573 54,652,134 (1) The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of December 31, 2015. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (or “FASB”) issued new guidance related to revenue recognition. This new standard will replace all current GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition update guidance provides a unified model to determine how revenue is recognized. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. Therefore, the new standard will be effective commencing with our quarter ending March 31, 2018. In August 2014, FASB issued new guidance related to the disclosure around going concern. The new standard provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosure if substantial doubt exists. The new standard is effective for annual periods ending after December 15, 2016 and for annual periods and interim periods thereafter. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial statements. In January 2015, the FASB issued an update related to the presentation of extraordinary and unusual items. The update eliminates the concept of extraordinary items found in Subtopic 225-20, which required that an entity separately classify, present and disclose extraordinary events and transactions when the event or activity met both criteria of being unusual in nature and infrequent in occurrence. Although the concept of extraordinary items will be eliminated, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in nature and infrequently occurring. The standard is effective for annual and interim periods within those annual years beginning after December 15, 2015. The Company expects that the adoption of the update will not materially affect its financial statements. In February 2015, FASB issued an amendment to ASC 810 Consolidation. The amendments affect reporting entities that are required to evaluate whether they should consolidate certain legal entities. The amendments are effective for the fiscal years and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently assessing the impact of adopting this new accounting standard on its financial statements. In April 2015, the FASB issued Accounting Standards Update 2015-3, Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued Accounting Standards Update 2015-11, Simplifying the Measurement of Inventory In January 2016, the FASB issued Accounting Standards Update 2016-01 Financial Instruments-Overall In February 2016, the FASB issued Accounting Standards Update 2016-02- Leases

Note 2 - Summary of Significa28

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	December 31, Customers 2015 2014 Customer H 23 % ** Customer C 26 % 19 % Customer G 10 % ** Customer I * 23 % Customer E ** 28 % Years Ended December 31, Customers 2015 2014 2013 Customer B ** ** 15 % Customer C ** 10 % 10 % Customer E 37 % 47 % 20 % Customer F ** ** 12 % Customer J 10 % ** *
Property, Plant and Equipment Useful Life [Table Text Block]	Machinery and equipment (in years) 7 - 15 Buildings (in years) 15 Computers and software (in years) 3 - 5 Furniture and office equipment (in years) 5 Vehicles (in years) 5
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	December 31, 2015 2014 Foreign currency translation adjustment, net of tax $ (47,198 ) $ (29,977 ) Total accumulated other comprehensive loss $ (47,198 ) $ (29,977 )
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years Ended December 31, 2015 2014 2013 Numerator: Net income (loss) attributable to Amyris, Inc. common stockholders $ (217,952 ) $ 2,286 $ (235,111 ) Adjustment to exclude fair value gain on liability classified warrants (1) (3,825 ) — — Net income (loss) attributable to Amyris, Inc. common stockholders (for basic income (loss) per share) (221,777 ) 2,286 (235,111 ) Interest on convertible debt — 9,365 — Accretion of debt discount — 5,597 — Gain from change in fair value of derivative instruments — (127,109 ) — Net loss attributable to Amyris, Inc. common stockholders after assumed conversion $ (221,777 ) $ (109,861 ) $ (235,111 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 126,961,576 78,400,098 75,472,770 Basic income (loss) per share $ (1.75 ) $ 0.03 $ (3.12 ) Weighted average shares of common stock outstanding 126,961,576 78,400,098 75,472,770 Effect of dilutive securities: Convertible promissory notes — 43,459,343 — Weighted common stock equivalents — 43,459,343 — Diluted weighted-average common shares 126,961,576 121,859,441 75,472,770 Diluted loss per share $ (1.75 ) $ (0.90 ) $ (3.12 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Years Ended December 31, 2015 2014 2013 Period-end stock options to purchase common stock 12,930,112 10,539,978 8,409,605 Convertible promissory notes (1) 72,537,306 26,887,005 42,905,005 Period-end common stock warrants 2,901,926 1,021,087 1,021,087 Period-end restricted stock units 5,554,844 1,975,503 2,316,437 Total 93,924,188 40,423,573 54,652,134

Note 3 - Fair Value of Financ29

Note 3 - Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 2,078 $ — $ — $ 2,078 Certificates of deposit 1,520 — — 1,520 Total financial assets $ 3,598 $ — $ 0 $ 3,598 Financial Liabilities Loans payable (1) $ — $ 9,541 $ — $ 9,541 Credit facilities (1) — 34,893 — 34,893 Convertible notes (1) — — 96,291 96,291 Compound embedded derivative liabilities — — 46,430 46,430 Currency interest rate swap derivative liability — 5,009 — 5,009 Total financial liabilities $ — $ 49,443 $ 142,721 $ 192,164 Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 20,160 $ — $ — $ 20,160 Certificates of deposit 1,375 — — 1,375 Loans to affiliate — — 1,745 1,745 Total financial assets $ 21,535 $ — $ 1,745 $ 23,280 Financial Liabilities Loans payable (1) $ — $ 16,720 $ — $ 16,720 Credit facilities (1) — 39,332 — 39,332 Convertible notes (1) — — 222,031 222,031 Compound embedded derivative liabilities — — 56,026 56,026 Currency interest rate swap derivative liability — 3,710 — 3,710 Total financial liabilities $ — $ 59,762 $ 278,057 $ 337,819
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	2015 2014 Balance at January 1 $ 222,031 $ 131,952 Additions to convertible notes 31,984 123,273 Conversion/extinguishment of convertible notes (127,583 ) (13,539 ) Change in fair value of convertible notes (30,141 ) (19,655 ) Balance at December 31 $ 96,291 $ 222,031
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	2015 2014 Balance at January 1 $ 56,026 $ 131,117 Additions to Level 3 40,359 90,174 Derecognition on conversion/extinguishment (30,806 ) (1,104 ) Gain from change in fair value of derivative liabilities (1) (19,149 ) (164,161 ) Balance at December 31 $ 46,430 $ 56,026
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	December 31, 2015 December 31, 2014 Risk-free interest rate 1.26% - 1.40% 0.75% - 1.51% Risk-adjusted yields 35.80% - 45.93% 21.40% - 31.50% Stock-price volatility 45% 45% Probability of change in control 5% 5% Stock price $1.62 $2.06 Credit spread 34.48% - 44.55% 19.97% - 29.99% Estimated conversion dates 2016 - 2019 2017 - 2019 Initial recognition Expected dividend yield 0 Risk-free interest rate 2 % Expected term (in years) 10.0 Expected volatility 74 %
Derivative Instruments, Gain (Loss) [Table Text Block]	Income Years Ended December 31, Type of Derivative Contract Statement Classification 2015 2014 2013 Gain (Loss) Recognized Currency interest rate swap (1) Gain (loss) from change in fair value of derivative instruments $ (3,367 ) $ (480 ) $ (2,404 )
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	December 31, 2015 2014 Fair market value of swap obligation $ 5,009 $ 3,710 Fair value of compound embedded derivative liabilities 46,430 56,026 Total derivative liabilities $ 51,439 $ 59,736

Note 4 - Balance Sheet Compon30

Note 4 - Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of Inventory, Current [Table Text Block]	December 31, 2015 2014 Raw materials $ 2,204 $ 2,665 Work-in-process 3,583 5,269 Finished goods 5,099 6,572 Inventories, net $ 10,886 $ 14,506
Schedule of Prepaid and Other Current Assets [Table Text Block]	December 31, 2015 2014 Maintenance $ 124 $ 399 Prepaid insurance 581 701 Manufacturing catalysts 2,698 1,166 Recoverable VAT and other taxes — 2,411 Debt issuance costs 1,357 — Other 1,112 1,857 Prepaid expenses and other current assets $ 5,872 $ 6,534
Property, Plant and Equipment [Table Text Block]	December 31, 2015 2014 Leasehold improvements $ 38,519 $ 39,132 Machinery and equipment 72,876 90,657 Computers and software 9,117 8,946 Furniture and office equipment 2,234 2,445 Buildings 3,922 6,321 Vehicles 215 353 Construction in progress 5,736 38,815 132,619 186,669 Less: accumulated depreciation and amortization (72,822 ) (67,689 ) Property, plant and equipment, net $ 59,797 $ 118,980
Schedule of Other Assets, Noncurrent [Table Text Block]	December 31, 2015 2014 Deposits on property and equipment, including taxes $ 243 $ 1,738 Recoverable taxes from Brazilian government entities 8,887 9,747 Debt issuance costs 2,806 851 Other 1,214 1,299 Total other assets $ 13,150 $ 13,635
Schedule of Accrued and Other Current Liabilities [Table Text Block]	December 31, 2015 2014 Professional services $ 4,017 $ 2,015 Accrued vacation 2,023 2,213 Payroll and related expenses 3,122 5,393 Tax-related liabilities 2,505 277 Withholding tax related to conversion of related party notes 4,723 — Deferred rent, current portion 1,111 1,111 Accrued interest 1,984 1,308 SMA relocation accrual 3,641 — Other 1,142 1,248 Total accrued and other current liabilities $ 24,268 $ 13,565

Note 5 - Debt (Tables)

Note 5 - Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	December 31, 2015 2014 FINEP credit facility $ 840 $ 1,614 BNDES credit facility 1,956 4,314 Hercules loan facility 31,653 29,779 Total credit facilities 34,449 35,707 Convertible notes 64,603 60,418 Related party convertible notes 43,029 115,239 Loans payable 13,975 21,097 Total debt 156,056 232,461 Less: current portion (37,570 ) (17,100 ) Long-term debt $ 118,486 $ 215,361
Schedule of Long-term Debt Instruments [Table Text Block]	Years ending December 31: Related Party Convertible Debt Convertible Debt Loans Payable Credit Facility Total 2016 $ 1,255 $ 11,426 $ 5,341 $ 37,919 $ 55,941 2017 6,460 24,841 2,120 1,279 34,700 2018 16,476 18,610 2,030 267 37,383 2019 35,145 90,965 1,939 65 128,114 2020 — — 1,849 — 1,849 Thereafter — — 2,743 — 2,743 Total future minimum payments 59,336 145,842 16,022 39,530 260,730 Less: amount representing interest (1) (21,833 ) (81,240 ) (2,046 ) (5,081 ) (110,200 ) Present value of minimum debt payments 37,503 64,602 13,976 34,449 150,530 Less: current portion — — (4,681 ) (32,889 ) (37,570 ) Add: fair value change due to conversions 5,526 — — — 5,526 Noncurrent portion of debt $ 43,029 $ 64,602 $ 9,295 $ 1,560 $ 118,486

Note 6 - Commitments and Cont32

Note 6 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of Future Minimum Payments for Lease Obligations [Table Text Block]	Years ending December 31: Capital Operating Total Lease 2016 $ 565 $ 6,724 $ 7,289 2017 188 6,644 6,832 2018 — 6,701 6,701 2019 — 6,749 6,749 2020 — 6,985 6,985 Thereafter — 18,047 18,047 Total future minimum lease payments 753 $ 51,850 $ 52,603 Less: amount representing interest (54 ) Present value of minimum lease payments 699 Less: current portion (523 ) Long-term portion $ 176

Note 7 - Joint Ventures and N33

Note 7 - Joint Ventures and Noncontrolling Interest (Tables)	12 Months Ended
	Dec. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments [Table Text Block]	December 31, (In thousands) 2015 2014 Balance at January 1 $ 2,192 $ — Loans to affiliate 1,579 1,745 Capital contribution (cash) — 2,312 Share in net loss offset to equity investment (848 ) (2,910 ) Share in net loss offset to loans to affiliate (1,743 ) — Accretion of imputed interest 413 1,045 Impairment (1,593 ) — Balance at December 31 $ — $ 2,192
Schedule of Variable Interest Entities [Table Text Block]	December 31, (In thousands) 2015 2014 Assets * $ 6,993 $ 22,812 Liabilities $ 1,221 $ 290
Noncontrolling Interest [Table Text Block]	2015 2014 Balance at January 1 $ 611 $ 584 Foreign currency translation adjustment (320 ) (92 ) Income attributable to noncontrolling interest 100 119 Balance at December 31 $ 391 $ 611

Note 9 - Goodwill and Intangi34

Note 9 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	December 31, 2015 December 31, 2014 Useful Life Gross Accumulated Net Gross Accumulated Net In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (3,035 ) $ 5,525 Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (3,807 ) $ 6,085 December 31, 2014 December 31, 2015 Net Carrying Value Impairment Net Carrying Value In-process research and development $ 5,525 $ (5,525 ) $ — Acquired licenses and permits — — — Goodwill 560 — 560 $ 6,085 $ (5,525 ) $ 560

Note 11 - Stock-based Compens35

Note 11 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]	Number Weighted- Weighted- Aggregate (in thousands) Outstanding - December 31, 2014 10,539,978 $ 6.10 7.22 $ 50 Options granted 4,720,278 $ 1.84 — — Options exercised (13,250 ) $ 1.38 — — Options cancelled (2,316,894 ) $ 4.89 — — Outstanding - December 31, 2015 12,930,112 $ 4.77 7.39 $ 22 Vested and expected to vest after December 31, 2015 11,967,864 $ 4.98 7.21 $ 20 Exercisable at December 31, 2015 6,226,620 $ 7.43 5.57 $ 12
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	RSUs Weighted- Weighted Average Outstanding - December 31, 2014 1,975,503 $ 3.28 0.93 Awarded 4,988,539 $ 1.82 — Vested (1,046,468 ) $ 3.10 — Forfeited (362,730 ) $ 2.90 — Outstanding - December 31, 2015 5,554,844 $ 2.03 1.61 Expected to vest after December 31, 2015 4,698,610 $ 2.05 1.47
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Exercise Price Number of Options Weighted- Weighted-Average Exercise Price Number of Options Weighted-Average Exercise Price $0.28—$1.67 1,363,293 9.43 $ 1.62 65,593 $ 1.44 $1.69—$1.75 1,338,225 9.64 $ 1.73 — $ — $1.78—$1.80 121,000 9.33 $ 1.79 437 $ 1.80 $1.96—$1.96 1,390,783 9.44 $ 1.96 — $ — $1.98—$2.79 1,661,324 7.41 $ 2.62 930,882 $ 2.71 $2.81—$3.05 1,322,620 7.23 $ 2.94 902,484 $ 2.94 $3.08—$3.44 323,669 7.55 $ 3.33 192,283 $ 3.30 $3.51—$3.51 1,922,290 8.06 $ 3.51 829,483 $ 3.51 $3.55—$3.93 1,481,696 4.89 $ 3.87 1,324,343 $ 3.88 $4.08—$30.17 2,005,212 4.07 $ 16.16 1,981,115 $ 16.30 $0.28—$30.17 12,930,112 7.39 $ 4.77 6,226,620 $ 7.43
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Years Ended December 31, 2015 2014 2013 Research and development $ 2,306 $ 3,508 $ 4,281 Sales, general and administrative 6,828 10,597 13,766 Total stock-based compensation expense $ 9,134 $ 14,105 $ 18,047
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Years Ended December 31, 2015 2014 2013 Expected dividend yield — % — % — % Risk-free interest rate 1.8 % 1.9 % 1.4 % Expected term (in years) 6.08 6.10 6.10 Expected volatility 74 % 75 % 82 %

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Years Ended December 31, 2015 2014 2013 United States $ (193,128 ) $ 10,847 $ (216,583 ) Foreign (24,457 ) (5,275 ) (19,171 ) Income (loss) before income taxes and loss from investment in affiliate $ (217,585 ) $ 5,572 $ (235,754 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years Ended December 31, 2015 2014 2013 Current: Federal $ — $ — $ — State — — — Foreign 468 495 (847 ) Total current provision (benefit) 468 495 (847 ) Deferred: Federal — — — State — — — Foreign — — — Total deferred provision (benefit) — — — Total provision (benefit) for income taxes $ 468 $ 495 $ (847 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Years Ended December 31, 2015 2014 2013 Statutory tax rate (34.0 )% (34.0 )% (34.0 )% State tax rate, net of federal benefit (0.3 )% 23.3 % (0.7 )% Stock-based compensation 0.1 % (2.8 )% 0.1 % Federal R&D credit (0.6 )% 31.0 % (0.8 )% Derivative liabilities 3.6 % 541.5 % 13.9 % Non-Deductible Interest 5.5 % — % 0.0 % Other 0.1 % (7.8 )% (0.6 )% Foreign losses (1.2 )% 32.3 % (1.4 )% Change in valuation allowance 27.1 % (592.4 )% 23.1 % Effective income tax rate 0.3 % (8.9 )% (0.4 )%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2015 2014 2013 Net operating loss carryforwards $ 207,241 $ 195,536 $ 167,354 Fixed assets 10,519 1,299 822 Research and development credits 16,612 14,701 11,654 Foreign Tax Credit 1,899 1,431 935 Accruals and reserves 26,366 16,425 17,893 Stock-based compensation 19,048 18,773 17,521 Capitalized start-up costs 9,568 13,095 15,133 Capitalized research and development costs 63,339 56,880 45,968 Other 9,999 6,700 6,741 Total deferred tax assets 364,591 324,840 284,021 Fixed assets — — — Debt discount and derivative (4,402 ) (12,517 ) — Total deferred tax liabilities (4,402 ) (12,517 ) — Net deferred tax asset prior to valuation allowance 360,189 312,323 284,021 Less: Valuation allowance (360,189 ) (312,323 ) (284,021 ) Net deferred tax assets (liabilities) $ — $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Balance at December 31, 2012 $ 3,918 Increases in tax positions for prior period 469 Increases in tax positions during current period 1,693 Balance at December 31, 2013 $ 6,080 Increases in tax positions for prior period 4,736 Increases in tax positions during current period 6,265 Balance at December 31, 2014 $ 17,081 Decreases in tax positions for prior period (9,404 ) Increases in tax positions during current period 957 Balance at December 31, 2015 $ 8,634

Note 15 - Reporting Segments (T

Note 15 - Reporting Segments (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Years Ended December 31, 2015 2014 2013 United States $ 20,897 $ 21,331 $ 21,235 Brazil 5,070 5,961 4,071 Europe 3,557 9,738 10,340 Asia 4,629 6,244 5,473 Total $ 34,153 $ 43,274 $ 41,119
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	December 31, 2015 2014 United States $ 18,401 $ 44,418 Brazil 41,093 74,197 Europe 303 365 Total $ 59,797 $ 118,980

Supplementary Financial Data 38

Supplementary Financial Data - Selected Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]	Quarter First Second Third Fourth (In thousands, except share and per share amounts) Year Ended December 31, 2015 Total revenues $ 7,872 $ 7,843 $ 8,591 $ 9,847 Product sales $ 2,095 $ 3,340 $ 4,228 $ 5,233 Gross profit (loss) from product sales $ (4,548 ) $ (7,619 ) $ (4,227 ) $ (6,084 ) Net income (loss) attributable to common stockholders (for basic income (loss) per share) (1) $ (52,240 ) $ (47,130 ) $ (76,664 ) $ (48,352 ) Net income (loss) attributable to common stockholders (for diluted income (loss) per share) $ (52,240 ) $ (54,527 ) $ (76,664 ) $ (68,316 ) Net income (loss) per share: Basic (1) $ (0.66 ) $ (0.59 ) $ (0.55 ) $ (0.23 ) Diluted $ (0.66 ) $ (0.62 ) $ (0.55 ) $ (0.30 ) Shares used in calculation: Basic 79,222,051 80,041,152 140,374,297 206,661,506 Diluted 79,222,051 87,421,439 140,374,297 231,014,248 Year Ended December 31, 2014 Total revenues $ 6,041 $ 9,307 $ 16,341 $ 11,585 Product sales $ 2,845 $ 4,410 $ 11,480 $ 4,704 Gross profit (loss) from product sales $ (3,391 ) $ (3,101 ) $ 1,334 $ (4,605 ) Net income (loss) attributable to common stockholders $ 16,385 $ (35,479 ) $ (36,641 ) $ 58,021 Net income (loss) per share: Basic $ 0.21 $ (0.45 ) $ (0.46 ) $ 0.73 Diluted $ (0.34 ) $ (0.45 ) $ (0.46 ) $ (0.21 ) Shares used in calculation: Basic 76,830,388 78,604,692 78,980,402 79,148,281 Diluted 117,097,976 78,604,692 78,980,402 146,804,047

Schedule II Valuation and Qua39

Schedule II Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Summary of Valuation Allowance [Table Text Block]	Balance at Beginning of Additions Write-off Balance at Deferred Tax Assets Valuation Allowance: Year ended December 31, 2015 $ 312,323 $ 47,866 $ — $ 360,189 Year ended December 31, 2014 $ 284,021 $ 28,302 $ — $ 312,323 Year ended December 31, 2013 $ 236,288 $ 47,733 $ — $ 284,021 Balance at Additions Write-off Balance at Allowance for Doubtful Accounts: Year ended December 31, 2015 $ 479 $ 490 $ — $ 969 Year ended December 31, 2014 $ 479 $ — $ — $ 479 Year ended December 31, 2013 $ 481 $ — $ (2 ) $ 479

Note 1 - The Company (Details)

Note 1 - The Company (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Disclosure Text Block [Abstract]
Number of Operating Segments	2
Working Capital	$ (41,100)
Retained Earnings (Accumulated Deficit)	(1,037,104)	$ (819,152)
Cash, Cash Equivalents, and Short-term Investments	13,500
Debt Instrument, Unamortized Discount	48,600
Long-term Debt	156,056	232,461
Long-term Debt, Current Maturities	37,570	$ 17,100
Interest Payable	$ 15,500
Percentage of Outstanding Principle to be Maintained in Unencumbered Cash	50.00%

Note 2 - Summary of Significa41

Note 2 - Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Variable Interest Entity Number of Entities	2
Certificates of Deposits, Maturities	90 days
Restricted Cash and Cash Equivalents	$ 1,200,000	$ 1,600,000
Other Asset Impairment Charges	28,500,000	1,800,000	$ 7,700,000
Impairment of Intangible Assets (Excluding Goodwill)	5,525,000	$ 3,035,000	$ 0
Intangible Assets, Net (Excluding Goodwill)	$ 0
Squalene Products [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Product Warranty, Term	2 years
Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Investment Maturity Period, Cash and Cash Equivalents	90 days
Investments Maturity Period	1 year
Maximum [Member] | Computer Equipment and Software [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Investments Original Maturities	90 days
Minimum [Member] | Computer Equipment and Software [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Note 2 - Summary of Significa42

Note 2 - Summary of Significant Accounting Policies (Details) - Concentration of Credit Risk - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Customer H [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	23.00%			[1]
Customer C [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	26.00%		19.00%
Customer C [Member] | Revenues [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		[1]	10.00%		10.00%
Customer G [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%			[1]
Customer I [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		[2]	23.00%
Customer E [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		[1]	28.00%
Customer E [Member] | Revenues [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	37.00%		47.00%		20.00%
Customer B [Member] | Revenues [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		[1]		[1]	15.00%
Customer F [Member] | Revenues [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		[1]		[1]	12.00%
Customer J [Member] | Revenues [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%			[1]		[3]
[1]	Less than 10%
[2]	No outstanding balance
[3]	Not a customer

Note 2 - Summary of Significa43

Note 2 - Summary of Significant Accounting Policies (Details) - Depreciation and Amortization for Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2015
Building [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Depreciation and Amortization for Property, Plant and Equipment [Line Items]
Property, Plant and Equipment Useful Life	15 years
Furniture and Office Equipment [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Depreciation and Amortization for Property, Plant and Equipment [Line Items]
Property, Plant and Equipment Useful Life	5 years
Vehicles [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Depreciation and Amortization for Property, Plant and Equipment [Line Items]
Property, Plant and Equipment Useful Life	5 years
Minimum [Member] | Machinery and Equipment [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Depreciation and Amortization for Property, Plant and Equipment [Line Items]
Property, Plant and Equipment Useful Life	7 years
Minimum [Member] | Computer Equipment and Software [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Depreciation and Amortization for Property, Plant and Equipment [Line Items]
Property, Plant and Equipment Useful Life	3 years
Maximum [Member] | Machinery and Equipment [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Depreciation and Amortization for Property, Plant and Equipment [Line Items]
Property, Plant and Equipment Useful Life	15 years
Maximum [Member] | Computer Equipment and Software [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Depreciation and Amortization for Property, Plant and Equipment [Line Items]
Property, Plant and Equipment Useful Life	5 years

Note 2 - Summary of Significa44

Note 2 - Summary of Significant Accounting Policies (Details) - Components of Accumulated Other Comprehensive Loss - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Components of Accumulated Other Comprehensive Loss [Abstract]
Foreign currency translation adjustment, net of tax	$ (47,198)	$ (29,977)
Total accumulated other comprehensive loss	$ (47,198)	$ (29,977)

Note 2 - Summary of Significa45

Note 2 - Summary of Significant Accounting Policies (Details) - Basic and Diluted Net Loss Per Share - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended									12 Months Ended
		Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net income (loss) attributable to Amyris, Inc. common stockholders											$ (217,952)	$ 2,286	$ (235,111)
Adjustment to exclude fair value gain on liability classified warrants(1)	[1]										(3,825)
Net income (loss) attributable to Amyris, Inc. common stockholders (for basic income (loss) per share)		$ (48,352)	[2]	$ (76,664)	$ (47,130)	$ (52,240)	$ 58,021	$ (36,641)	$ (35,479)	$ 16,385	(217,952)	2,286	(235,111)
Interest on convertible debt												9,365
Accretion of debt discount												5,597
Gain from change in fair value of derivative instruments												(127,109)
Net loss attributable to Amyris, Inc. common stockholders after assumed conversion		$ (68,316)		$ (76,664)	$ (54,527)	$ (52,240)					$ (221,777)	$ (109,861)	$ (235,111)
Denominator:
Weighted average shares of common stock outstanding (in Shares)		206,661,506,000		140,374,297,000	80,041,152,000	79,222,051,000	79,148,281,000	78,980,402,000	78,604,692,000	76,830,388,000	126,961,576	78,400,098	75,472,770
Effect of dilutive securities:
Convertible promissory notes (in Shares)												43,459,343
Weighted common stock equivalents (in Shares)												43,459,343
Diluted weighted-average common shares (in Shares)		231,014,248,000		140,374,297,000	87,421,439,000	79,222,051,000	146,804,047,000	78,980,402,000	78,604,692,000	117,097,976,000	126,961,576	121,859,441	75,472,770
Diluted loss per share (in Dollars per share)		$ (300)		$ (550)	$ (620)	$ (660)	$ (210)	$ (460)	$ (450)	$ (340)	$ (1.75)	$ (0.90)	$ (3.12)
Basic income (loss) per share (in Dollars per share)		$ (230)	[2]	$ (550)	$ (590)	$ (660)	$ 730	$ (460)	$ (450)	$ 210	$ (1.75)	$ 0.03	$ (3.12)
[1]	The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company's consolidated statement of operations for the year ended December 31, 2015. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company's common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain.
[2]	Basic loss per share for the fourth quarter of 2015 is calculated by excluding from net income (loss) attributable to common stockholders a gain of $6,424 (thousand) related to a change in the fair value of a liability classified common stock warrant included in the Company's consolidated statement of operations. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company's common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain.

Note 2 - Summary of Significa46

Note 2 - Summary of Significant Accounting Policies (Details) - Antidilutive Securities Excluded from Computation of Earnings Per Share - shares		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share		93,924,188	40,423,573	54,652,134
Period-end Stock Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share		12,930,112	10,539,978	8,409,605
Convertible Promissory Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	[1]	72,537,306	26,887,005	42,905,005
Period-end Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share		2,901,926	1,021,087	1,021,087
Period-end Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share		5,554,844	1,975,503	2,316,437
[1]	The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of December 31, 2015. A portion ofthe convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 3 - Fair Value of Financ47

Note 3 - Fair Value of Financial Instruments (Details) $ in Thousands, BRL in Millions	Dec. 15, 2015USD ($)shares	Apr. 30, 2014shares	Jan. 31, 2013shares	Dec. 31, 2015USD ($)	Jul. 29, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Jun. 30, 2012USD ($)	Jun. 30, 2012BRL
Note 3 - Fair Value of Financial Instruments (Details) [Line Items]
Derivative, Gain (Loss) on Derivative, Net				$ (19,500)
Proceeds from Warrant Exercises				285
Stock Issued During Period, Shares, New Issues (in Shares) | shares		943,396	5,033,557
Temasek Funding Warrant [Member]
Note 3 - Fair Value of Financial Instruments (Details) [Line Items]
Derivative Liability	$ 18,900				$ 19,400
Proceeds from Warrant Exercises	$ 100
Stock Issued During Period, Shares, New Issues (in Shares) | shares	12,700,000
Banco Pine July 2012 Loan Agreement [Member] | Interest Rate Swap [Member]
Note 3 - Fair Value of Financial Instruments (Details) [Line Items]
Derivative, Notional Amount								$ 5,600	BRL 22
Derivative, Fixed Interest Rate								3.94%	3.94%
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member]
Note 3 - Fair Value of Financial Instruments (Details) [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value				46,430		$ 56,026	$ 131,117
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | Derivative Liabilities [Member]
Note 3 - Fair Value of Financial Instruments (Details) [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value				$ 46,400		$ 56,000

Note 3 - Fair Value of Financ48

Note 3 - Fair Value of Financial Instruments (Details) - Fair Value, Assets, and Liabilities Measured on Recurring Basis - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2015		Dec. 31, 2014
Financial Assets
Money market funds	$ 2,078		$ 20,160
Certificates of deposit	1,520		1,375
Total financial assets	3,598		23,280
Loans to affiliate			1,745
Financial Liabilities
Loans payable	9,541	[1]	16,720	[2]
Credit facilities	34,893	[1]	39,332	[2]
Convertible notes	96,291	[1]	222,031	[2]
Compound embedded derivative liability	46,430		56,026
Currency interest rate swap derivative liability	5,009		3,710
Total financial liabilities	192,164		337,819
Fair Value, Inputs, Level 1 [Member]
Financial Assets
Money market funds	2,078		20,160
Certificates of deposit	1,520		1,375
Total financial assets	$ 3,598		$ 21,535
Financial Liabilities
Loans payable		[1]		[2]
Credit facilities		[1]		[2]
Convertible notes		[1]		[2]
Fair Value, Inputs, Level 2 [Member]
Financial Liabilities
Loans payable	$ 9,541	[1]	$ 16,720	[2]
Credit facilities	$ 34,893	[1]	$ 39,332	[2]
Convertible notes		[1]		[2]
Currency interest rate swap derivative liability	$ 5,009		$ 3,710
Total financial liabilities	49,443		59,762
Fair Value, Inputs, Level 3 [Member]
Financial Assets
Total financial assets	$ 0		1,745
Loans to affiliate			$ 1,745
Financial Liabilities
Loans payable		[1]		[2]
Credit facilities		[1]		[2]
Convertible notes	$ 96,291	[1]	$ 222,031	[2]
Compound embedded derivative liability	46,430		56,026
Total financial liabilities	$ 142,721		$ 278,057
[1]	These liabilities are carried on the consolidated balance sheet on a historical cost basis (noting that the Remaining Notes subject to the Maturity Treatment Agreement were revalued to fair value on July 29, 2015, see Note 5 "Debt" for details).
[2]	These liabilities are carried on the consolidated balance sheet on a historical cost basis.

Note 3 - Fair Value of Financ49

Note 3 - Fair Value of Financial Instruments (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - Fair Value, Inputs, Level 3 [Member] - Convertible Debt [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at January 1	$ 222,031	$ 131,952
Balance at December 31	96,291	222,031
Additions to convertible notes	31,984	123,273
Conversion/extinguishment of convertible notes	(127,583)	(13,539)
Change in fair value of convertible notes	$ (30,141)	$ (19,655)

Note 3 - Fair Value of Financ50

Note 3 - Fair Value of Financial Instruments (Details) - Reconciliation for Compound Embedded Derivative Liability - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain from change in fair value of derivative liabilities(1)	[1]	$ (3,825)
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at January 1		56,026	$ 131,117
Additions to Level 3		40,359	90,174
Derecognition on conversion/extinguishment		(30,806)	(1,104)
Gain from change in fair value of derivative liabilities(1)		(19,149)	(164,161)
Balance at December 31		$ 46,430	$ 56,026
[1]	The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company's consolidated statement of operations for the year ended December 31, 2015. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company's common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain.

Note 3 - Fair Value of Financ51

Note 3 - Fair Value of Financial Instruments (Details) - Market-based Assumption and Estimates - $ / shares	Jul. 29, 2015	Dec. 31, 2015	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility		45.00%	45.00%
Probability of change in control		5.00%	5.00%
Stock price (in Dollars per share)		$ 1.62	$ 2.06
Temasek Funding Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.00%
Expected term (in years)	10 years
Yield	0.00%
Volatility	74.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		1.26%	0.75%
Yield		35.80%	21.40%
Credit spread		34.48%	19.97%
Estimated conversion dates		2,016	2,017
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		1.40%	1.51%
Yield		45.93%	31.50%
Credit spread		44.55%	29.99%
Estimated conversion dates		2,019	2,019

Note 3 - Fair Value of Financ52

Note 3 - Fair Value of Financial Instruments (Details) - Derivative Instruments Classification - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Currency Interest Rate Swap [Member] | Not Designated as Hedging Instrument [Member] | Gain (Loss) from Change in Fair Value of Derivative Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Currency interest rate swap (1)	$ (3,367)	$ (480)	$ (2,404)

Note 3 - Fair Value of Financ53

Note 3 - Fair Value of Financial Instruments (Details) - Derivative Liabilities - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Derivative Liability [Abstract]
Fair market value of swap obligation	$ 5,009	$ 3,710
Fair value of compound embedded derivative liabilities	46,430	56,026
Total derivative liabilities	$ 51,439	$ 59,736

Note 4 - Balance Sheet Compon54

Note 4 - Balance Sheet Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Note 4 - Balance Sheet Components (Details) [Line Items]
Property, Plant and Equipment, Gross	$ 132,619	$ 186,669
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	72,822	67,689
Depreciation, Depletion and Amortization	12,920	14,969	$ 16,639
Capital Lease Obligations [Member]
Note 4 - Balance Sheet Components (Details) [Line Items]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	500	2,300
Loss on Purchase Commitments and Impairment of Property, Plant and Equipment [Member] | SMSA Site [Member]
Note 4 - Balance Sheet Components (Details) [Line Items]
Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss	27,600
Restructuring Reserve	3,600
Loss on Purchase Commitments and Impairment of Property, Plant and Equipment [Member] | SMSA Site [Member] | Brazilian VAT [Member]
Note 4 - Balance Sheet Components (Details) [Line Items]
Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset	1,200
Machinery and Equipment and Furniture and Office Equipment Under Capital Lease [Member] | Capital Lease Obligations [Member]
Note 4 - Balance Sheet Components (Details) [Line Items]
Property, Plant and Equipment, Gross	2,700	4,100
Property Plant and Equipment Including Capital Leases [Member]
Note 4 - Balance Sheet Components (Details) [Line Items]
Depreciation, Depletion and Amortization	$ 12,800	$ 15,000

Note 4 - Balance Sheet Compon55

Note 4 - Balance Sheet Components (Details) - Inventory, Current - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory, Current [Abstract]
Raw materials	$ 2,204	$ 2,665
Work-in-process	3,583	5,269
Finished goods	5,099	6,572
Inventories, net	$ 10,886	$ 14,506

Note 4 - Balance Sheet Compon56

Note 4 - Balance Sheet Components (Details) - Prepaid and Other Current Assets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Prepaid and Other Current Assets [Abstract]
Maintenance	$ 124	$ 399
Prepaid insurance	581	701
Manufacturing catalysts	2,698	1,166
Recoverable VAT and other taxes		2,411
Debt issuance costs	1,357
Other	1,112	1,857
Prepaid expenses and other current assets	$ 5,872	$ 6,534

Note 4 - Balance Sheet Compon57

Note 4 - Balance Sheet Components (Details) - Property, Plant and Equipment - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment	$ 132,619	$ 186,669
Less: accumulated depreciation and amortization	(72,822)	(67,689)
Property, plant and equipment, net	59,797	118,980
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment	38,519	39,132
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment	72,876	90,657
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment	9,117	8,946
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment	2,234	2,445
Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment	3,922	6,321
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment	215	353
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment	$ 5,736	$ 38,815

Note 4 - Balance Sheet Compon58

Note 4 - Balance Sheet Components (Details) - Other Assets, Noncurrent - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Assets, Noncurrent [Abstract]
Deposits on property and equipment, including taxes	$ 243	$ 1,738
Recoverable taxes from Brazilian government entities	8,887	9,747
Debt issuance costs	2,806	851
Other	1,214	1,299
Total other assets	$ 13,150	$ 13,635

Note 4 - Balance Sheet Compon59

Note 4 - Balance Sheet Components (Details) - Accrued and Other Current Liabilities - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued and Other Current Liabilities [Abstract]
Professional services	$ 4,017	$ 2,015
Accrued vacation	2,023	2,213
Payroll and related expenses	3,122	5,393
Tax-related liabilities	2,505	277
Withholding tax related to conversion of related party notes	4,723
Deferred rent, current portion	1,111	1,111
Accrued interest	1,984	1,308
SMA relocation accrual	3,641
Other	1,142	1,248
Total accrued and other current liabilities	$ 24,268	$ 13,565

Note 5 - Debt (Details)

Note 5 - Debt (Details) $ / shares in Units, l in Millions, BRL in Millions

Mar. 21, 2016USD ($)

Feb. 15, 2016USD ($)$ / shares

Feb. 12, 2016USD ($)

Feb. 12, 2016EUR (€)

Oct. 14, 2015USD ($)$ / sharesshares

Jul. 29, 2015USD ($)$ / sharesshares

Apr. 02, 2015

Aug. 31, 2013USD ($)$ / sharesshares

Feb. 29, 2016USD ($)$ / sharesshares

Nov. 30, 2015USD ($)

Jul. 31, 2015$ / shares

Jun. 30, 2015

Jun. 30, 2014USD ($)

May. 31, 2014USD ($)$ / shares

Apr. 30, 2014USD ($)$ / shares

Mar. 31, 2014USD ($)

Jan. 31, 2014USD ($)$ / shares

Oct. 31, 2013USD ($)$ / sharesl

Aug. 31, 2013USD ($)$ / sharesshares

Jun. 30, 2013USD ($)$ / shares

Jan. 31, 2013USD ($)

Dec. 31, 2012USD ($)

Jul. 31, 2012USD ($)

Jul. 31, 2012BRL

Jul. 30, 2012USD ($)$ / shares

Dec. 31, 2011USD ($)

Dec. 31, 2011BRL

Nov. 30, 2010USD ($)

Jun. 30, 2015USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Feb. 16, 2016$ / shares

Dec. 31, 2015BRL

Dec. 01, 2015USD ($)

Apr. 30, 2015USD ($)

Mar. 31, 2015USD ($)

Jan. 31, 2015USD ($)$ / shares

Dec. 31, 2014BRL

Oct. 31, 2014USD ($)

Jul. 31, 2014USD ($)$ / shares

May. 29, 2014USD ($)

Sep. 30, 2013USD ($)shares

Jul. 31, 2013USD ($)

Mar. 31, 2013USD ($)$ / shares

Sep. 14, 2012USD ($)

Jul. 31, 2012BRL

Jun. 30, 2012USD ($)

Feb. 28, 2012USD ($)$ / shares

Dec. 31, 2011BRL

Nov. 30, 2010BRL

Note 5 - Debt (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity | BRL

BRL 6.4

Proceeds from Issuance of Long-term Debt

$ 66,931,000

$ 83,171,000

$ 10,535,000

Proceeds from Issuance of Private Placement

$ 4,000,000

$ 15,000,000

$ 37,200,000

24,625,000

4,000,000

19,980,000

Debt Instrument, Unamortized Discount

48,600,000

Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments

0.75%

Debt Instrument, Convertible, Conversion Rate, Shares (in Shares) | shares

443.6557

Long-term Debt

156,056,000

232,461,000

Extinguishment of Debt, Amount

$ 5,000,000

Gains (Losses) on Extinguishment of Debt

(1,141,000)

(10,512,000)

(19,914,000)

Letters of Credit Outstanding, Amount

$ 1,000,000

Restricted Cash and Cash Equivalents, Noncurrent

957,000

1,619,000

Private Placement [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

1,602,562

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

$ 0.01

Class of Warrant or Right, Term

5 years

5 years

Subsequent Event [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Rate, Shares (in Shares) | shares

445.2252

Debt Instrument, Convertible, Conversion Rate, Principle Amount (in Dollars per share) | $ / shares

$ 1,000

Subsequent Event [Member] | Private Placement February 2016 [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

13.50%

Debt Instrument, Face Amount

$ 20,000,000

Proceeds from Issuance of Private Placement

$ 2,000,000

$ 18,000,000

$ 20,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

TJLP Adjustment Factor [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate of the Central Bank of Brazil Used as a Threshold

6.00%

6.00%

Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Debt

43,000,000

115,200,000

Long-term Debt

43,029,000

115,239,000

Future Cancellation of Debt, Amount

$ 14,600,000

Gains (Losses) on Extinguishment of Debt

$ (9,400,000)

(5,900,000)

(10,500,000)

$ (19,900,000)

Debt Instrument, Debt Discount, Related Party

1,600,000

53,800,000

Rule 144A Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Unamortized Discount

1,600,000

Convertible Debt

14,600,000

Loans Payable [Member]

Note 5 - Debt (Details) [Line Items]

Long-term Debt

13,975,000

21,097,000

Exchange Warrants [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

Loans Payable [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.24%

Debt Instrument, Term

9 months

Loans Payable to Bank, Current

$ 600,000

Loans Payable to Bank

0

300,000

$ 600,000

FINEP Credit Facility [Member]

Note 5 - Debt (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 1,600,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

5.00%

Debt Default, Penalty and Fine on Obligation in Default, Percentage

10.00%

10.00%

Debt Instrument Interest On Late Balance Percentage Per Month

1.00%

1.00%

Debt Instrument, Number of Monthly Installments

81

81

Long-term Line of Credit

900,000

1,600,000

BRL 3.4

BRL 4.3

FINEP Credit Facility [Member] | Threshold Met [Member] | TJLP Adjustment Factor [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

5.00%

FINEP Credit Facility [Member] | Threshold not Met [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

11.00%

11.00%

BNDES Credit Facility [Member]

Note 5 - Debt (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 5,700,000

BRL 22.4

Debt Instrument, Interest Rate, Stated Percentage

7.00%

7.00%

Debt Instrument, Number of Monthly Installments

60

60

Long-term Line of Credit

1,900,000

4,300,000

BRL 7.6

BRL 11.5

Line of Credit Facility, Unused Capacity, Commitment Fee Percentage

0.10%

0.10%

Collateral Provided by Company Certain Equipment and Other Tangible Assets Amount

$ 6,400,000

BRL 24.9

Line of Credit Facility Bank Guarantee Percentage

10.00%

10.00%

Guarantor Obligations, Liquidation Proceeds, Percentage

130.00%

130.00%

BNDES Credit Facility [Member] | The First Tranche [Member]

Note 5 - Debt (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity | BRL

BRL 19.1

BNDES Credit Facility [Member] | The Second Tranche [Member]

Note 5 - Debt (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity | BRL

3.3

Line of Credit Facility Bank Guarantee Percentage

90.00%

90.00%

Line of Credit Facility, Borrowings Above Which is New Tranche

$ 4,900,000

BRL 19.1

Letter of Credit [Member]

Note 5 - Debt (Details) [Line Items]

Restricted Cash and Cash Equivalents, Noncurrent

1,000,000

1,000,000

Total [Member] | Subsequent Event [Member]

Note 5 - Debt (Details) [Line Items]

Extinguishment of Debt, Amount | €

€ 50,000

Temasek [Member] | August 2013 Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Bridge Loan

35,000,000

Temasek [Member] | Rule 144A Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Debt

$ 10,000,000

Foris Ventures, LLC [Member] | Rule 144A Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Debt

$ 5,000,000

Total [Member] | Subsequent Event [Member]

Note 5 - Debt (Details) [Line Items]

Extinguishment of Debt, Amount

$ 5,000,000

Hercules Technology Growth Capital, Inc. (Hercules) [Member]

Note 5 - Debt (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 15,000,000

Long-term Line of Credit

$ 25,000,000

Loans Payable

$ 25,000,000

31,700,000

Debt Instrument, Prepayment Penalty, Percentage

3.00%

Debt Instrument, Facility Charge, Percentage

1.00%

Debt Instrument, End of Term Fee, Percentage

10.00%

Debt Instrument, Forbearance Fee, Forgiven

$ 10,000,000

Debt Instrument, Required Equity Financing, Amount

$ 50,000,000

Debt Instrument, Unencumbered, Unrestricted, Cash Required, Percentage

50.00%

50.00%

Line of Credit Facility, Amount to be Raised Through Equity Triggering Withdrawal of the Credit Facility

$ 20,000,000

Line of Credit Facility, Commitment Fee Percentage

3.00%

5.00%

Debt Instrument, Unamortized Discount

300,000

Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Minimum [Member] | Prime Rate [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

6.25%

Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Maximum [Member] | Prime Rate [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

9.50%

Hercules Technology Growth Capital, Inc. (Hercules) [Member] | After the Initial Twelve-month Period [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Prepayment Penalty, Percentage

1.00%

Nossa Caixa and Banco Pine Agreements [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.50%

5.50%

Collateral Provided by Company Certain Equipment and Other Tangible Assets Amount

$ 17,400,000

BRL 68

Debt Instrument, Face Amount

13,300,000

BRL 52

Certain Farnesene Production Assets Pledged as Collateral for Loans (in Brazil Real) | BRL

52

Debt Instrument, Period of Interest Only QuarterlyPayments

2 years

Nossa Caixa and Banco Pine Agreements [Member] | Loans Payable [Member]

Note 5 - Debt (Details) [Line Items]

Long-term Debt

11,000,000

18,600,000

Banco Pine [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount | BRL

22

Nossa Caixa [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount | BRL

BRL 30

Temasek [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 2.30

Debt Conversion, Original Debt, Amount

$ 71,000,000

Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares

30,860,633

Debt Conversion, Withholding Tax Expense

4,700,000

Temasek [Member] | Temasek Warrant 1 [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

14,677,861

Class of Warrant or Right, Term

10 years

Temasek [Member] | Temasek Warrant 2 [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Term

10 years

Class of Warrant or Right, Threshold Number of Securities (in Shares) | shares

2,000,000

Class of Warrant or Right, Numerator One

30.60%

Class of Warrant or Right, Denominator One

69.40%

Class of Warrant or Right, Numerator Two

13.30%

Class of Warrant or Right, Denominator Two

86.70%

Temasek [Member] | Temasek Warrant Three [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Term

10 years

Class of Warrant or Right, Threshold Number of Securities (in Shares) | shares

2,000,000

Class of Warrant or Right, Common Stock Shares Used In Calculation (in Shares) | shares

880,339

Temasek [Member] | The 2013 Warrant [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

1,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

Temasek [Member] | If Total R&D Warrant is Exercised in Full [Member] | Temasek Warrant Three [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

880,339

Total [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Notes Payable

$ 25,000,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 2.30

Debt Conversion, Original Debt, Amount

$ 70,000,000

Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares

30,434,782

Total [Member] | Total Funding Warrant [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

18,924,191

Class of Warrant or Right, Term

5 years

Total [Member] | Total R&D Warrant [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

2,000,000

Class of Warrant or Right, Term

5 years

Total and Temasek [Member]

Note 5 - Debt (Details) [Line Items]

Interest Expense, Debt

$ 39,200,000

Hercules Credit Additional Amount [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Additional Amount Required

$ 5,000,000

Hercules Credit Additional Amount [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Minimum [Member] | Prime Rate [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

5.25%

Hercules Credit Additional Amount [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Maximum [Member] | Prime Rate [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

8.50%

Third Hercules Amendment [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.50%

9.50%

Debt Instrument, Basis Spread on Variable Rate

6.25%

Loans Payable

$ 31,700,000

Debt Instrument, Unencumbered, Unrestricted, Cash Required, Percentage

50.00%

Proceeds from Issuance of Long-term Debt

$ 10,960,000

Repayments of Long-term Debt

9,100,000

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

767,200

Debt Issuance Cost

1,000,000

Third Hercules Amendment [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Portion of Debt Costs Owed in Connection with Expired Facility [Member]

Note 5 - Debt (Details) [Line Items]

Debt Issuance Cost

750,000

Third Hercules Amendment [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Portion of Debt Costs Related to the Third Hercules Amendment [Member]

Note 5 - Debt (Details) [Line Items]

Debt Issuance Cost

$ 250,000

Third Hercules Amendment [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Prime Rate [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

6.25%

Fidelity Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 7.0682

Convertible Promissory Note, Acquisition Right Amount Redeemable, Percentage

101.00%

Convertible Promissory Note, Maximum Allowable Debt

$ 200,000,000

Convertible Promissory Notes, Debt Percentage of Total Assets

50.00%

Convertible Promissory Note, Maximum Amount of Secured Debt

$ 125,000,000

Convertible Promissory Note, Secured Debt as a Percentage of consolidated Total Assets

30.00%

Convertible Promissory Note, Bridge Loan Amount, Convertible Promissory Note Covenants Waived

35,000,000

Additional Consideration for Covenant Waiving, Convertible Promissory Notes

7,600,000

Fidelity Convertible Notes [Member] | Convertible Subordinated Debt [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Notes Payable

$ 25,000,000

Debt Instrument, Interest Rate, Effective Percentage

3.00%

Rule 144A Convertible Note Offering [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 3.74

Convertible Note Offering

$ 75,000,000

Additional Convertible Note Offering

15,000,000

Proceeds from Convertible Debt

72,000,000

Proceeds from Convertible Debt Used to Repay Previously Issued Convertible Debt

$ 9,700,000

Debt Instrument, Convertible, Threshold Trading Days

20

Debt Instrument, Convertible, Threshold Consecutive Trading Days

30 days

Debt Instrument, Convertible, Threshold Days for Conversion Notification

5 days

Convertible Note Substantial Change, Percentage of Principal Repurchase Price

100.00%

Rule 144A Convertible Note Offering [Member] | Convertible Debt Securities [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Effective Percentage

6.50%

Rule 144A Convertible Note Offering [Member] | Numerator [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Ratio

267.037

Rule 144A Convertible Note Offering [Member] | Denominator [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Ratio

1,000

Rule 144A Convertible Note Offering [Member] | Affiliated Entity [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.50%

Amount of Convertible Debt Purchased by Affiliated Entities

$ 24,700,000

Rule 144A Convertible Note Offering [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Proceeds from Convertible Debt

9,700,000

Rule 144A Convertible Note Offering [Member] | Temasek [Member]

Note 5 - Debt (Details) [Line Items]

Proceeds from Convertible Debt

10,000,000

Rule 144A Convertible Note Offering [Member] | Foris Ventures, LLC [Member]

Note 5 - Debt (Details) [Line Items]

Proceeds from Convertible Debt

5,000,000

Convertible Senior Notes, 9.5% [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Debt Instrument, Face Amount

$ 57,600,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 2.25

Proceeds from Convertible Debt

$ 54,400,000

Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments

0.75%

Convertible Note Substantial Change, Percentage of Principal Repurchase Price

100.00%

Debt Instrument, Repurchase Amount

$ 3,700,000

Debt Instrument, Convertible, Conversion Rate, Shares (in Shares) | shares

443.6557

Debt Instrument, Convertible, Conversion Rate, Principle Amount (in Dollars per share) | $ / shares

$ 1,000

Debt Instrument, Convertible, Percentage of Average Price Per Share the Stock will be Valued Upon Early Conversion

92.50%

Debt Instrument, Convertible, Number of Equity Instruments

38,415,626

Gains (Losses) on Extinguishment of Debt

500,000

Debt Conversion, Original Debt, Amount

1,300,000

Convertible Senior Notes, 9.5% [Member] | Subsequent Event [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Rate, Shares (in Shares) | shares

445.2252

Debt Instrument, Convertible, Conversion Rate, Principle Amount (in Dollars per share) | $ / shares

$ 1,000

Class of Warrant or Right, Term

5 years

5 years

Convertible Senior Notes, 6.5% [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.50%

Debt Instrument, Repurchase Amount

$ 18,300,000

Debt Instrument, Repurchased Face Amount

$ 22,900,000

Convertible Senior Notes, 3% [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.00%

Debt Instrument, Repurchase Amount

$ 8,800,000

Debt Instrument, Repurchased Face Amount

$ 9,700,000

Total Purchase Agreement [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 105,000,000

Convertible Promissory Note, Acquisition Right Amount Redeemable, Percentage

101.00%

Debt Restrictions, Maximum Outstanding Debt

$ 200,000,000

Debt Restrictions, Maximum Outstanding Debt, Percentage of Consolidated Total Assets

50.00%

Total Purchase Agreement [Member] | Total [Member] | Secured Debt [Member]

Note 5 - Debt (Details) [Line Items]

Debt Restrictions, Maximum Outstanding Debt

$ 125,000,000

Debt Restrictions, Maximum Outstanding Debt, Percentage of Consolidated Total Assets

30.00%

Unsecured Senior Convertible Promissory Notes [Member] | Related Party Convertible Notes [Member] | Second Closing [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 20,000,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.50%

1.50%

1.50%

Debt Instrument, Face Amount

$ 69,000,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 4,110,000

Debt Instrument Default Rate

2.50%

Number of Trading Days Notes Become Convertible

10 years

Debt Instrument Percentage Outstanding and Payable

70.00%

Percentage of Outstanding Notes To Be Cancelled

30.00%

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Initial Closing [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.50%

1.50%

Debt Instrument, Face Amount

$ 38,300,000

$ 15,000,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 7.0682

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Second Closing [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 3.08

Number of Installments

2

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Third Closing [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 10,850,000

$ 10,850,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 4.11

Convertible Debt, Number of Installments

2

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Two Installments In Third Closing [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 21,700,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Initial Tranche [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

10,850,000

21,700,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | New Funding [Member] | Initial Closing [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 15,000,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Diesel Research and Development Funding [Member] | Initial Closing [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 23,300,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 10,000,000

20,000,000

Debt Instrument, Notes Related Party Committed to Purchase, Completed

$ 30,000,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Related Party Convertible Notes [Member] | Second Closing [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

10,000,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Related Party Convertible Notes [Member] | Two Installments in Second Closing [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 30,000,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Subsequent Event [Member]

Note 5 - Debt (Details) [Line Items]

Extinguishment of Debt, Amount

$ 1,300,000

March 2013 Letter Agreement [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 3.08

$ 7.0682

Debt Instrument Closing Price Plus Incremental Rate (in Dollars per share) | $ / shares

0.01

March 2013 Letter Agreement [Member] | Total [Member] | Minimum [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 3.08

August 2013 Convertible Notes [Member] | Private Placement [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 110,000,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

1,000,000

August 2013 Convertible Notes [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Cancellation of Convertible Debt

$ 13,000,000

August 2013 Convertible Notes [Member] | Total [Member] | First Tranche [Member]

Note 5 - Debt (Details) [Line Items]

Cancellation of Convertible Debt

7,600,000

August 2013 Convertible Notes [Member] | Total [Member] | Second Tranche [Member]

Note 5 - Debt (Details) [Line Items]

Cancellation of Convertible Debt

5,400,000

August 2013 Convertible Notes [Member] | Temasek [Member]

Note 5 - Debt (Details) [Line Items]

Proceeds from Convertible Debt

$ 60,000,000

Bridge Loan

$ 35,000,000

August 2013 Convertible Notes [Member] | Temasek [Member] | Common Stock [Member]

Note 5 - Debt (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

1,000,000

1,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

$ 0.01

August 2013 Convertible Notes [Member] | Temasek [Member] | First Tranche [Member]

Note 5 - Debt (Details) [Line Items]

Proceeds from Convertible Debt

$ 35,000,000

August 2013 Convertible Notes [Member] | Temasek [Member] | Second Closing [Member]

Note 5 - Debt (Details) [Line Items]

Proceeds from Convertible Debt

25,000,000

August 2013 Convertible Notes [Member] | Total and Temasek [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 73,000,000

$ 73,000,000

Bridge Loan

$ 5,000,000

Private Placement Convertible Notes, Period

24 months

Debt Instrument, Number of Tranches

2

August 2013 Convertible Notes [Member] | Total and Temasek [Member] | First Tranche [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 42,600,000

$ 42,600,000

August 2013 Convertible Notes [Member] | Total and Temasek [Member] | Second Tranche [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 30,400,000

30,400,000

Proceeds from Convertible Debt

6,000,000

August 2013 Convertible Notes [Member] | Total and Temasek [Member] | Second Closing [Member]

Note 5 - Debt (Details) [Line Items]

Proceeds from Convertible Debt

25,000,000

Senior Secured Convertible Note [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.50%

Debt Instrument, Face Amount

10,850,000

Senior Secured Convertible Note [Member] | Total [Member] | Initial Tranche [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 21,700,000

July 2012 Agreements [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 10,850,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 7.0682

March 2014 Letter Agreement [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 4.11

$ 4.11

$ 4.11

Convertible Debt

$ 75,000,000

Replacement Notes [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Unamortized Discount

0

13,100,000

Long-term Debt

5,000,000

51,000,000

Temasek Bridge Loan [Member] | Temasek [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.50%

Bridge Loan

$ 35,000,000

First Tranche [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 51,800,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 2.44

Proceeds from Convertible Debt

$ 7,600,000

Cancellation of Convertible Debt

44,200,000

Debt Instrument, Amended Additional Investor Amount

$ 7,600,000

Future Cancellation of Debt, Amount

9,200,000

Gains (Losses) on Extinguishment of Debt

$ (19,900,000)

Convertible Promissory Notes, Period After Which Notes Will Be Due

60 months

Convertible Notes, Discount Percentage to Determine Conversion Price

15.00%

Convertible Note Discount, Number of Days for Trailing Weighted-average Closing Price

60 days

Convertible Notes, Period After Which Convertible at the Option of Holder

18 months

Debt Instrument, Convertible, Conversion Price, Event Date Price (in Dollars per share) | $ / shares

$ 2.15

Plant Manufacturing Production, Product Sales, Percentage

5.00%

Plant Manufacturing Production, Volume (in Liters) | l

1

Plant Manufacturing Production, Period

45 days

Plant Manufacturing Gross Margin

8.00%

Debt Instrument, Interest Rate, Stated Percentage, per Six Months

5.00%

Debt Instrument, Convertible, Conversion Price, Interest Accrued, Rate Applicable to the First 180 Days

6.50%

Debt Instrument, Convertible, Conversion Price, Interest Accrued Thereafter

8.00%

Debt Instrument, Convertible, Conversion Price, Interest Accrued for Defaults

6.50%

Convertible Notes, Period Over Which Interest is Payable in Kind

30 months

Convertible Notes, Initial Prepayment Term

30 months

Convertible Notes, Recurring Term of Option to Prepay After Initial Payment Period

6 months

First Tranche [Member] | Total [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Extinguishment of Debt, Amount

$ 9,200,000

First Tranche [Member] | Temasek [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Extinguishment of Debt, Amount

35,000,000

The Second Tranche [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 34,000,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 2.87

Future Cancellation of Debt, Amount

$ 5,400,000

Convertible Promissory Notes, Period After Which Notes Will Be Due

60 months

Debt Instrument, Convertible, Conversion Price, Interest Accrued, Rate Applicable to the First 180 Days

13.00%

Debt Instrument, Convertible, Conversion Price, Interest Accrued Thereafter

16.00%

Debt Instrument, Convertible, Conversion Price, Interest Accrued for Defaults

12.00%

Convertible Notes Exchanged and Cancelled

$ 6,000,000

Debt Instrument, Term

12 months

Debt Instrument, Convertible, Conversion Price, Interest Accrued

10.00%

Debt Instrument, Convertible, Conversion Price, Interest Period

36 months

The Second Tranche [Member] | Temasek [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Notes Purchased

$ 25,000,000

The Second Tranche [Member] | Wolverine [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Notes Purchased

3,000,000

The Second Tranche [Member] | Total [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Notes Purchased

$ 6,000,000

Tranche I and Tranche II Notes [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Unamortized Discount

0

30,700,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 1.42

$ 1.40

Convertible Debt

23,300,000

49,200,000

Percentage of Principal Amount of Notes, Required to Be Repaid in Change of Control

101.00%

Tranche I and Tranche II Notes [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Notes Payable

$ 15,300,000

Rule 144A Related Party Convertible Notes [Member] | Total [Member] | Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Proceeds from Convertible Debt

9,700,000

Convertible Debt

52,100,000

75,000,000

$ 75,000,000

Extinguishment of Debt, Amount

$ 9,700,000

Gains (Losses) on Extinguishment of Debt

$ (1,100,000)

Related Party Convertible Notes [Member]

Note 5 - Debt (Details) [Line Items]

Gains (Losses) on Extinguishment of Debt

(5,900,000)

Related Party Convertible Notes [Member] | Secured Debt [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 10,850,000

ABC Brasil Agreement [Member] | Banco ABC Brasil S.A. (ABC) [Member]

Note 5 - Debt (Details) [Line Items]

Long-term Debt

1,600,000

Export Financing Agreement

$ 2,500,000

Additional Export Financing Agreement

$ 2,200,000

$ 1,600,000

Rule 144A Convertible Notes [Member] | Temasek [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Notes Payable

10,000,000

Rule 144A Convertible Notes [Member] | Total [Member]

Note 5 - Debt (Details) [Line Items]

Convertible Notes Payable

9,700,000

Related Party and Non-Related Party Convertible Debt [Member]

Note 5 - Debt (Details) [Line Items]

Debt Instrument, Unamortized Discount

$ 48,600,000

Exchange and Maturity Treatment Agreements [Member]

Note 5 - Debt (Details) [Line Items]

Extinguishment of Debt, Amount

178,100,000

Gains (Losses) on Extinguishment of Debt

$ (5,900,000)

Note 5 - Debt (Details) - Debt

Note 5 - Debt (Details) - Debt - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Note 5 - Debt (Details) - Debt [Line Items]
Long-term Debt	$ 156,056	$ 232,461
Less: current portion	(37,570)	(17,100)
Long-term debt	118,486	215,361
FINEP Credit Facility [Member]
Note 5 - Debt (Details) - Debt [Line Items]
Long-term Debt	840	1,614
BNDES Credit Facility [Member]
Note 5 - Debt (Details) - Debt [Line Items]
Long-term Debt	1,956	4,314
Hercules Loan Facility [Member]
Note 5 - Debt (Details) - Debt [Line Items]
Long-term Debt	31,653	29,779
Credit Facility [Member]
Note 5 - Debt (Details) - Debt [Line Items]
Long-term Debt	34,449	35,707
Convertible Debt [Member]
Note 5 - Debt (Details) - Debt [Line Items]
Long-term Debt	64,603	60,418
Related Party Convertible Notes [Member]
Note 5 - Debt (Details) - Debt [Line Items]
Long-term Debt	43,029	115,239
Loans Payable [Member]
Note 5 - Debt (Details) - Debt [Line Items]
Long-term Debt	$ 13,975	$ 21,097

Note 5 - Debt (Details) - Long-

Note 5 - Debt (Details) - Long-term Debt Instruments $ in Thousands	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
2,016	$ 55,941
2,017	34,700
2,018	37,383
2,019	128,114
2,020	1,849
Thereafter	2,743
Total future minimum payments	260,730
Less: amount representing interest(1)	(110,200)	[1]
Present value of minimum debt payments	150,530
Less: current portion	(37,570)
Add: fair value change due to conversions	5,526
Noncurrent portion of debt	118,486
Related Party Convertible Notes [Member]
Debt Instrument [Line Items]
2,016	1,255
2,017	6,460
2,018	16,476
2,019	35,145
Total future minimum payments	59,336
Less: amount representing interest(1)	(21,833)	[1]
Present value of minimum debt payments	37,503
Add: fair value change due to conversions	5,526
Noncurrent portion of debt	43,029
Convertible Debt [Member]
Debt Instrument [Line Items]
2,016	11,426
2,017	24,841
2,018	18,610
2,019	90,965
Total future minimum payments	145,842
Less: amount representing interest(1)	(81,240)	[1]
Present value of minimum debt payments	64,602
Noncurrent portion of debt	64,602
Loans Payable [Member]
Debt Instrument [Line Items]
2,016	5,341
2,017	2,120
2,018	2,030
2,019	1,939
2,020	1,849
Thereafter	2,743
Total future minimum payments	16,022
Less: amount representing interest(1)	(2,046)	[1]
Present value of minimum debt payments	13,976
Less: current portion	(4,681)
Noncurrent portion of debt	9,295
Credit Facility [Member]
Debt Instrument [Line Items]
2,016	37,919
2,017	1,279
2,018	267
2,019	65
Total future minimum payments	39,530
Less: amount representing interest(1)	(5,081)	[1]
Present value of minimum debt payments	34,449
Less: current portion	(32,889)
Noncurrent portion of debt	$ 1,560
[1]	Including debt discount of $48.6 million related to the embedded derivative associated with the related party and non-related party convertible debt which will be accreted to interest expense under the effective interest method over the term of the convertible debt.

Note 6 - Commitments and Cont63

Note 6 - Commitments and Contingencies (Details)

Apr. 08, 2015USD ($)

Dec. 02, 2013USD ($)$ / shares

Dec. 31, 2015USD ($)

Dec. 31, 2015BRL

Apr. 30, 2013USD ($)

Dec. 31, 2011USD ($)

Dec. 31, 2011BRL

Aug. 31, 2011USD ($)

Mar. 31, 2011USD ($)

May. 31, 2008USD ($)

Dec. 31, 2013USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2015BRL

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Dec. 01, 2013$ / shares

Mar. 31, 2013USD ($)

Dec. 31, 2010USD ($)

Nov. 30, 2010

Oct. 31, 2010ft²

Note 6 - Commitments and Contingencies (Details) [Line Items]

Operating Leases, Rent Expense

$ 2,523

BRL 9,853

$ 5,500,000

$ 5,400,000

$ 4,800,000

Restricted Cash and Cash Equivalents

1,200,000

1,200,000

1,600,000

Purchase Obligation

1,300,000

1,300,000

Contractual Obligation

500,000

500,000

Performance Guarantee [Member] | Payment Guarantee [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Restricted Cash and Cash Equivalents

$ 0

0

600,000

FINEP Credit Facility [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

FINEP Credit Facility [Member] | Chattel Mortgage [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired

1,500,000

BRL 6,000,000

BNDES Credit Facility [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Collateral Provided by Company Certain Equipment and Other Tangible Assets Amount

$ 6,400,000

BRL 24,900,000

Debt Instrument, Interest Rate, Stated Percentage

7.00%

Machinery and Equipment [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Capital Leased Assets, Gross

$ 3,000,000

Sale Leaseback Transaction, Unrealized Loss

$ 1,300,000

Capital Lease Obligations

$ 1,200,000

300,000

1,200,000

Incremental Borrowing Rate, Capital Lease

6.50%

Building Operating Lease [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Period of Lease Term

10 years

Incentive from Lessor

$ 11,400,000

Area of Real Estate Property (in Square Feet) | ft²

22,000

Cash Received from Lessor, Amended Lease Agreement, Operating Lease

$ 1,000,000

Amyris Brasil S.A. Subsidiary [Member] | Building Operating Lease [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Period of Lease Term

5 years

Estimated Annual Rent Expense, Operating Leases

$ 153,504

Paraiso Bioenergia S.A. Agreement [Member] | Land and Land Improvements Operating Leases [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Period of Lease Term

15 years

Estimated Annual Rent Expense, Operating Leases

$ 61,463

BNDES [Member] | BNDES Credit Facility [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Collateral Provided by Company Certain Equipment and Other Tangible Assets Amount

6,400,000

24,900,000

Banco ABC Brasil S.A. (ABC) [Member] | ABC Brasil Agreement [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Export Financing Agreement

$ 1,600,000

$ 2,200,000

Export Funding Agreement, Term

1 year

Notes Payable, Other Payables [Member] | Amendment of Lease Agreement - Emeryville [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Lease Incentive Elimination of Debt, Amount

$ 1,600,000

Monthly Rent Credit, Current

71,000

Monthly Rent Credit,Noncurrent

$ 42,000

Unsecured Senior Convertible Promissory Notes [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Convertible Promissory Note, Held by Third Party

$ 5,000,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 2.20

$ 7.0682

Unsecured Senior Convertible Promissory Notes [Member] | JV Agreements [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 7.0682

Nossa Caixa and Banco Pine Agreements [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Collateral Provided by Company Certain Equipment and Other Tangible Assets Amount

$ 17,400,000

BRL 68,000,000

Related Party Convertible Notes [Member] | Unsecured Debt [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Face Amount

$ 69,000,000

$ 69,000,000

Debt Instrument, Interest Rate, Stated Percentage

1.50%

1.50%

Related Party Convertible Notes [Member] | Secured Debt [Member]

Note 6 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Face Amount

$ 10,850,000

$ 10,850,000

Purchase Obligation, Due in Second Year

$ 10,850,000

$ 10,850,000

Note 6 - Commitments and Cont64

Note 6 - Commitments and Contingencies (Details) - Future Minimum Payments for Lease Obligations - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Future Minimum Payments for Lease Obligations [Abstract]
2,016	$ 565
2,016	6,724
2,016	7,289
2,017	188
2,017	6,644
2,017	6,832
2,018	0
2,018	6,701
2,018	6,701
2,019	0
2,019	6,749
2,019	6,749
2,020	0
2,020	6,985
2,020	6,985
Thereafter	0
Thereafter	18,047
Thereafter	18,047
Total future minimum lease payments	753
Total future minimum lease payments	51,850
Total future minimum lease payments	52,603
Less: amount representing interest	(54)
Present value of minimum lease payments	699
Less: current portion	(523)	$ (541)
Long-term portion	$ 176	$ 275

Note 7 - Joint Ventures and N65

Note 7 - Joint Ventures and Noncontrolling Interest (Details)

Mar. 21, 2016USD ($)

Mar. 21, 2016EUR (€)

Feb. 12, 2016EUR (€)

Jul. 26, 2015USD ($)

Feb. 29, 2016USD ($)

Dec. 31, 2015USD ($)shares

Dec. 31, 2015BRLshares

Nov. 30, 2014USD ($)

Oct. 31, 2014USD ($)

Sep. 30, 2014USD ($)

May. 31, 2014USD ($)

Apr. 30, 2014USD ($)

Feb. 28, 2014

Mar. 31, 2013USD ($)

Dec. 31, 2012USD ($)

Jan. 31, 2011

Apr. 30, 2010

Oct. 31, 2014USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Dec. 31, 2015BRL

Dec. 31, 2015EUR (€)

May. 01, 2015USD ($)

Nov. 30, 2013

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Income (Loss) from Equity Method Investments

$ (4,184,000)

$ (2,910,000)

Extinguishment of Debt, Amount

$ 5,000,000

Equity Method Investment, Number of Members of Board of Directors Appointed by Each Venture

2

Operating Leases, Rent Expense

$ 2,523

BRL 9,853

$ 5,500,000

5,400,000

$ 4,800,000

Variable Interest Entity Number of Entities

2

Glycotech Agreement [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Period of Initial Term of Collaboration Agreement

2 years

Variable Interest Entity, Financial or Other Support, Percentage

100.00%

Variable Interest Entity Number of Entities

2

Variable Interest Entity, Consolidated, Carrying Amount, Property and Equipment

5,200,000

$ 5,200,000

Variable Interest Entity, Consolidated, Carrying Amount, Other Assets

300,000

300,000

Variable Interest Entity, Consolidated, Carrying Amount, Current Assets

1,500,000

1,500,000

Variable Interest Entity, Consolidated, Carrying Amount, Accounts Payable and Accrued Liabilities

1,100,000

1,100,000

Variable Interest Entity, Consolidated, Carrying Amount, Loan Obligations

100,000

Novvi LLC [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

50.00%

Equity Method Investment, Number of MembersOfBoard of Directors

6

Joint Venture, Number of Managers Representing Each Investor

3

Initial Term of Joint Venture

20 years

IP License, Value

$ 10,000,000

Carrying Value of the Licenses Granted Under the IP License Agreement

$ 0

Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures

$ 2,100,000

Loan Granted to Joint Venture

1,600,000

$ 1,900,000

$ 3,700,000

1,600,000

$ 1,100,000

Loan Granted to Joint Venture, Stated Annual Interest Rate

0.36%

Loan to Joint Venture, Percentage Provided by Each the Company and the Partner

50.00%

50.00%

Loan Granted to Joint Venture, Amount Disbursed by Company

$ 1,000,000

$ 1,800,000

Loan Granted to Joint Venture, Number of Installments Paid by the Company

2

Loan Granted to Joint Venture, Amount of First Installment Paid by Company

$ 1,200,000

Loan Granted to Joint Venture, Amount of Second Installment Paid by Company

$ 600,000

Loan Granted to Joint Venture Outstanding, Amount Net of Imputed Interest

2,700,000

1,700,000

Imputed Interest on Loan to Joint Venture

1,600,000

1,000,000

1,700,000

Due From Joint Venture, Reserve

500,000

Income (Loss) from Equity Method Investments

2,900,000

Equity Method Investment, Other than Temporary Impairment

1,593,000

Equity Method Investments

0

0

$ 2,192,000

Novvi LLC [Member] | Subsequent Event [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price

$ 600,000

Novvi S.A. [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price

$ 200,000

JVCO Joint Venture [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

Equity Method Investment, Preferred Stock Ownership Percentage

100.00%

Capitalization, Long-term Debt and Equity

100,000

100,000

€ 100,000

Total Amyris Biosolutions B.V. [Member] | Subsequent Event [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Equity Method Investment, Ownership Percentage

25.00%

Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions

25.00%

25.00%

SMA Industria Quimica S.A. [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

Equity Method Investment, Number of MembersOfBoard of Directors

4

Initial Term of Joint Venture

20 years

Equity Method Investment, Number of Members of Executive Committee

3

Equity Method Investment, Number of Company-appointed Members of Executive Committee

2

Equity Method Investment, Period Company is Required to Purchase Output of Joint Venture

4 years

Operation Commencement Timeline Requirement, Extension

18 months

SMA Industria Quimica S.A. [Member] | Loss on Purchase Commitments and Impairment of Property, Plant and Equipment [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss

28,500,000

Novvi LLC [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Income (Loss) from Equity Method Investments

2,600,000

Total [Member] | Subsequent Event [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Extinguishment of Debt, Amount | €

€ 50,000

Total [Member] | Pilot Plant Agreements [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Related Party Agreement, Term

5 years

5 years

Total [Member] | Pilot Plant Agreements [Member] | Scale-up Services and Training [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

$ 900,000

$ 900,000

Number of Installments for Annual Fee

3

Total [Member] | Pilot Plant Agreement Amendment [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Related Party Transaction, Fees Waived

$ 2,000,000

Total [Member] | Subsequent Event [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Extinguishment of Debt, Amount

$ 1,300,000

€ 50,000

Proceeds from Issuance of Senior Long-term Debt

3,700,000

SMSA [Member] | SMA Industria Quimica S.A. [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Due from Joint Ventures

15,800,000

$ 15,800,000

BRL 61,800,000

Cosan [Member] | Novvi LLC [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

Obligation to Fund Agreement, Cash Portion

$ 10,000,000

Total Amyris Biosolutions B.V. [Member] | JVCO Joint Venture [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

Total [Member] | Subsequent Event [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Extinguishment of Debt, Amount

$ 5,000,000

Total [Member] | Total Amyris Biosolutions B.V. [Member] | Subsequent Event [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions

75.00%

75.00%

Amyris Brasil Ltda. [Member] | SMSA [Member]

Note 7 - Joint Ventures and Noncontrolling Interest (Details) [Line Items]

Share Purchase and Sale Agreement, Purchase Price of Shares

$ 12,805

BRL 50,000

Share Purchase and Sale Agreement, Shares (in Shares) | shares

50,000

50,000

Share Purchase and Sale Agreement, Term to Remove Assets

12 months

12 months

Note 7 - Joint Ventures and N66

Note 7 - Joint Ventures and Noncontrolling Interest (Details) - Reconciliation of Equity and Loans in Novvi - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]
Loans to affiliate	$ 1,579	$ 2,790
Share in net loss offset	(4,184)	(2,910)
Novvi LLC [Member]
Schedule of Equity Method Investments [Line Items]
Balance at January 1	2,192
Loans to affiliate	1,579	1,745
Capital contribution (cash)		2,312
Share in net loss offset		2,900
Accretion of imputed interest	413	1,045
Impairment	(1,593)
Balance at December 31	0	2,192
Offset to Equity Investment [Member] | Novvi LLC [Member]
Schedule of Equity Method Investments [Line Items]
Share in net loss offset	(848)	$ (2,910)
Offset to Loans to Affiliate [Member] | Novvi LLC [Member]
Schedule of Equity Method Investments [Line Items]
Share in net loss offset	$ (1,743)

Note 7 - Joint Ventures and N67

Note 7 - Joint Ventures and Noncontrolling Interest (Details) - Variable Interest Entities - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Variable Interest Entity [Line Items]
Assets*	[1]	$ 6,993	$ 22,812
Liabilities		$ 1,221	$ 290
[1]	*Net of impairment at December 31, 2015 of $28.5 million related to SMA assets (see Note 4 "Balance Sheet Components" for details).

Note 7 - Joint Ventures and N68

Note 7 - Joint Ventures and Noncontrolling Interest (Details) - Noncontrolling Interest - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Note 7 - Joint Ventures and Noncontrolling Interest (Details) - Noncontrolling Interest [Line Items]
Balance at January 1	$ (611)
Foreign currency translation adjustment	(320)	$ (92)	$ (89)
Income attributable to noncontrolling interest	(100)	(119)	204
Balance at December 31	(391)	(611)
Noncontrolling Interest [Member]
Note 7 - Joint Ventures and Noncontrolling Interest (Details) - Noncontrolling Interest [Line Items]
Balance at January 1	611	584
Foreign currency translation adjustment	(320)	(92)
Income attributable to noncontrolling interest	100	119
Balance at December 31	$ 391	$ 611	$ 584

Note 8 - Significant Agreemen69

Note 8 - Significant Agreements (Details) $ / shares in Units, BRL in Millions

Feb. 15, 2016USD ($)$ / shares

Feb. 12, 2016USD ($)

Oct. 14, 2015USD ($)$ / sharesshares

Jul. 29, 2015$ / sharesshares

Jul. 24, 2015$ / sharesshares

Apr. 30, 2015USD ($)

Apr. 30, 2014USD ($)$ / shares

Feb. 29, 2016USD ($)$ / sharesshares

Nov. 30, 2015USD ($)

Sep. 30, 2015USD ($)

Jul. 31, 2015$ / sharesshares

Jun. 30, 2015

Mar. 31, 2015USD ($)

Feb. 28, 2015USD ($)

Jan. 31, 2015USD ($)

Jul. 31, 2014USD ($)

Jun. 30, 2014USD ($)

Apr. 30, 2014USD ($)$ / sharesshares

Mar. 31, 2014USD ($)$ / sharesshares

Mar. 31, 2013USD ($)

Jan. 31, 2013USD ($)shares

Dec. 31, 2012USD ($)shares

Jul. 30, 2012USD ($)

Jan. 31, 2015USD ($)

Dec. 31, 2015USD ($)$ / sharesshares

Dec. 31, 2014USD ($)$ / sharesshares

Dec. 31, 2013USD ($)shares

Dec. 31, 2013USD ($)

Dec. 01, 2015USD ($)

May. 31, 2015USD ($)

Mar. 30, 2015USD ($)

May. 31, 2014

Nov. 30, 2011USD ($)

Sep. 30, 2011USD ($)

Nov. 30, 2010BRL

Jun. 30, 2010USD ($)

Note 8 - Significant Agreements (Details) [Line Items]

Grants and Collaborations Revenue

$ 19,257,000

$ 19,835,000

$ 22,664,000

Sales Revenue Product Net

$ 14,032,000

$ 22,793,000

14,428,000

Stock Issued During Period, Shares, New Issues (in Shares) | shares

943,396

5,033,557

Share Price (in Dollars per share) | $ / shares

$ 1.62

$ 2.06

Proceeds from Issuance of Common Stock

$ 614,000

$ 2,488,000

1,134,000

Line of Credit Facility, Maximum Borrowing Capacity | BRL

BRL 6.4

Proceeds from Issuance of Long-term Debt

66,931,000

83,171,000

10,535,000

Proceeds from Issuance of Private Placement

$ 4,000,000

$ 15,000,000

$ 37,200,000

24,625,000

4,000,000

19,980,000

Debt Instrument, Convertible, Conversion Rate, Shares (in Shares) | shares

443.6557

Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments

0.75%

Gains (Losses) on Extinguishment of Debt

(1,141,000)

(10,512,000)

(19,914,000)

Private Placement [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

1,602,562

Class of Warrant or Right, Term

5 years

5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

$ 0.01

Flavors and Fragrances Compounds [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Sales Revenue Product Net

1,400,000

Subsequent Event [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Debt Instrument, Convertible, Conversion Rate, Shares (in Shares) | shares

445.2252

Debt Instrument, Convertible, Conversion Rate, Principle Amount (in Dollars per share) | $ / shares

$ 1,000

Subsequent Event [Member] | Private Placement February 2016 [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

Debt Instrument, Interest Rate, Stated Percentage

13.50%

Debt Instrument, Face Amount

$ 20,000,000

Proceeds from Issuance of Private Placement

$ 2,000,000

$ 18,000,000

$ 20,000,000

Research and Development Collaboration with Total [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Additional Amount to the Initial Amount Research and Development Collaborative Agreement Contribution Amount

$ 30,000,000

Initial Amount Research and Development Collaborative Agreement Contributed by Collaborator

$ 50,000,000

Research and Development Collaboration Agreement Amount to be Considered as Part of Initial Amount Pledged

$ 10,000,000

$ 10,000,000

$ 10,000,000

Remaining Percentage of Research and Development Collaboration Funding

50.00%

Advanced Payments Recognized and no Longer Contigently Repayable

$ 46,500,000

Amount from Advanced Payment Rolled into Unsecured Convertible Promissory Note

23,300,000

Research and Development Arrangement, Contract to Perform for Others, Compensation Earned

23,200,000

Reduction in Capitalized Deferred Charge Asset

14,400,000

Technology Investment Agreement with DARPA [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Collaboration Agreement Period

4 years

Maximum DARPA Funding to be Received if all Milestones are Achieved

$ 35,000,000

Collective Obligation Due

$ 15,500,000

Nomis Bay Common Stock Purchase Agreement [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Common Stock Purchase Agreement Amount

$ 50,000,000

Common Stock Purchase Agreement Term

24 months

Common Stock Purchase Agreement, Number of Draw Down Notices

24

Common Stock Purchase Agreement Number Consecutive Trading Days in Draw Down Share Price Determination

10 days

Common Stock Purchase Agreement Share Purchase Amount Per Draw Down Period

9.90%

Common Stock Purchase Agreement Commitment Fee

$ 100,000

Common Stock Purchase Agreement Additional Commitment Fee

$ 300,000

Nomis Bay Common Stock Purchase Agreement [Member] | Nomis Bay's Legal Fees and Expense [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Common Stock Purchase Agreement Legal Fees Paid by Company

35,000

Nomis Bay Common Stock Purchase Agreement [Member] | Financial West Group (FWG) [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Common Stock Purchase Agreement Legal Fees Paid by Company

$ 15,000

Securities Purchase Agreement With Naxyris S.A. [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Securities Purchase Agreement Amount

$ 10,000,000

Security Purchase Agreement Amount of New Financing Cancelling Agreement

10,000,000

Security Purchase Agreement Commitment Fee

$ 200,000

Collaboration Partner [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Additional Grants and Collaboration Funding

5,000,000

Collaboration Partner [Member] | Flavors and Fragrances Compounds [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Revenue Recognition, Milestone Method, Revenue Recognized

$ 6,000,000

Collaboration Agreement Annual Funding Year Three

$ 10,000,000

Collaboration Agreement Annual Funding Year Two

10,000,000

Collaboration Agreement Annual Funding Year One

$ 10,000,000

Proceeds from Collaborators

$ 10,000,000

Grants and Collaborations Revenue

11,000,000

10,000,000

Collaboration Partner [Member] | Master Collaboration Agreement [Member] | Flavors and Fragrances Compounds [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Revenue Recognition, Milestone Method, Revenue Recognized

1,000,000

Sales Margin Collaborator Percentage Split

70.00%

Sales Margin Company Percentage Split

30.00%

Return Required for Collaboration Partner Before Adjusting Split on Sales Margin

$ 15,000,000

Sales Margin Collaborator Percentage Split Following Return Requirements

50.00%

Sales Margin Company Percentage Split Following Return Requirements

50.00%

Success Bonus

$ 2,500,000

Research and Development Collaboration Term

6 years

Michelin [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Proceeds from Collaborators

$ 5,000,000

Advances on Collaboration Services

$ 5,000,000

Braskem and Michelin [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Collaboration Agreement Period

3 years

Braskem [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Revenue Recognition, Milestone Method, Revenue Recognized

2,200,000

900,000

Proceeds from Collaborators

$ 2,000,000

$ 2,000,000

$ 4,000,000

Kuraray [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Proceeds from Collaborators

$ 2,000,000

$ 2,000,000

2,000,000

$ 4,000,000

Collaboration Agreement Period

2 years

Collaborative Agreement Number of Installments

2

Collaboration Arrangement, Shares To Be Sold (in Shares) | shares

943,396

Collaboration Arrangement, Price Per Share (in Dollars per share) | $ / shares

$ 4.24

Stock Issued During Period, Shares, New Issues (in Shares) | shares

943,396

Share Price (in Dollars per share) | $ / shares

$ 4.24

$ 4.24

Proceeds from Issuance of Common Stock

$ 4,000,000

Deferred Revenue, Revenue Recognized

$ 1,600,000

$ 900,000

Naxyris S.A. [Member] | Securities Purchase Agreement With Naxyris S.A. [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

5.00%

Common Stock [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares) | shares

14,177,849

16,025,642

943,396

6,567,299

Common Stock [Member] | Private Placement [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares) | shares

16,025,642

16,025,642

Share Price (in Dollars per share) | $ / shares

$ 1.56

$ 1.56

Benefical Owner Ownership Percentage of Common Stock

5.00%

Common Stock [Member] | Naxyris S.A. [Member] | Private Placement [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares) | shares

2,243,594

Common Stock [Member] | Foris Ventures, LLC [Member] | Private Placement [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares) | shares

9,615,384

Common Stock [Member] | Total [Member] | Private Placement [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares) | shares

1,282,051

Minimum [Member] | Nomis Bay Common Stock Purchase Agreement [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Common Stock Purchase Agreement Share Price Discount Percentage

3.00%

Common Stock Purchase Agreement Share Purchase Amount Per Draw Down Period

325000.00%

Maximum [Member] | Nomis Bay Common Stock Purchase Agreement [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Common Stock Purchase Agreement Share Price Discount Percentage

6.25%

Common Stock Purchase Agreement Share Purchase Amount Per Draw Down Period

3250000.00%

First Payment [Member] | Collaboration Partner [Member] | Flavors and Fragrances Compounds [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Proceeds from Collaborators

$ 10,000,000

Second Payment [Member] | Collaboration Partner [Member] | Flavors and Fragrances Compounds [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Proceeds from Collaborators

$ 10,000,000

Total [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Revenue from Related Parties

$ 900,000

$ 600,000

$ 200,000

Total [Member] | Research and Development Collaboration with Total [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Revenue from Related Parties

$ 8,900,000

Total [Member] | Common Stock [Member] | Private Placement [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares) | shares

1,282,051

Hercules Technology Growth Capital, Inc. (Hercules) [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

15,000,000

Loans Payable

$ 25,000,000

31,700,000

Debt Instrument, Unencumbered, Unrestricted, Cash Required, Percentage

50.00%

50.00%

Second Hercules Amendment [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

15,000,000

Line of Credit Facility, Early Draw Down Equity Raise Requirement

$ 20,000,000

Third Hercules Amendment [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Proceeds from Issuance of Long-term Debt

$ 10,960,000

Loans Payable

$ 31,700,000

Debt Instrument, Interest Rate, Stated Percentage

9.50%

9.50%

Debt Instrument, Basis Spread on Variable Rate

6.25%

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 767,200

Debt Issuance Cost

$ 1,000,000

Debt Instrument, Unencumbered, Unrestricted, Cash Required, Percentage

50.00%

Third Hercules Amendment [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Portion of Debt Costs Owed in Connection with Expired Facility [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Debt Issuance Cost

$ 750,000

Third Hercules Amendment [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Portion of Debt Costs Related to the Third Hercules Amendment [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Debt Issuance Cost

$ 250,000

Convertible Senior Notes, 9.5% [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Debt Instrument, Face Amount

$ 57,600,000

Proceeds from Convertible Debt

$ 54,400,000

Debt Instrument, Repurchase Amount

$ 3,700,000

Debt Instrument, Convertible, Conversion Rate, Shares (in Shares) | shares

443.6557

Debt Instrument, Convertible, Conversion Rate, Principle Amount (in Dollars per share) | $ / shares

$ 1,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 2.25

Debt Instrument, Post Conversion Interest Payment Period, Maximum

3 years

Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments

0.75%

Debt Instrument, Convertible, Percentage of Average Price Per Share the Stock will be Valued Upon Early Conversion

92.50%

Early Payment Simple Daily Average Price Per Share, Number of Trading Days

10 days

Convertible Note Substantial Change, Percentage of Principal Repurchase Price

100.00%

Debt Instrument, Convertible, Number of Equity Instruments

38,415,626

Gains (Losses) on Extinguishment of Debt

500,000

Debt Conversion, Original Debt, Amount

1,300,000

Convertible Senior Notes, 9.5% [Member] | Subsequent Event [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Class of Warrant or Right, Term

5 years

Debt Instrument, Convertible, Conversion Rate, Shares (in Shares) | shares

445.2252

Debt Instrument, Convertible, Conversion Rate, Principle Amount (in Dollars per share) | $ / shares

$ 1,000

Convertible Senior Notes, 6.5% [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.50%

Debt Instrument, Repurchase Amount

$ 18,300,000

Debt Instrument, Repurchased Face Amount

$ 22,900,000

Convertible Senior Notes, 3% [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.00%

Debt Instrument, Repurchase Amount

$ 8,800,000

Debt Instrument, Repurchased Face Amount

$ 9,700,000

Convertible Senior Notes, 3% and 6.5% [Member]

Note 8 - Significant Agreements (Details) [Line Items]

Gains (Losses) on Extinguishment of Debt

$ 5,300,000

Note 9 - Goodwill and Intangi70

Note 9 - Goodwill and Intangible Assets (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 31, 2011	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)			$ 5,525,000	$ 3,035,000	$ 0
Draths Corporation [Member] | In Process Research and Development, Indefinite [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Indefinite-lived Intangible Assets Acquired	$ 8,600,000
Impairment of Intangible Assets (Excluding Goodwill)		$ 5,500,000
Acquired Licenses and Permits [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Amortization of Intangible Assets			$ 0	$ 0	$ 32,000

Note 9 - Goodwill and Intangi71

Note 9 - Goodwill and Intangible Assets (Details) - Intangible Assets and Goodwill - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Note 9 - Goodwill and Intangible Assets (Details) - Intangible Assets and Goodwill [Line Items]
Useful life
Accumulated Amortization/Impairment	$ (9,332,000)	$ (3,807,000)
Net Carrying Value	$ 0
Goodwill
Goodwill	$ 560,000	560,000
Goodwill	560,000	560,000
	9,892,000	9,892,000
	(9,332,000)	(3,807,000)
	560,000	6,085,000
	$ (5,525,000)
In Process Research and Development, Indefinite [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Intangible Assets and Goodwill [Line Items]
Useful life
Gross Carrying Amount	$ 8,560,000	8,560,000
Accumulated Amortization/Impairment	(8,560,000)	(3,035,000)
Net Carrying Value		5,525,000
Impairment	$ (5,525,000)
Goodwill
	$ (8,560,000)	(3,035,000)
Acquired Licenses and Permits [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Intangible Assets and Goodwill [Line Items]
Useful life	2 years
Gross Carrying Amount	$ 772,000	772,000
Accumulated Amortization/Impairment	$ (772,000)	(772,000)
Goodwill	2 years
	$ (772,000)	$ (772,000)

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended						12 Months Ended
	Apr. 30, 2014	Oct. 31, 2013	Mar. 31, 2013	Jan. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2015	Jan. 31, 2015	Sep. 28, 2010
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	943,396			5,033,557
Stock Issued During Period, Price Per Share, New Issues (in Dollars per share)	$ 4.24				$ 2.98
Proceeds from Issuance of Private Placement (in Dollars)	$ 4,000			$ 15,000	$ 37,200		$ 24,625	$ 4,000	$ 19,980
Extinguishment of Debt, Amount (in Dollars)					$ 5,000
Extinguishment of Debt, Common Stock, Shares					1,677,852
Proceeds from Issuance of Private Placement, First Payment Received (in Dollars)					$ 22,200
Common Stock, Shares, Outstanding							206,130,282	79,221,883
Common Stock, Shares Authorized							400,000,000	300,000,000
Preferred Stock, Shares Authorized							5,000,000	5,000,000
Preferred Stock, Shares Outstanding							0	0
Fair Value Assumptions, Expected Volatility Rate							45.00%	45.00%
Class of Warrant or Right, Outstanding							4,343,733	1,021,087
Equity Incentive Plan, 2010 [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized											3,961,094	30,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage Increase of Common Stock, Shares, Outstanding											5.00%
Employee Stock Purchase Plan, 2010 [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized											792,219	10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage Increase of Common Stock, Shares, Outstanding											1.00%
Common Stock [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues					14,177,849		16,025,642	943,396	6,567,299
Common Stock, Shares, Outstanding					68,709,660		206,130,282	79,221,883	76,662,812
Warrants in Connection With Capital Lease Arrangement [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						21,087
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$ 10.67
Warrants and Rights Outstanding (in Dollars)						$ 200
Class of Warrant or Right, Fair Value Assumptions, Expected Term						10 years
Class of Warrant or Right, Fair Value Assumptions, Risk Free Interest Rate						2.00%
Class of Warrant or Right, Fair Value Assumptions, Expected Volatility Rate						86.00%
Class of Warrant or Right, Fair Value Assumptions, Expected Dividend Rate						0.00%
Warrants in Connection with Issuance of Tranche I Convertible Promissory Notes [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 0.01
Warrants and Rights Outstanding (in Dollars)		$ 1,300
Class of Warrant or Right, Fair Value Assumptions, Expected Term		3 years 146 days
Class of Warrant or Right, Fair Value Assumptions, Risk Free Interest Rate		0.77%
Class of Warrant or Right, Fair Value Assumptions, Expected Volatility Rate		45.00%
Class of Warrant or Right, Fair Value Assumptions, Expected Dividend Rate		0.00%
Class of Warrant or Right, Cashless Exercise Provision, Number Exercised							0	0
Total and Temasek [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate							2.00%
Fair Value Assumptions, Expected Volatility Rate							74.00%
Fair Value Assumptions, Expected Dividend Rate							0.00%
Warrants in Connection with Issuance of Tranche III Convertible Promissory Notes [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										1,602,562
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$ 0.01
Class of Warrant or Right, Outstanding							1,442,307
Biolding Investment SA [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			1,533,742
Stock Issued During Period, Price Per Share, New Issues (in Dollars per share)			$ 3.26
Proceeds from Issuance of Private Placement (in Dollars)			$ 5,000
Commitment to purchase company common stock (in Dollars)			$ 15,000		$ 15,000
Commitment Fulfilled [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Commitment to purchase company common stock (in Dollars)					$ 10,000

Note 11 - Stock-based Compens73

Note 11 - Stock-based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2015	Sep. 28, 2010
Note 11 - Stock-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	12,930,112	10,539,978
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)	$ 4.77	$ 6.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	13,250
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)	$ 0	$ 600	$ 600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	4,720,278	3,683,791	2,849,919
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$ 1.21	$ 2.31	$ 1.98
Allocated Share-based Compensation Expense (in Dollars)	$ 9,134	$ 14,105	$ 18,047
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Compensation Cost (in Dollars)	$ 0	$ 100	$ 1,000
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number	0	0	458,424
Equity Incentive Plan, 2010 [Member]
Note 11 - Stock-based Compensation (Details) [Line Items]
Common Stock, Additional Capital Shares Reserved For Issuance					2,148,585
Shares Available for Issuance Percentage of Total Outstanding Shares					5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				3,961,094	30,000,000
Share-based Compensation Arrangement By Share-based Payment Award Options Period Available to Grant	10 years
Share-based Compensation Arrangement By Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date	100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Shareholder Triggering Higher Exercise Price	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value On Grant Date Of Ten Percent Or Greater Shareholder Of Company	110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	11,321,194	8,692,818
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,833,004	5,133,576
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)	$ 4.27	$ 5.72
Stock Options And Stock Issuance Plans, 2005 [Member]
Note 11 - Stock-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement By Share-based Payment Award Options Period Available to Grant	10 years
Share-based Compensation Arrangement By Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date	100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Shareholder Triggering Higher Exercise Price	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value On Grant Date Of Ten Percent Or Greater Shareholder Of Company	110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,548,918	1,787,160
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)	$ 8.46	$ 8.04
Employee Stock Purchase Plan, 2010 [Member]
Note 11 - Stock-based Compensation (Details) [Line Items]
Shares Available for Issuance Percentage of Total Outstanding Shares					1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				792,219	10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,221,896	815,569			168,627
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	385,892	352,816
Allocated Share-based Compensation Expense (in Dollars)	$ 300	$ 500	$ 600
Employee Stock Option [Member]
Note 11 - Stock-based Compensation (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars)	6,000	10,100	13,100
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	$ 8,000	$ 11,400	15,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years	2 years 292 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments (in Dollars)	$ 0
Restricted Stock Units (RSUs) [Member]
Note 11 - Stock-based Compensation (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars)	2,800	$ 3,300	4,100
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	$ 7,700	$ 3,600	$ 3,600
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	4,988,539	1,083,300	1,222,250
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$ 1.82	$ 3.51	$ 2.85
Minimum [Member] | Equity Incentive Plan, 2010 [Member]
Note 11 - Stock-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Maximum [Member] | Equity Incentive Plan, 2010 [Member]
Note 11 - Stock-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years

Note 11 - Stock-based Compens74

Note 11 - Stock-based Compensation (Details) - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Abstract]
Number outstanding	12,930,112	10,539,978
Weighted-average exercise price	$ 4.77	$ 6.10
Weighted-average remaining contractual term	7 years 142 days	7 years 80 days
Aggregate intrinsic value	$ 22	$ 50
Vested and expected to vest after December 31, 2015	11,967,864
Vested and expected to vest after December 31, 2015	$ 4.98
Vested and expected to vest after December 31, 2015	7 years 76 days
Vested and expected to vest after December 31, 2015	$ 20
Exercisable at December 31, 2015	6,226,620
Exercisable at December 31, 2015	$ 7.43
Exercisable at December 31, 2015	5 years 208 days
Exercisable at December 31, 2015	$ 12
Options granted	4,720,278
Options granted	$ 1.84
Options exercised	(13,250)
Options exercised	$ 1.38
Options cancelled	(2,316,894)
Options cancelled	$ 4.89

Note 11 - Stock-based Compens75

Note 11 - Stock-based Compensation (Details) - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Note 11 - Stock-based Compensation (Details) - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Line Items]
Number outstanding	5,554,844	1,975,503
Weighted-average grant-date fair value	$ 2.03	$ 3.28
Weighted average remaining contractual life	1 year 222 days	339 days
Expected to vest after December 31, 2015	4,698,610
Expected to vest after December 31, 2015	$ 2.05
Expected to vest after December 31, 2015	1 year 171 days
Awarded	4,988,539	1,083,300	1,222,250
Awarded	$ 1.82	$ 3.51	$ 2.85
Vested	(1,046,468)
Vested	$ 3.10
Forfeited	(362,730)
Forfeited	$ 2.90

Note 11 - Stock-based Compens76

Note 11 - Stock-based Compensation (Details) - Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	$ 0.28
Exercise Price - upper range limit	$ 30.17
Options Outstanding - Number of Options (in Shares) | shares	12,930,112
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	7 years 142 days
Options Outstanding - Weighted-Average Exercise Price	$ 4.77
Options Exercisable - Number of Options (in Shares) | shares	6,226,620
Options Exercisable - Weighted-Average Exercise Price	$ 7.43
Exercise Price Range 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	0.28
Exercise Price - upper range limit	$ 1.67
Options Outstanding - Number of Options (in Shares) | shares	1,363,293
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	9 years 156 days
Options Outstanding - Weighted-Average Exercise Price	$ 1.62
Options Exercisable - Number of Options (in Shares) | shares	65,593
Options Exercisable - Weighted-Average Exercise Price	$ 1.44
Exercise Price Range 2 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	1.69
Exercise Price - upper range limit	$ 1.75
Options Outstanding - Number of Options (in Shares) | shares	1,338,225
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	9 years 233 days
Options Outstanding - Weighted-Average Exercise Price	$ 1.73
Exercise Price Range 3 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	1.78
Exercise Price - upper range limit	$ 1.80
Options Outstanding - Number of Options (in Shares) | shares	121,000
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	9 years 120 days
Options Outstanding - Weighted-Average Exercise Price	$ 1.79
Options Exercisable - Number of Options (in Shares) | shares	437
Options Exercisable - Weighted-Average Exercise Price	$ 1.80
Exercise Price Range 4 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	1.96
Exercise Price - upper range limit	$ 1.96
Options Outstanding - Number of Options (in Shares) | shares	1,390,783
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	9 years 160 days
Options Outstanding - Weighted-Average Exercise Price	$ 1.96
Exercise Price Range 5 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	1.98
Exercise Price - upper range limit	$ 2.79
Options Outstanding - Number of Options (in Shares) | shares	1,661,324
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	7 years 149 days
Options Outstanding - Weighted-Average Exercise Price	$ 2.62
Options Exercisable - Number of Options (in Shares) | shares	930,882
Options Exercisable - Weighted-Average Exercise Price	$ 2.71
Exercise Price Range 6 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	2.81
Exercise Price - upper range limit	$ 3.05
Options Outstanding - Number of Options (in Shares) | shares	1,322,620
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	7 years 83 days
Options Outstanding - Weighted-Average Exercise Price	$ 2.94
Options Exercisable - Number of Options (in Shares) | shares	902,484
Options Exercisable - Weighted-Average Exercise Price	$ 2.94
Exercise Price Range 7 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	3.08
Exercise Price - upper range limit	$ 3.44
Options Outstanding - Number of Options (in Shares) | shares	323,669
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	7 years 200 days
Options Outstanding - Weighted-Average Exercise Price	$ 3.33
Options Exercisable - Number of Options (in Shares) | shares	192,283
Options Exercisable - Weighted-Average Exercise Price	$ 3.30
Exercise Price Range 8 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	3.51
Exercise Price - upper range limit	$ 3.51
Options Outstanding - Number of Options (in Shares) | shares	1,922,290
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	8 years 21 days
Options Outstanding - Weighted-Average Exercise Price	$ 3.51
Options Exercisable - Number of Options (in Shares) | shares	829,483
Options Exercisable - Weighted-Average Exercise Price	$ 3.51
Exercise Price Range 9 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	3.55
Exercise Price - upper range limit	$ 3.93
Options Outstanding - Number of Options (in Shares) | shares	1,481,696
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	4 years 324 days
Options Outstanding - Weighted-Average Exercise Price	$ 3.87
Options Exercisable - Number of Options (in Shares) | shares	1,324,343
Options Exercisable - Weighted-Average Exercise Price	$ 3.88
Exercise Price Range 10 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price - lower range limit	4.08
Exercise Price - upper range limit	$ 30.17
Options Outstanding - Number of Options (in Shares) | shares	2,005,212
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	4 years 25 days
Options Outstanding - Weighted-Average Exercise Price	$ 16.16
Options Exercisable - Number of Options (in Shares) | shares	1,981,115
Options Exercisable - Weighted-Average Exercise Price	$ 16.30

Note 11 - Stock-based Compens77

Note 11 - Stock-based Compensation (Details) - Employee Service Share-based Compensation, Allocation of Recognized Period Costs - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 9,134	$ 14,105	$ 18,047
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	2,306	3,508	4,281
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 6,828	$ 10,597	$ 13,766

Note 11 - Stock-based Compens78

Note 11 - Stock-based Compensation (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Note 11 - Stock-based Compensation (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate	1.80%	1.90%	1.40%
Expected term (in years)	6 years 29 days	6 years 36 days	6 years 36 days
Expected volatility	74.00%	75.00%	82.00%

Note 12 - Employee Benefit Pl79

Note 12 - Employee Benefit Plan (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	90.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	90.00%
Defined Contribution Plan, Minimum Service Vesting Period	1 year
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0.5	$ 0.4

Note 13 - Related Party Trans80

Note 13 - Related Party Transactions (Details) - USD ($)

Jul. 29, 2015

Jul. 26, 2015

Jul. 24, 2015

Jul. 31, 2015

May. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Oct. 31, 2013

Aug. 31, 2013

Mar. 31, 2013

Jan. 31, 2013

Dec. 31, 2012

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Jan. 31, 2015

Jul. 31, 2014

Dec. 02, 2013

Dec. 01, 2013

Sep. 30, 2013

Jul. 31, 2013

Jun. 30, 2013

Note 13 - Related Party Transactions (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

943,396

5,033,557

Stock Issued During Period, Price Per Share, New Issues (in Dollars per share)

$ 4.24

$ 2.98

Proceeds from Issuance of Private Placement

$ 4,000,000

$ 15,000,000

$ 37,200,000

$ 24,625,000

$ 4,000,000

$ 19,980,000

Extinguishment of Debt, Amount

5,000,000

Gains (Losses) on Extinguishment of Debt

$ (1,141,000)

$ (10,512,000)

(19,914,000)

Share Price (in Dollars per share)

$ 1.62

$ 2.06

Due to Related Parties, Noncurrent

$ 43,029,000

$ 115,239,000

Derivative, Gain (Loss) on Derivative, Net

(19,500,000)

Accounts Receivable, Related Parties

1,176,000

455,000

Private Placement [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Class of Warrant or Right, Term

5 years

5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 0.01

$ 0.01

Class of Warrant or Right, Securities Called by Warrants As Percentage of Shares Purchased By Investor

10.00%

Biolding Investment SA [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

1,533,742

Stock Issued During Period, Price Per Share, New Issues (in Dollars per share)

$ 3.26

Proceeds from Issuance of Private Placement

$ 5,000,000

Commitment to purchase company common stock

$ 15,000,000

$ 15,000,000

Total [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Revenue from Related Parties

900,000

600,000

$ 200,000

Total [Member] | Pilot Plant Agreements [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.50%

Related Party Agreement, Term

5 years

5 years

Proceeds from Fees Received

1,700,000

Total [Member] | Pilot Plant Agreements [Member] | Scale-up Services and Training [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

$ 900,000

$ 900,000

Total [Member] | Product Sales [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Accounts Receivable, Related Parties

1,200,000

300,000

Accrued and Other Current Liabilities [Member] | Total [Member] | Pilot Plant Agreements [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Proceeds Received from Related Parties

$ 0

$ 200,000

Common Stock [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

14,177,849

16,025,642

943,396

6,567,299

Common Stock [Member] | Private Placement [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

16,025,642

16,025,642

Share Price (in Dollars per share)

$ 1.56

$ 1.56

Common Stock [Member] | Total [Member] | Private Placement [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

1,282,051

Common Stock [Member] | Foris Ventures, LLC [Member] | Private Placement [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

9,615,384

Common Stock [Member] | Naxyris S.A. [Member] | Private Placement [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

2,243,594

Sublease Agreement [Member] | Total [Member] | Pilot Plant Agreements [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

100,000

Proceeds from Fees Received

2,000,000

Sublease Payments and Service Fees [Member] | Total [Member] | Pilot Plant Agreements [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

$ 900,000

$ 700,000

Unsecured Senior Convertible Promissory Notes [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 2.20

$ 7.0682

Unsecured Senior Convertible Promissory Notes [Member] | Related Party Financings [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.50%

1.50%

Debt Instrument, Face Amount

$ 20,000,000

$ 10,000,000

Related Party Convertible Notes [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Gains (Losses) on Extinguishment of Debt

$ (9,400,000)

(5,900,000)

(10,500,000)

$ (19,900,000)

Convertible Debt

43,000,000

115,200,000

Due to Related Parties, Noncurrent

43,000,000

115,200,000

Debt Instrument, Debt Discount, Related Party

1,600,000

53,800,000

Derivative Liability

7,900,000

39,800,000

Derivative, Gain (Loss) on Derivative, Net

$ 10,500,000

$ 141,200,000

(76,200,000)

August 2013 Convertible Notes [Member] | Private Placement [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount

$ 110,000,000

August 2013 Convertible Notes [Member] | Total and Temasek [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount

$ 73,000,000

Benefical Owner Ownership Percentage of Common Stock

5.00%

Bridge Loan

$ 5,000,000

August 2013 Convertible Notes [Member] | Total and Temasek [Member] | First Tranche [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount

$ 42,600,000

August 2013 Convertible Notes [Member] | Total and Temasek [Member] | Second Tranche [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount

30,400,000

Proceeds from Convertible Debt

6,000,000

August 2013 Convertible Notes [Member] | Total and Temasek [Member] | Second Closing [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Proceeds from Convertible Debt

25,000,000

August 2013 Convertible Notes [Member] | Temasek [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Proceeds from Convertible Debt

60,000,000

Bridge Loan

$ 35,000,000

August 2013 Convertible Notes [Member] | Temasek [Member] | First Tranche [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Proceeds from Convertible Debt

35,000,000

August 2013 Convertible Notes [Member] | Temasek [Member] | Second Closing [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Proceeds from Convertible Debt

$ 25,000,000

August 2013 Convertible Notes [Member] | Common Stock [Member] | Temasek [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 0.01

Temasek Bridge Loan [Member] | Temasek [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.50%

Bridge Loan

$ 35,000,000

Debt Interest Accraul Term

4 months

Debt Instrument Interest Rate Stated Default Percentage

2.00%

First Tranche [Member] | Related Party Convertible Notes [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount

$ 51,800,000

Proceeds from Convertible Debt

7,600,000

Gains (Losses) on Extinguishment of Debt

$ (19,900,000)

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 2.44

First Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Extinguishment of Debt, Amount

$ 35,000,000

First Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Extinguishment of Debt, Amount

$ 9,200,000

Unsecured Senior Convertible Promissory Notes [Member] | Temasek [Member] | Second Tranche [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount

$ 25,000,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.50%

1.50%

1.50%

Debt Instrument, Face Amount

$ 69,000,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 4,110,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Second Tranche [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount

$ 6,000,000

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Initial Tranche [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount

$ 10,850,000

$ 21,700,000

July 2012 Agreements [Member] | Total [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount

$ 10,850,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 7.0682

March 2014 Letter Agreement [Member] | Total [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 4.11

$ 4.11

$ 4.11

Convertible Debt

$ 75,000,000

Rule 144A Convertible Note Offering [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Proceeds from Convertible Debt

$ 72,000,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 3.74

Rule 144A Convertible Note Offering [Member] | Temasek [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Proceeds from Convertible Debt

$ 10,000,000

Rule 144A Convertible Note Offering [Member] | Total [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Proceeds from Convertible Debt

9,700,000

Rule 144A Convertible Note Offering [Member] | Foris Ventures, LLC [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

Proceeds from Convertible Debt

$ 5,000,000

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 14 - Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)	$ 468	$ 495	$ (847)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	47,900	28,300	47,700
Unrecognized Tax Benefits	8,634	17,081	$ 6,080	$ 3,918
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	0	0
Increase in Unrecognized Tax Benefits is Reasonably Possible	0
Decrease in Unrecognized Tax Benefits is Reasonably Possible	0
Additional Provision [Member]
Note 14 - Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)	0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Note 14 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	570,300	525,600
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Portion Resulting from Exercises of Employee Stock Options and Vesting of Restriction Stock Units [Member]
Note 14 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	27,100	27,100
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Note 14 - Income Taxes (Details) [Line Items]
Tax Credit Carryforward, Amount	9,800	8,500
State and Local Jurisdiction [Member]
Note 14 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	200,300	200,700
State and Local Jurisdiction [Member] | Portion Resulting from Exercises of Employee Stock Options and Vesting of Restriction Stock Units [Member]
Note 14 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	12,900	13,800
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member] | Research Tax Credit Carryforward [Member]
Note 14 - Income Taxes (Details) [Line Items]
Tax Credit Carryforward, Amount	$ 10,400	$ 9,400

Note 14 - Income Taxes (Detai82

Note 14 - Income Taxes (Details) - Components of Income Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Components of Income Loss [Abstract]
United States	$ (193,128)	$ 10,847	$ (216,583)
Foreign	(24,457)	(5,275)	(19,171)
Income (loss) before income taxes and loss from investment in affiliate	$ (217,585)	$ 5,572	$ (235,754)

Note 14 - Income Taxes (Detai83

Note 14 - Income Taxes (Details) - Components of Benefit (Provision) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$ 0
State	0
Foreign	468	$ 495	$ (847)
Total current provision (benefit)	468	495	(847)
Deferred:
Federal	0
State	0
Foreign	0
Total deferred provision (benefit)	0
Total provision (benefit) for income taxes	$ 468	$ 495	$ (847)

Note 14 - Income Taxes (Detai84

Note 14 - Income Taxes (Details) - Effective Tax Rate Reconciliation	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Tax Rate Reconciliation [Abstract]
Statutory tax rate	(34.00%)	(34.00%)	(34.00%)
State tax rate, net of federal benefit	(0.30%)	23.30%	(0.70%)
Stock-based compensation	0.10%	(2.80%)	0.10%
Federal R&D credit	(0.60%)	31.00%	(0.80%)
Derivative liabilities	3.60%	541.50%	13.90%
Non-Deductible Interest	5.50%		0.00%
Other	0.10%	(7.80%)	(0.60%)
Foreign losses	(1.20%)	32.30%	(1.40%)
Change in valuation allowance	27.10%	(592.40%)	23.10%
Effective income tax rate	0.30%	(8.90%)	(0.40%)

Note 14 - Income Taxes (Detai85

Note 14 - Income Taxes (Details) - Deferred Tax Assets and Liabilities - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets and Liabilities [Abstract]
Net operating loss carryforwards	$ 207,241	$ 195,536	$ 167,354
Fixed assets	10,519	1,299	822
Research and development credits	16,612	14,701	11,654
Foreign Tax Credit	1,899	1,431	935
Accruals and reserves	26,366	16,425	17,893
Stock-based compensation	19,048	18,773	17,521
Capitalized start-up costs	9,568	13,095	15,133
Capitalized research and development costs	63,339	56,880	45,968
Other	9,999	6,700	6,741
Total deferred tax assets	364,591	324,840	284,021
Debt discount and derivative	(4,402)	(12,517)
Total deferred tax liabilities	(4,402)	(12,517)
Net deferred tax asset prior to valuation allowance	360,189	312,323	284,021
Less: Valuation allowance	(360,189)	(312,323)	(284,021)
Net deferred tax assets (liabilities)	$ 0	$ 0	$ 0

Note 14 - Income Taxes (Detai86

Note 14 - Income Taxes (Details) - Uncertain Tax Benefits - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Uncertain Tax Benefits [Abstract]
Balance	$ 17,081	$ 6,080	$ 3,918
Increases in tax positions for prior period	(9,404)	4,736	469
Increases in tax positions during current period	957	6,265	1,693
Balance	$ 8,634	$ 17,081	$ 6,080

Note 15 - Reporting Segments (D

Note 15 - Reporting Segments (Details)	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Number of Business Activities	1

Note 15 - Reporting Segments 88

Note 15 - Reporting Segments (Details) - Revenues by Geography - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Note 15 - Reporting Segments (Details) - Revenues by Geography [Line Items]
Revenues	$ 9,847	$ 8,591	$ 7,843	$ 7,872	$ 11,585	$ 16,341	$ 9,307	$ 6,041	$ 34,153	$ 43,274	$ 41,119
UNITED STATES
Note 15 - Reporting Segments (Details) - Revenues by Geography [Line Items]
Revenues									20,897	21,331	21,235
BRAZIL
Note 15 - Reporting Segments (Details) - Revenues by Geography [Line Items]
Revenues									5,070	5,961	4,071
Europe [Member]
Note 15 - Reporting Segments (Details) - Revenues by Geography [Line Items]
Revenues									3,557	9,738	10,340
Asia [Member]
Note 15 - Reporting Segments (Details) - Revenues by Geography [Line Items]
Revenues									$ 4,629	$ 6,244	$ 5,473

Note 15 - Reporting Segments 89

Note 15 - Reporting Segments (Details) - Long-Lived Assets by Geography - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Note 15 - Reporting Segments (Details) - Long-Lived Assets by Geography [Line Items]
Long-Lived Assets	$ 59,797	$ 118,980
UNITED STATES
Note 15 - Reporting Segments (Details) - Long-Lived Assets by Geography [Line Items]
Long-Lived Assets	18,401	44,418
BRAZIL
Note 15 - Reporting Segments (Details) - Long-Lived Assets by Geography [Line Items]
Long-Lived Assets	41,093	74,197
Europe [Member]
Note 15 - Reporting Segments (Details) - Long-Lived Assets by Geography [Line Items]
Long-Lived Assets	$ 303	$ 365

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details) $ / shares in Units, $ in Thousands

Mar. 21, 2016USD ($)$ / shares

Mar. 21, 2016EUR (€)

Mar. 08, 2016USD ($)

Feb. 15, 2016USD ($)$ / sharesshares

Feb. 12, 2016USD ($)$ / sharesshares

Feb. 12, 2016EUR (€)

Feb. 29, 2016USD ($)

Apr. 30, 2014USD ($)

Jan. 31, 2013USD ($)

Dec. 31, 2012USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Oct. 14, 2015USD ($)$ / shares

Jul. 29, 2015$ / shares

Jan. 31, 2015

Jul. 31, 2014$ / shares

Mar. 31, 2013

Note 16 - Subsequent Events (Details) [Line Items]

Proceeds from Issuance of Private Placement (in Dollars)

$ 4,000

$ 15,000

$ 37,200

$ 24,625

$ 4,000

$ 19,980

Extinguishment of Debt, Amount

$ 5,000

Subsequent Event [Member] | Private Placement February 2016 [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Debt Instrument, Face Amount (in Dollars)

$ 20,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

Proceeds from Issuance of Private Placement (in Dollars)

$ 2,000

$ 18,000

20,000

Debt Instrument, Interest Rate, Stated Percentage

13.50%

Subsequent Event [Member] | At the Market Offering [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Common Stock, Value, Subscriptions (in Dollars)

$ 50,000

Commission Rate

3.00%

Novvi LLC [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

50.00%

Novvi LLC [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price (in Dollars)

$ 600

Equity Method Investment, Ownership Percentage

50.00%

Total Amyris Biosolutions B.V. [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Equity Method Investment, Ownership Percentage

25.00%

Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions

25.00%

25.00%

Total [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Extinguishment of Debt, Amount | €

€ 50,000

Total [Member] | Total Amyris Biosolutions B.V. [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Equity Method Investment, Ownership Percentage Exchanged for Cancellation of Debt

25.00%

Equity Method Investment, Ownership Percentage by Counterparty

75.00%

Total [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Extinguishment of Debt, Amount

$ 1,300

€ 50,000

Proceeds from Issuance of Senior Long-term Debt (in Dollars)

3,700

Total [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Extinguishment of Debt, Amount

$ 5,000

Total [Member] | Total Amyris Biosolutions B.V. [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions

75.00%

75.00%

Total [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 2.30

Unsecured Promissory Notes, 2016 [Member] | Subsequent Event [Member] | Private Placement February 2016 [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Debt Instrument, Face Amount (in Dollars)

$ 2,000

$ 18,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

285,714

2,571,428

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

Convertible Senior Notes, 9.5% [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Debt Instrument, Face Amount (in Dollars)

$ 57,600

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Debt Instrument, Repurchase Amount (in Dollars)

$ 3,700

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 2.25

Convertible Senior Notes, 9.5% [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Class of Warrant or Right, Term

5 years

5 years

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Debt Instrument, Face Amount (in Dollars)

$ 69,000

Debt Instrument, Interest Rate, Stated Percentage

1.50%

1.50%

1.50%

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 4,110,000

Debt Instrument Default Rate

2.50%

Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Extinguishment of Debt, Amount

$ 1,300

March 2016 R&D Note [Member] | Total [Member] | Subsequent Event [Member]

Note 16 - Subsequent Events (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.50%

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 3.08

Debt Instrument Default Rate

2.50%

Convertible Promissory Note, Acquisition Right Amount Redeemable, Percentage

101.00%

Supplementary Financial Data 91

Supplementary Financial Data - Selected Quarterly Financial Data (Details) $ in Thousands	3 Months Ended
	Dec. 31, 2015USD ($)
Quarterly Financial Information Disclosure [Abstract]
Fair Value Adjustment of Warrants	$ 6,424

Supplementary Financial Data 92

Supplementary Financial Data - Selected Quarterly Financial Data (Details) - Selected Quarterly Financial Data - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Selected Quarterly Financial Data [Abstract]
Total revenues	$ 9,847		$ 8,591	$ 7,843	$ 7,872	$ 11,585	$ 16,341	$ 9,307	$ 6,041	$ 34,153	$ 43,274	$ 41,119
Product sales	5,233		4,228	3,340	2,095	4,704	11,480	4,410	2,845	14,896	23,439	15,808
Gross profit (loss) from product sales	(6,084)		(4,227)	(7,619)	(4,548)	(4,605)	1,334	(3,101)	(3,391)
Net income (loss) attributable to common stockholders	(48,352)	[1]	(76,664)	(47,130)	(52,240)	58,021	(36,641)	(35,479)	16,385	(217,952)	2,286	(235,111)
Net income (loss) attributable to common stockholders (for basic income (loss) per share)(1)	(48,352)	[1]	(76,664)	(47,130)	(52,240)	$ 58,021	$ (36,641)	$ (35,479)	$ 16,385	(217,952)	2,286	(235,111)
Net income (loss) attributable to common stockholders (for diluted income (loss) per share)	$ (68,316)		$ (76,664)	$ (54,527)	$ (52,240)					$ (221,777)	$ (109,861)	$ (235,111)
Net income (loss) per share:
Basic (in Dollars per share)	$ (230)	[1]	$ (550)	$ (590)	$ (660)	$ 730	$ (460)	$ (450)	$ 210	$ (1.75)	$ 0.03	$ (3.12)
Diluted (in Dollars per share)	$ (300)		$ (550)	$ (620)	$ (660)	$ (210)	$ (460)	$ (450)	$ (340)	$ (1.75)	$ (0.90)	$ (3.12)
Shares used in calculation:
Basic (in Shares)	206,661,506,000		140,374,297,000	80,041,152,000	79,222,051,000	79,148,281,000	78,980,402,000	78,604,692,000	76,830,388,000	126,961,576	78,400,098	75,472,770
Diluted (in Shares)	231,014,248,000		140,374,297,000	87,421,439,000	79,222,051,000	146,804,047,000	78,980,402,000	78,604,692,000	117,097,976,000	126,961,576	121,859,441	75,472,770
[1]	Basic loss per share for the fourth quarter of 2015 is calculated by excluding from net income (loss) attributable to common stockholders a gain of $6,424 (thousand) related to a change in the fair value of a liability classified common stock warrant included in the Company's consolidated statement of operations. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company's common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain.

Schedule II Valuation and Qua93

Schedule II Valuation and Qualifying Accounts (Details) - Schedule II Valuation and Qualifying Accounts - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation Allowance of Deferred Tax Assets [Member]
Deferred Tax Assets Valuation Allowance:
Balance at Beginning Period	$ 312,323	$ 312,323	$ 284,021	$ 236,288
Additions	47,866		28,302	47,733
Write-off/Adjustments			0	0
Balance at End of Period	360,189	360,189	312,323	284,021
Allowance for Doubtful Accounts [Member]
Deferred Tax Assets Valuation Allowance:
Balance at Beginning Period		479	479	481
Additions		490	0	0
Write-off/Adjustments		0	0	(2)
Balance at End of Period	$ 969	$ 969	$ 479	$ 479